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Abstract
Cytochrome P450 3A represents the most abundant P450 subfamily in human 
liver, and is responsible for the metabolism of >50 % of drugs on the market today. 
An area of intense study has been the xenobiotic regulation of CYP3A gene 
expression: this phenomenon potentially leads to altered
pharmacokinetics/pharmacodynamics of substrates and adverse drug reactions.
The use of hepatoma cell lines is common in dmg metabolism studies; HuH7 
is a human hepatoma cell line increasingly being used in both academia and the 
pharmaceutical industry. However, little is known regarding the expression profile of 
these cells. Recent data have made it increasingly clear that the gene expression 
profile of a cell system, and its alteration in response to external stimuli, is important 
in controlling expression of cytochrome P450 3As. Using quantitative PGR, 
transcript levels of CYP3A subfamily members and transcription factors implicated 
in their regulation were obtained in human adult and foetal RNA samples. These 
levels were then compared to those obtained from both primary human hepatocytes 
and HuH7 cells, showing that in general, primary or hepatoma cells show a distinct 
profile compared to either adult or foetal samples, with the major variables between 
the cell types being ratios of the transcription factors COUP-TFl and RXRa to PXR.
Whereas exposure to the CYP3A transcriptional activators PCN, rifampicin, 
dexamethasone and phénobarbital produced induction in primary human hepatocytes, 
no transcriptional activation was observed in HuH7 cells, suggesting that regulatory 
pathways were disrupted. Alterations in the gene expression profile, particulaiiy the 
levels of COUP-TFl and PXR, and in the chromatin conformation sunounding the 
CYP3A gene cluster, were implicated to underlie this disruption.
In conclusion, I have demonstrated that there are a number of levels of 
control of CYP3A gene expression, with both transcription factor expression levels 
and chromatin status having an impact on transcriptional activation of CYP3A genes 
in human hepatocytes.
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1 Introduction
1.1 Function of drug metabolism
Drugs are eliminated from the body by two processes, metabolism and 
excretion (Gibson and Skett, 2001). Metabolism involves the conversion of the dmg 
from one chemical entity to another and excretion involves the loss of the dmg, and 
its metabolites, from the body. Drug metabolism consists of two phases, namely 
phase I and phase II reactions. Phase I reactions, or functionalisation reactions, 
prepare the dmg for phase II reactions, or direct excretion, by providing a chemically 
reactive functional group for the phase II reactions to use. Phase I reactions include 
oxidation, reduction, hydrolysis, hydration and isomérisation. The microsomal mixed 
function oxidase system (MFO; cytochrome P450 and NADPH-cytochiome P450 
reductase) dominates many phase I reactions, where oxygen is incorporated into the 
dmg molecule to increase the overall chemical reactivity and water solubility, 
allowing conjugation reactions to occur. The MFO reaction is characterised by the 
following stoichiometry: MFO
System
NADPH H* + O2 + RH -----------------► NADP"^  + HjO + ROH
where RH represents an oxidisable dmg substrate. The products of phase I reactions 
aie often more chemically reactive than the paient dmg and so can be more toxic, 
causing mutations, caicinogenesis or cell damage or death. Alternatively, the paient 
compound may be an inactive pro-dmg, and is metabolised to the active drug during 
phase I functionalisation. In general the main function of phase I reactions is to 
prepare the chemical for phase II metabolism (Gibson and Skett, 2001).
Phase II reactions are conjugation reactions. The functional groups produced 
by the phase I reactions serve as the point of attack for the conjugating systems to 
attach a constitutive substituent. Examples of conjugation reactions aie 
glucuronidation, sulphation, méthylation, acétylation and glutathione, amino acid or 
fatty acid conjugation. Enzymes involved in phase II reactions include glutathione-S- 
transferase and UDP-glucuronyltransferase. Phase II is generally regai'ded as the
‘detoxification’ of dmgs, giving water-soluble and easily excreted products (Gibson 
and Skett, 2001).
Together phase I and II enzymes provide a dmg metabolising system capable 
of catalysing almost any chemical reaction that a drug can undergo. The type of 
reaction depends on the substrate itself, the enzymes available and also the presence 
of co-factors. The liver is the major organ responsible for drug metabolism in most 
species, and high expression of drug metabolising enzymes, especially cytochiome 
P450, a component of the MFO system, is observed in this tissue. Dmg metabolising 
enzymes aie also expressed in other areas of the body. The intestine, a key aiea of 
the body involved in absorption of drugs into the body, has a relatively high 
expression of dmg metabolising enzymes (Gibson and Skett, 2001).
1.2 The cytochrome P450 superfamilv
1.2.1 General Overview
Cytochrome P450 (P450) is a superfamily of haem-thiolate proteins 
responsible for the metabolism of a vast range of compounds. These enzymes are 
present in both prokaiyotes and eukaryotes (Nelson et al., 1996) and were first 
identified in 1958 (Klingenberg, 1958). The name is derived from the ability of the 
haemoprotein to bind carbon monoxide and form a complex, whose spectral 
absorbance peaks at 450nm when in the reduced (Fe^ )^ state. P450s aie found 
embedded in the membrane of the endoplasmic reticulum of cells, with the exception 
of some bacterial P450s, and are proteins of monmeric molecular weight in the range 
of 45-55 kDa. The haem prosthetic group (ferric protopoiphyrin IX, Fig 1.1) of 
cytochi’ome P450 is non-covalently bound to the apoprotein, via a haem-binding 
segment of 15 amino acid residues, a sequence conserved in all cytochrome P450s 
studied to date. Differences in the apoprotein sequence dictate the substrate 
specificity of the enzyme, at the appropriate substrate recognition sites (Guengerich, 
1994). Cytochrome P450s are present in all mammalian tissues, but the highest 
concentration is seen in hepatic endoplasmic reticulum, where they act as mono­
oxygenases as pai't of the MFO system (Gibson and Skett, 2001).
Figure 1.1: Structure of ferrie protoporphyrin IX.
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1.2.2 Evolution and nomenclature of CYP450
Since its initial discovery, numerous studies have emphasised that 
cytochi'ome P450s exist as multiple forms derived from distinct genes. Over 2000 
different genes for cytochrome P450s have been identified, including P450s from all 
major phyla including the animalia, plantae, fungi, protista and monera kingdoms; 
humans alone express over 50 different cytochi'ome P450s 
(http://drnelson.utmem.edu/CytochiomeP450.html). The presence of P450s in 
diverse organisms implies the existence of a common ancestor before the eukaiyote- 
prokaryote divergence, over 3.5 billion yeai's ago. It has been proposed that 
cytochrome P450s were initially required for the biosynthesis of steroids, and 
therefore membrane integrity, but, later in evolution, the development of the 
digestive tract led to the extension of P450 function to include detoxification of 
foreign compounds (Nebert and Gonzalez, 1987).
Because of the increasing number of P450s identified, a standai'd system of 
nomenclature was recommended and has been universally adopted (Nelson et al.,
1996). The basis of this nomenclature system is sequence similaiity between the 
cytochrome P450s. P450s aie grouped into families and sub-families based on the 
degree of DNA sequence similarity. Within a P450 gene family, all genes in that 
family have greater than 40 % DNA sequence identity i.e. CYPl, CYP2 etc. These 
families can then be further sub-divided into sub-families, with each member having 
greater than 70 % identity e.g. CYPl A, CYPIB etc. This nomenclature system does 
not take into account any classification of catalytic activity or substrate specificity.
1.2.3 Cytochrome P450 Function
Cytochi'ome P450s aie involved in the metabolism of both endogenous 
compounds and xenobiotics. They have a role in the biosynthetic pathways of 
steroids, fatty acids, prostaglandins and leukotrienes (Nebert and Gonzalez, 1987), as 
well as being the major enzymes involved in phase I dmg metabolism. Table 1.1 
summai'izes the functions of some cytochrome P450 families. Cytochrome P450 
families 1-3 aie the major enzymes involved in metabolism of xenobiotics in humans 
and animals. Among these xenobiotic metabolising P450s, the members of the 
CYP3A subfamily aie the most abundant and are involved in the metabolism of a 
lai'ge number of xenobiotics (Lewis et al., 1998).
Table 1.1; Functions of the cytochrome P450 families.
P450 Family Function
CYP1-3 Drug, xenobiotic and steroid metabolism
CYP4 Fatty acid, prostagiandin and leukotriene metabolism
CYP5 Thromboxane synthesis
CYP7 Cholesterol 7a-hydroxylation
CYP11 Cholesterol side chain cleavage + steroid 11 (3-hydroxyiation
CYP17 Steroid 17a-hydroxylation
CYP19 Aromatisation of steroids
CYP21 Steroid 21-hydroxylation
CYP24 Vitamin D hydroxylation
CYP27 Cholesterol 27-hydroxylation
Adapted from Smith et al., 1998
4
The commonest type of reaction performed by cytochi'ome P450 consists of 
the hydroxylation of lipophilic substrates (endogenous or xenobiotics). P450s are the 
terminal oxidase components of an electron transfer system that provide electrons for 
the mono-oxygenation of these substrates. The catalytic cycle of cytochrome P450, 
shown in Fig 1.2, also requires lipids, NADH-cytochrome bs reductase, cytochrome 
bg and NADPH-cytochrome P450 reductase (Gibson and Skett, 2001). The precise 
role for lipids in the cycle is unclear', but it may facilitate substrate binding or 
electron transfer.
Fig 1.2; The catalytic cycle of cytochrome P450.
ROH
NADH "
NADH-ci^ochrome 
bs reductase
cytochrom e
F e - R H
NADPH- I
cytochrom e P 450  Og -
NADPH
F e — RH
Fe 3 +
F e - R H
RH
F e - R H
NADPH
NADPH-cytochrome 
P450 reductase
F e - R H
O,
Oa
Taken from Gibson and Skett, 2001.
1.2.4 Cytochrome P450 Regulation
Like many other proteins in the body, the expression of P450s can be 
regulated by both endogenous and exogenous compounds (Nebert and Gonzalez, 
1987). Such regulation is important for the rapid elimination of toxic compounds as 
well as the homeostasis of endogenous compounds. P450 enzymes can be suppressed 
or inhibited by a wide range of different compounds. Mechanisms include inhibition 
of synthesis, inactivation or destmction of the P450s. Examples of cytochrome P450 
inhibitors and their mechanism of action are shown in Table 1.2.
Table 1.2: Cytochrome P450 inhibitors and their mechanisms of action.
Compound Mechanism of Inhibition
Ethylene 
Cobalt 
Interleukin 6
Isoniazid
Simvastatin /  Itraconazole
Destruction of pre-existing P450
Inhibition of enzyme synthesis
Down regulation of CYP1A1 and 1A2 at the 
transcriptional level
Inactivation of the enzyme
Competitive Inhibition of CYP3A4
Ortiz de Montellano & Mico, 1980; Eaton et al., 1980; Fukuda et al., 1992; Ishigam 
et al., 2001; Wen et al., 2002.
As well as inhibition of cytochrome P450s, these enzymes can also be 
induced. As with P450 inhibition, induction of the enzyme can have potential clinical 
importance. The intensity and duration of action of a drug on the body is very often 
determined by its rate of metabolism, and therefore alteration in its metabolism, by 
induction or inhibition, may alter the phaimacological effect of the dmg. Also to be 
taken into consideration is the toxicological effect of the drug, which can also be 
altered by changes in rate of metabolism. Hence, dmg metabolism is a balancing act; 
any change in the balance i.e. by enzyme induction or inhibition, will alter the 
balance between pharmacological and toxicological effects. There are several 
mechanisms of P450 induction, examples of which are shown in Table 1.3.
Table 1.3: Mechanisms of P450 induction.
P450 Inducer Main Mechanism of Action
1A1 Dioxin Transcriptional activation via AhR
1A2 3-Methylcholanthrene mRNA stabilisation
2E1 Ethanol Protein stabilisation
3A4 Rifampicin Transcriptional activation via PXR
4A6 Ciofibrate Transcriptional activation via PPAR
Adapted from Waxman and Azaioff, 1992. AhR Aryl hydrocarbon receptor; PXR 
Pregnane X receptor; PPAR peroxisome proliferator activated receptor.
1.3 Cytochrome P450 3A subfamily
1.3.1 Human CYP3A
The cytochrome P450 3As ar'e the most abundant P450s in human liver, 
comprising approximately 30 % of the total P450 content (Watkins,. 1994). In 
addition, approximately 60 % of pharmaceutical drugs currently in use are 
metabolised by CYP3As (Cholerton et al., 1992). CYP3A enzymes are also 
expressed in the intestine, where they play a major role in the first-pass metabolism 
of xenobiotics (Engman et al., 2001). The CYP3A family is therefore of great 
clinical importance for the metabolism of xenobiotics in humans. There are four 
human CYP3A enzymes; CYP3A4, CYP3A5, CYP3A7 and CYP3A43. The genes 
encoding these enzymes are located in a cluster on the long arm of chromosome 7 
(http://drnelson.utmem.edu/human.genecount.htmlk and similarities between 
nucleotide sequences are shown in Table 1.4. With the release of the 35^  ^draft of the 
human genome, there is little chance that additional human CYP3A members will be 
discovered.
Table 1.4: Nucleotide sequence similarities of human CYP3A genes.
CYP3A4 CYP3A5 CYP3A7
CYP3A4 100%
CYP3A5 83% 100%
CYP3A7 95% 89% 100%
CYP3A43 84% 83% 82%
Hashimoto et al., 1993; Kolai's et al., 1994; Salto et al., 2001; Westlind et al., 2001.
1.3.1.1 CYP3A4
CYP3A4 is the major human CYP3A enzyme expressed in adult liver and 
small intestine (Kolars et al., 1994; Schuetz et al., 1994). It is undetectable in foetal 
liver but rapidly appears in neonatal liver to become the major adult P450 in the 
liver, with up to 30 % of total liver P450 being CYP3A4 (Schuetz et al., 1994). 
Gender differences have been observed for CYP3A4 expression (Hunt et al., 1992; 
Schmidt et al., 2001) with females having slightly higher CYP3A4 activity compared 
to males. However, as CYP3A4 activity shows large interindividual variation and the 
observed gender differences are minor, this gender difference is considered largely 
unimportant. Also, other studies have observed no apparent gender differences in 
CYP3A4 expression (Schuetz et al., 1994; Scripture et al., 2001). CYP3A4 is also 
expressed in approximately 14 % of adult human kidneys (Schuetz et al., 1992). The 
catalytic properties of CYP3A4 have been analysed extensively. CYP3A4 catalyses 
the oxidation of many steroids and xenobiotics (Brian et al., 1990; Waxman et al., 
1991), as well as activating various promutagens to mutagens (Aoyama et al., 1990; 
Thornton-Manning et al., 1991). An evaluation of different structural classes of 
chemicals that ar'e substrates of CYP3A4, has demonstrated that CYP3A4 is capable 
of catalysing reactions by a number of different pathways; N-oxidation, C-oxidation, 
N-dealkylation, O-dealkylation, nitro-reduction, dehydration and C-hydroxylation 
(Li et al., 1995). The active site of CYP3A4 has been proposed to be very large, 
explaining the broad substrate selectivity and also the ability of the enzyme to 
metabolise large substrates such as rifampicin (Shou et al., 1994).
The broad substi'ate selectivity of CYP3A4 explains why it is responsible for 
the metabolism of the majority of clinical pharmaceuticals and is therefore a key 
enzyme with respect to the action and duration of drugs (Cholerton et al., 1992). 
CYP3A4 is also highly inducible; a number of substrates for CYP3A4 aie also able 
to induce the enzyme. CYP3A4 can also be inhibited by a number of chemicals. 
Because of this, CYP3A4 may also play a role in drug-drug interactions (Pichai'd et 
a l, 1989; Lucey et al, 1990).
1.3.1.2 CYP3A5
Initial data suggested that CYP3A5 was only a small proportion of total 
hepatic CYP3A content in only 20 % of liver samples (Wrighton et al, 1989). 
However, more recent evidence suggests that CYP3A5 is expressed in a third of 
Caucasian samples and 60 % of African-American livers tested, and that in some 
individuals may represent more than 50 % of total CYP3A (Kuehl et a l, 2001). High 
levels of CYP3A5 expression were shown to be related to possession of the 
CYPSAS^^l allele, whereas individuals possessing the CYP3A5*3 and CYP3A5'*6 
alleles express insignificant levels (Kuehl et al, 2001). CYP3A5 is also expressed in 
other tissues such as kidney, lung and peripheral blood (Schuetz et al, 1992; 
Wheeler et al., 1992; Janai’dan et al, 1996). CYP3A5 does not appear to be sex- 
regulated (Wrighton et al., 1990) and is not inducible by prototypical CYP3A 
inducers (Schuetz et al, 1993a). With respect to substrate specificity, CYP3A5 is 
similar to CYP3A4 but is approximately five times less active (Williams et a l, 
2002).
1.3.1.3 CYP3A7
CYP3A7 is the major form of cytochiome P450 detected in human foetal 
liver, accounting for 30-50 % of total P450 (Shimada et a l, 1996), and was at first 
regai'ded to be exclusively expressed in human foetal liver (Komori et a l, 1990). 
Since then, CYP3A7 mRNA expression has been detected in 54-88 % of adult livers, 
albeit at a fraction of foetal liver levels (Schuetz et al, 1994; Greuet et al., 1996), 
indicating polymorphic expression. Approximately 11 % of subjects tested belonged 
to a distinct sub-group of high expression phenotype, with two thirds of this group 
carrying the CYP3A7^1C or (less frequently) the CYP3A7^1B promoter allele (Burk 
et al, 2002). Functional differences between binding motifs in CYP3A7 wild-type
and CYP3A7^1C promoter alleles have been identified as the mechanism responsible 
for the high CYP3A7 expression in CYP3A7"^1C carriers (Burk et al., 2002). 
CYP3A7 is not exclusively a hepatic P450; expression has been reported in placenta, 
endometrium, lung, kidney, intestine and also certain tumours of the adult (Schuetz 
et al., 1993b; Kivisto et al., 1996; Murray et al., 1999; Kolars et al., 1994). CYP3A7 
has been reported to have a substantially lower metabolic capability than either 
CYP3A4 or CYP3A5 (Williams et al., 2002), which suggests that even in individuals 
possessing the CYP3A7^1C allele, CYP3A7 would still have only a minor role in 
hepatic metabolism.
1.3.1.4 CYP3A43
CYP3A43 is the fourth human CYP3A to be identified and the most recently 
discovered (Gellner et al., 2001; Westlind et al., 2001; Domanski et al., 2001). In 
liver, CYP3A43 expression appeals to be relatively low, with levels approximately 
0.1-0.2 % of those seen for CYP3A4 (Gellner et al., 2001; Westlind et al, 2001). 
However, CYP3A43 expression has been observed in other tissues including 
prostate, testis, brain, lung, kidney, skeletal muscle, heai't, pancreas, stomach, thymus 
and placenta. Highest expression levels are observed in the prostate, whereas other 
tissues express relatively low CYP3A43 levels (Gellner et al, 2001; Westlind et al, 
2001; Domanski et al., 2001). CYP3A43 expression has also been observed in foetal 
liver and skeletal muscle (Domanski et al., 2001). As with CYP3A5, analysis of 
multiple CYP3A43 cDNA clones reveals a number of alternatively spliced forms of 
CYP3A43 (Gellner et al., 2001). Functional analysis of the CYP3A43 enzyme 
indicates that CYP3A43 has no appreciable testosterone or progesterone hydroxylase 
activity, suggesting that this enzyme may have different substrate specificity to the 
other CYP3A forms (Domanski et al, 2001). Further investigation is required to 
determine appropriate substrates for CYP3A43, to allow further chaiacterisation of 
the metabolic capabilities of this enzyme.
1.3.2 CYP3As in other species
At present over 50 different CYP3A genes have been chaiacterised at the 
level of gene, cDNA or protein, across all species studied so far. A list of these 
CYP3A members, and their host species, is shown in Table 1.5. In terms of drug 
discovery and development, perhaps the most relevant of these non-human enzymes
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aie CYP3A23 and CYP3A11, the predominant CYP3As in rat and mouse liver 
respectively, animals that aie commonly used in pre-clinical dmg metabolism 
studies.
Table 1.5: Known members of tbe CYP3A subfamily.
CYP3A form Species CYP3A form Species
CYP3A1 Rat GYP3A27 Rainbow Trout
CYP3A2 Rat CYP3A28 Gow
CYP3A4 Human CYP3A29 Pig
CYP3A5 Human CYP3A30 Teleost
CYP3A6 Rabbit GYP3A31 Syrian Hamster
CYP3A7 Human GYP3A32 Minke Whale
CYP3A8 Monkey GYP3A33 Dali’s Porpoise
CYP3A9 Rat GYP3A34 Sealion
CYP3A10 Hamster GYP3A35 Spotted seal
CYP3A11 Mouse GYP3A36 Ribbon Seal
CYP3A12 Dog GYP3A37 Ghicken
CYP3A13 Mouse GYP3A38 Medaka Fish
CYP3A14 Guinea Pig GYP3A39 Pig
CYP3A15 Guinea Pig GYP3A40 Medaka Fish
CYP3A16 Mouse GYP3A41 Mouse
CYP3A17 Guinea Pig GYP3A42 Royal Python
CYP3A18 Rat GYP3A43 Human
CYP3A19 Goat GYP3A44 Mouse
CYP3A20 Guinea Pig GYP3A45 Rainbow Trout
CYP3A21 Marmoset GYP3A46 Pig
CYP3A22 Miniature Pig GYP3A47 Pufferflsh
CYP3A23 Rat GYP3A48 Pufferfish
CYP3A24 Sheep GYP3A49 Pufferflsh
CYP3A25 Mouse GYP3A56 Killifish
CYP3A26 Dog GYP3A57 Mouse
Adapted from http://drnelson.utmem.edu/P450db.html.
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1.4 Regulation of human cytochrome P450 3A
1.4.1 Introduction
CYP3A4 is a paiticulai'ly important member of the P450 enzymes. It is the 
major P450 enzyme in healthy adult liver and small intestine and is responsible for 
the metabolism of 60 % of currently used drugs, as well as a variety of other 
xenobiotics and endogenous substances (Forrester et al., 1992). The regulation of the 
cytochrome P450 3A subfamily is complex, with a wide range of structurally distinct 
compounds able to induce expression of the enzyme. As described in section 1.2.4, 
there are several possible induction mechanisms; however, in general CYP3A 
induction is a result of transcriptional activation.
1.4.2 CYP3A inducers
There aie many CYP3A inducers, and these include many chemically 
distinct compounds. Examples of some typical human CYP3A inducers aie 
dexamethasone (glucocorticoid), rifampicin (macrolide antibiotic) and lovastatin 
(cholesterol-lowering agent) (Schuetz et al., 1993a; Kocarek et al., 1995). The wide 
range of CYP3A substrates and inducers is the basis for some common dmg-drag 
interactions (see Table 1.6). Some of the clinical interactions caused by induction of 
CYP3A4 involve cyclosporin A, an immunosuppressant used to prevent graft 
rejection. Organ transplantation is a life or death situation, so clearly knowledge of 
interactions between the agents used to suppress the patient’s immune system is vital 
to avoid adverse effects.
Table 1.6: Clinical consequences of CYP3A4 induction.
CYP3A4 Substrate CYP3A4 Inducer Consequence
Cyclosporin A Rifampicin Organ rejection
Cyclosporin A Phenytoin Organ rejection
17a-0thinyl estradiol Barbiturates Menstrual bleeding
Allen et al., 1985; Freeman et al., 1984; Guengerich et al., 1990.
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1.4.3 CYP3A promoter regions
The CYP3A promoter regions, except for that of CYP3A43 which has yet to 
be chaiacterised, have been extensively analysed. Putative binding sites for 
transcription factors are numerous in these 5’-flanking regions, as shown in Fig 1.3.
The CYP3A7 promoter region exhibits 90 % sequence similarity to the 
CYP3A4 promoter up to -8.8 kb (Bertilsson et al., 2001), so the majority of putative 
binding sites seen in the CYP3A4 promoter region aie also observed in the CYP3A7 
promoter. The transcription factor now known to be key to the regulation of the 
CYP3A4 gene is the pregnane X receptor (PXR) (Bertilsson et al., 1998; Blumberg 
et al., 1998; Lehmann et al., 1998), but the high number of putative binding sites 
present in the 5’-flanking region suggest that several other factors may be involved, 
either in concert with or independent of PXR binding (El-Sankaiy et al., 2002; 
Tirona et al., 2003). The high degree of similaiity between the CYP3A4 and 
CYP3A7 promoters also suggests that these genes may be regulated in a similar 
manner, as observed in recent studies (Pascussi et al., 1999; Bertilsson et al., 2001). 
A binding site for PXR is found approximately -150 bp from the transcription start 
site in both CYP3A4 and CYP3A7 proximal promoters (Bertilsson et al., 1998; 
Blumberg et al., 1998; Lehmann et al., 1998; Pascussi et al., 1999). This response 
element is an ER6 motif, two everted hexameric core motifs (AG^/jCA) sepaiated 
by 6 nucleotides. Both genes also have a highly conserved xenobiotic responsive 
enhancer module (XREM), approximately -8 kb upstream from the transcription stait 
site. The XREM contains PXR binding sites, and has been shown to enhance the 
transcriptional response to xenobiotics, although the precise molecular mechanism 
undeipinning the involvement of the XREM remains to be claiified (Goodwin et al., 
1999; Bertilsson et al, 2001). The role of PXR in CYP3A4 and CYP3A7 induction 
appears to be well established, but the high number of putative binding sites for other 
factors, both in the proximal promoter and the XREM, suggests other factors are 
likely to be involved.
-8.8 kb downstream of the CYP3A4 and CYP3A7 promoters, the sequence 
similarity between the regions drops to approximately 25 %. This may indicate that 
this region is required for functions specific for each gene, for example this region of
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the promoter may be responsible for the perinatal switch in expression from 
CYP3A7 to CYP3A4 (Tateishi et al., 1997).
The CYP3A5 promoter region was first described in 1994 (Jounaidi et al., 
1994), however with the release of the first draft of the human genome, this promoter 
region appeal's to correspond to that of a CYP3A5 pseudogene (Gellner et al., 2001). 
The pseudogene has been shown to exhibit 90 % sequence identity with CYP3A5 
and, as such, putative binding sites in the CYP3A5 promoter are unchanged from the 
pseudogene. The CYP3A5 promoter does not appear* to display the same degree of 
similaiity to those of CYP3A4 and CYP3A7, with only 60 % and 59 % sequence 
identity up to -1.4 kb respectively (Jounaidi et al., 1994). The proximal promoter of 
the CYP3A5 gene does contain a PXR response element, but transcriptional 
activation of this gene by xenobiotics appears to occur mainly via a 
glucocorticoid-mediated pathway (Hukkanen et al., 2003; Schuetz et al., 1996a).
1.4.4 Host cell differences In CYP3A induction
Species differences are observed in CYP3A regulation by endo- and 
xenobiotics (Baiwick et al., 1996), in a cell-type specific manner, suggesting that the 
origin of the cell type can be cmcial to the expression of CYP3As. For example, the 
differences in CYP3A induction responses between humans and rats are proposed to 
be due to different PXR activation profiles in these species (Jones et al., 2000). Age 
can also be a determinant of CYP3A regulation; in foetal human liver CYP3A7 is 
expressed, whereas in adult liver CYP3A4 is expressed (Schuetz et al., 1994). This 
may be due to alterations in transcription factor expression during development, 
caused by hormonal changes.
Factors such as cell age, origin or level of differentiation need to be 
considered when examining CYP3A regulation in different cell lines. For example, 
many of the tianscription factors believed to be involved in CYP3A regulation aie 
liver specific therefore may not be available in non-liver cell types, or they may have 
been replaced by alternate factors. In both liver (HepG2) and non-liver (CaCo2) cell 
lines, C/EBPa is able to stimulate transcriptional activity of CYP3A4 (Ourlin et al.,
1997), but HNF3y can only enhance activation in liver derived cells (HepG2) 
(Rodrigues-Antona et al., 2001).
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Previous work in this laboratory has investigated host cell differences of thiee 
different hepatic cell lines, HepG2 (human), FaO and H4IIEC3 (rat) (Swales et al., 
2003). With respect to absolute levels of transcription factors, these cell lines do not 
appear* to show similarity to liver RNA of their respective species. However it was 
discovered that, with respect to relative receptor ratios, HepG2 cells are similar to 
human hepatocytes, FaO cells show similarity to rat hepatocytes but H4IIEC3 cells 
are not akin to either species’ hepatocytes. This correlates with functional studies 
showing that H4IIEC3 cells are non-responsive in reporter gene assays for CYP3A 
induction, whereas both HepG2 and FaO cells can support CYP3A induction (Swales 
et al., 2003).
1.4.5 The role of the pregnane X receptor in CYP3A induction
1.4.5.1 Regulation of CYP3 A4 by PXR
The discovery of the pregnane X receptor* (PXR; NR 112), by KJiewer* et al., 
1998, provided a long awaited clarification of the molecular mechanisms underlying 
CYP3A transcriptional regulation. PXR was first isolated from a mouse liver cDNA 
library, following a search for* sequences exhibiting similarity to ligand-binding 
domains of other nuclear* receptors (Kliewer* et al., 1998). Using this sequence, two 
clones with homology to mPXR were isolated from human cDNA libraries 
simultaneously by three different research groups; these clones differed only in their* 
5’ ends, and so were likely to be the result of alternative splicing. The longest of 
these clones has been termed human PXR, PAR (pregnane activated receptor) and 
SXR (steroid and xenobiotic receptor) (Lehmann et al., 1998; Bertilsson et al., 1998; 
Blumberg et al., 1998 respectively). For clarity, the term PXR will be used from this 
point on. Since the identification of this novel nuclear* receptor, it has been isolated 
from several different species, including man (Lehmann et al., 1998), rats (Zhang et 
al., 1999), rabbits (Jones et al., 2000) and chickens (Handschin et al., 2000).
In man, PXR is constitutively expressed in the liver and intestine (Lehmann 
et al., 1998; Bertilsson et al., 1998; Blumberg et al., 1998). The localisation of this 
receptor to these areas, which also have high levels of CYP3A4 expression, led 
researchers to examine the potential role for PXR in CYP3A4 regulation. Studies 
demonstrated that a range of drugs known to induce CYP3A4 expression were
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activators of PXR, including structurally diverse compounds such as rifampicin, 
phénobarbital and lovastatin (Jones et al., 2000). The chemical structures of some 
PXR activators are shown in Fig. 1.4. Following ligand activation, PXR is 
transported from the cytoplasm to the nucleus of the cell. The precise molecular 
mechanism of this localisation is unclear*, however* a nuclear* localisation signal 
(NLS) in the DNA-binding domain (DBD) of PXR is recognised by importin a, 
which facilitates transport of PXR through a pore complex in the nuclear membrane 
(Kawana et al., 2003).
In transient transfection experiments, the activation of PXR by ligands 
produced activation of a reporter gene construct containing the CYP3A4 proximal 
promoter, and binding studies also determined the presence of a binding motif, an 
ER6 site, able to interact with PXR, located approximately 150 bp upstream from the 
transcription start site (Lehmann et al., 1998; Bertilsson et al., 1998; Blumberg et al., 
1998). PXR binding was only observed following heterodimerisation with RXRa. 
Since these initial studies, further PXR binding sites have also been identified in an 
enhancer module 8 kb upstream from the CYP3A4 transcription start site (Goodwin 
et al., 1999). This enhancer* region has been termed XREM (xenobiotic responsive 
enhancer module), and PXR/RXRa heterodimer binding cooperates with proximal 
promoter activation to enhance the induction response.
The PXR ligand-binding domain (LBD) is similar* to known nuclear 
receptor* LBDs, but it contains several distinct features that appear* critical to its 
ability to bind a str*ucturally diverse range of compounds, demonstrating their 
structural diversity (Watkins et al., 2001). The binding cavity volume of the receptor 
is substantially larger* than many other receptors, allowing binding of structurally 
diverse molecules. A flexible loop involving residues 309-321 of PXR may be 
involved in accommodating large and small molecules in the ligand-binding pocket. 
The flexible loop is linked to the binding cavity by a non-solvent accessible pore, and 
the binding of a large compound such as rifampicin, may force this pore to open.
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Fig 1.4: Chemical structures of some PXR activators.
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enlai'ging the binding cavity. This structural flexibility may allow PXR to bind both 
small and much larger compounds.
Substantial inter-individual variations have been observed in the expression 
of CYP3A4 (Ozdemir et al., 2000). The reasons for this vaiiability are uncleai*, but 
clinical studies indicate that approximately 90 % of inter-individual vaiiability is 
genetically determined (Ozdemir et al., 2000). However, although several variants in 
the CYP3A4 gene have been described, their allelic frequencies and functional data 
indicate only a limited role for these valiants in CYP3A4 inter-individual variability 
(Ball et al., 1999; Westlind et al., 1999; Sata et al., 2000; Eiselt et al., 2001). 
Polymoiphisms in PXR, however, do appeai' to be determinants of inter-individual 
vaiiation of CYP3A4 activity. Six protein valiants of PXR have been identified in 
Caucasian and African populations; three of these valiants, with only single amino 
acid substitutions, have altered basal and/or induced trans-activation of the CYP3A4 
gene (Hustert et al., 2001). Interestingly, the missense mutations, in the PXR variants 
with altered trans-activation activity, are localised to, or aie at the boundaiy of, the 
ligand-binding domain of the receptor. In addition, the splice valiant of PXR, PXR2, 
identified in 1998 (Lehmann et al., 1998; Bertilsson et al., 1998; Blumberg et al.,
1998), which has a deletion of 37 amino acids within the ligand-binding domain, also 
has altered trans-activation activity (Hustert et al., 2001). These variations in amino 
acids within/proximal to the LBD may alter the activation of the receptor by ligands, 
which will then affect gene trans-activation, resulting in inter-individual variations in 
CYP3A4 expression.
A study by Xie et al., in 2000 (Xie et al., 2000a), highlighted the involvement 
of PXR in species differences in CYP3A induction. The significance of PXR was 
investigated by generating mPXR-null mice. This was achieved by the deletion of 2 
exons, including amino acid residues 63-170 of the DNA-binding domain. mPXR- 
null mice engineered to express human PXR showed mai'ked induction of CYP3A 
gene expression on exposure to rifampicin, a prototypical human CYP3A4 inducer 
(Xie et al., 2000a); this induction does not occur in wild type mice. Also, the hPXR 
transgenic mice do not respond to PCN, a prototypical inducer of CYP3A in rodents. 
hPXR therefore confers a human profile of CYP3A transcriptional activation to
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mPXR-deficient mice; thus the xenobiotic response in these mice is humanised. This 
ability of PXR to confer species-specific CYP3A induction has also been 
investigated in vitro (Xie et al., 2000a). The effect of a panel of CYP3A inducers was 
examined in primaiy cultures of rat hepatocytes. In control cultures, CYP3A23 was 
strongly induced by PCN but not by rifampicin. This activity reflects the activity of 
endogenous rat PXR. When hPXR was transfected into the primaiy rat hepatocytes, 
significant induction of CYP3A23 by rifampicin was observed, whereas activation 
by PCN remained unchanged. Four polai* residues within the binding cavity appeal' to 
be responsible, at least in part, for these species differences observed in PXR 
activation. When these four residues, which differ between mice and humans, aie 
mutated, they confer a human like activation profile on mPXR (Watkins et al., 2001).
1.4.5.2 The regulation of other CYP3A genes by PXR
A PXR responsive element has been identified in the CYP3A7 proximal 
promoter (Pascussi et al., 1999), at the same position as in the CYP3A4 promoter 
region. This is unsuiprising given the high sequence identity observed between the 
promoters of these two genes. Binding of PXR/RXR heterodimers to the ER6 motif 
in the CYP3A7 5’ flanking region trans-activates gene expression, indicating that the 
induction mechanisms of CYP3A4 and CYP3A7 are similar. The CYP3A7 5’ 
flanking region also contains an XREM region, which is capable of PXR binding and 
enhancement of the induction response in a similai* manner to the XREM in the 
CYP3A4 5’ flanking region (Bertilsson et al., 2001).
A recent study demonstrated induction of CYP3A5 by rifampicin and vitamin 
E, and this induction response is thought to be mediated via PXR as both these 
compounds are activators of this receptor (Landes et al., 2003). A PXR response 
element (ER6 motif) has also been identified in the 5’ flanking region of CYP3A5 
(-120 to -109 bp) (Iwano et al., 2001). However, this PXR response element does not 
appeal* to be involved in the basal regulation of CYP3A5, as reporter gene studies 
have shown the region -90 to -40 bp to be key to basal transcriptional expression 
(Iwano et al., 2001).
Limited studies have been performed on regulation of CYP3A43, however it 
has been demonstrated that in primary human hepatocytes, CYP3A43 is
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transcriptionally induced by 10 pM rifampicin (Gellner et al., 2001). This suggests 
that PXR may be involved in regulation of CYP3A43, but further investigation is 
required.
1.4.5.3 Endogenous role of PXR
The role of PXR in the transcriptional regulation of drug-metabolising 
enzymes by xenobiotics has become much cleaier in recent years, but its role, if any, 
in the basal expression of these genes is currently unclear. Studies have identified 
PXR as a cmcial component in the detoxification of bile acids. PXR has been shown 
to be activated by the toxic bile acid lithocholic acid (Staudinger et al., 2001), a 
substrate of CYP3A4, and also to regulate the expression of genes involved in 
detoxification and excretion of chemicals. PXR inhibits the expression of CYP7A, an 
enzyme involved in bile acid synthesis, and induces the expression of MDRl (Geick 
et al., 2001). MDRl is the gene encoding intestinal P-glycoprotein. P-glycoprotein 
acts as an efflux pump, actively transporting substances back into the intestinal 
lumen and, as such, has an important role in the absorption and pre-systemic 
elimination of drugs (Loo and Clai'ke, 1999). PXR induces the expression of OATP2 
(organic anion transporter 2) (Staudinger et al., 2001) and GSTA2 (glutathione S 
transferase A2) (Falkner et al., 2001). OATP2 is involved in hepatocellulai* uptake of 
compounds (Reichel et al., 1999), so increased expression would enhance uptake into 
hepatocytes, where hydroxylation by metabolising enzymes can occur; GSTA2 is a 
protein involved in detoxification of xenobiotics, by catalysing the conjugation of 
glutathione with the electrophilic centres of the toxicants (Ketterer, 1986). This 
prevents binding with cellular proteins and nucleic acids. GSTA2 also serves as an 
intfacellulai' binding protein for non-substrate ligands, which includes bile acids such 
as lithocholic acid. This role as a binding protein is thought to facilitate transport of 
potentially toxic compounds to either membrane transporters, or to membrane 
associated P450s therefore increasing removal of the toxicants. PXR induces both 
CYP3A4 (Lehmann et al., 1998) and carboxylesterase (Zhu et al., 2000), enzymes 
that play key roles in metabolism of xenobiotics (Satoh and Hosokawa, 1998), so 
up-regulation would facilitate removal from the system.
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Accordingly, identification of genes regulated by PXR has strongly indicated 
a critical role for this receptor in the absolution, transport, metabolism and excretion 
of potentially toxic compounds in the human body.
1.4.6 The role of the glucocorticoid receptor in CYP3A induction
Belonging to the family of steroid hormones, glucocorticoids affect a broad 
spectrum of physiological processes, including cell metabolism, proliferation and 
differentiation (Peck, 1984; Sanchez et al., 1993; Ailhaud et al., 1994). 
Glucocorticoids act via the glucocorticoid receptor (GR; NR3C1). Following ligand 
activation, glucocorticoid receptors dissociate from heat shock protein 90 (Hsp90), 
homodimerise and translocate into the nucleus (Sanchez et al., 1985; Chalepakis et 
al,, 1990). Once in the nucleus, GR homodimers bind to specific glucocorticoid 
responsive elements (GRE) on DNA where they can cause both up and down 
regulation of gene transcription (Subramaniam et al., 1999); the GR consensus 
sequence is GGTACAnnnTGTTCT (Beato et al., 1989).
Several studies have implicated GR in the transcriptional regulation of 
CYPBAs. Initially, it was observed that steroids, such as dexamethasone, known to 
be ligands of GR, were able to induce expression of the CYP3A4 gene. Following 
this, transient transfection studies using a reporter gene containing 1 kb of the 
CYP3A4 promoter region showed an increased response to xenobiotics when a GR 
expression plasmid was co-transfected (El-Sankary et al., 2000) and sequence 
analysis of the human CYP3A promoter regions show the presence of several 
putative sites similai* to GREs, as illustrated in Fig. 1.3, although these sequences 
appear to be non-consensus GREs. However, discrepancies were observed that direct 
activation by GR was not the major mechanism responsible for CYP3A4 induction 
by glucocorticoids. For example, anti-glucocorticoids, such as RU-486, enhanced 
rather than suppressed the CYP3A4 induction response. Also, studies performed in 
mice indicated no difference in either constitutive expression of CYP3A or the 
response to CYP3A-inducing xenobiotics, such as PCN or dexamethasone, between 
wild type and GR-null mice (Schuetz et al., 2000), suggesting GR is not essential for 
CYP3A induction. The discovery of PXR provided an explanation for these 
inconsistencies, as this receptor can be activated by both glucocorticoids and anti­
glucocorticoids.
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Nevertheless, there may be a direct mechanism of CYP3A4 induction by GR 
for some xenobiotics, as recent studies in this laboratory have indicated that 
dismption of a putative HNF3/CEBPa binding domain upstream from the PXRE 
results in a decreased induction response to glucocorticoids, but not to rifampicin 
(El-Sankai'y et al., 2002). This suggests that both PXR-dependent and -independent 
mechanisms aie responsible for xenobiotic induction of the CYP3 A4 gene.
The major role for GR in CYP3A4 induction appeal's to be indirect. GR may 
cause transcriptional activation of other nuclear receptors, including PXR, RXRa 
(Pascussi et al., 2000a) and CAR (Pascussi et al., 2000b), which in turn may then 
directly influence CYP3A4 expression. The role of the CAR receptor in CYP3A 
gene induction will be discussed in section 1.4.7. A diagram illustrating the inteiplay 
between GR and the other nuclear receptors, in the regulation of CYP3A4, is shown 
in Figure 1.5. It should be noted that GR might play a negative, as well as positive, 
role in the regulation of PXR and CAR. IL-6 may upregulate members of the AP-1 
family (Granger et al., 2000), factors that then interact physically with GR (De 
Bosscher et al,, 2001), preventing GR activation of PXR and CAR genes (Pascussi et 
al., 2000c).
Another possible role for GR in mediating CYP3A4 induction may involve 
chi'omatin modification. A previous study has shown that in cells treated with 
dexamethasone, disruption of the chromatin structure around a region of the rat 
tyrosine aminotransferase gene promoter occurs (Can* et al., 1990), The relevance of 
this chi'omatin change is unclear; changes in nucleosomal positioning induced by GR 
binding may allow the binding of other transcription factors, or indeed other GR 
molecules, to the promoter region, allowing gene trans-activation.
GR has also been reported to play a role in the transcriptional regulation of 
CYP3A5 expression. CYP3A5 mRNA levels in A549 cells, a human lung 
adenocai'cinoma cell line, were significantly increased following 24 hour exposure to 
glucocorticoids, with maximal induction occurring at -lOOnM concentrations. This 
induction response to glucocorticoids was blocked by RU-486, a GR antagonist 
(Hukkanen et al., 2000; 2003). A novel dexamethasone responsive enhancer region
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has previously been identified in the CYP3A5 gene (Schuetz et al., 1996a), however 
this study was performed on what is now known to be a CYP3A5 pseudogene. 
Whereas the pseudogene is highly similai' to CYP3A5 it is not identical, therefore 
further studies are required to confirm if this enhancer unit is functional in the tme 
CYP3A5 gene. The role of GR in control of CYP3A7 gene expression is likely to be 
similai' to CYP3A4. Induction of a CYP3A7 promoter reporter gene construct by 
dexamethasone was only observed on co-transfection of a GR expression plasmid in 
human hepatoma cells (Ogg et al., 1999), however it is likely this occurs because of 
GR mediated induction of PXR and CAR.
1.4.7 The role of the constitutive androstane receptor in CYP3A induction
The constitutive androstane receptor (CAR; NR1I3) belongs to the same 
nucleai' receptor family as PXR, and shaies the same heterodimerisation partner, 
RXRa (Honkakoski et al., 1998). With respect to amino acid sequence, human CAR 
shows 66% sequence identity to human PXR in the DNA-binding domain and 45% 
identity in the ligand-binding domain (Moore et al., 2002). CAR is expressed 
abundantly in the liver, with expression also observed in the small intestine, heart, 
lung and muscle (Baes et al., 1994; Wei et al., 2000). CAR appears to have strong 
constitutive activity (i.e. in the absence of any added ligand) in cell-based reporter 
gene assays, being able to enter the nucleus and activate tai'get genes (Baes et al., 
1994; Choi et al., 1997). This constitutive activity appears to be inhibited by 
androstanes, metabolites of testosterone, which act by preventing interaction of CAR 
with SRC-1, the steroid receptor coactivator 1 (Forman et al., 1998). In contrast to 
transfected cell lines, CAR does not appeal* to be present in the nucleus of primary 
hepatocytes, but instead is sequestered in the cytoplasm (Kawamoto et al., 1999). 
Treatment of these cells with CAR ligands, such as phénobarbital, results in 
translocation of the receptor to the nucleus, where it can heterodimerise and activate 
target genes (Kawamoto et al., 1999). An explanation for this difference between 
transfected hepatoma cell lines and in vivo has been suggested. In liver, endogenous 
inhibitory steroids, such as androstanol, aie able to bind to CAR and maintain the 
receptor in an inactive state. In the presence of phénobarbital, androstane binding to 
CAR will be abolished allowing recmitment of SRC-1 and receptor activity will
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therefore be de-repressed, allowing nuclear translocation and tai'get gene activation. 
In contrast, transfected cell lines, such as HepG2, may not have endogenous 
inhibitory androstanes present, and therefore the receptor will be constitutively 
active. This is supported by studies that have shown inhibition of endogenous 
CYP2B6 expression in CAR-transfected HepG2 cells exposed to androstenol; this 
inhibition is reversed following treatment with phenobaibital, allowing CYP2B6 
induction (Sueyoshi et al., 1999).
CAR is able to activate tai'get genes via binding to a DNA site composed of 
two imperfect direct repeats of a nuclear receptor half site motif separated by four 
nucleotides (DR4 motif). CAR has also been shown to activate genes via a DR5 
motif (Baes et al., 1994; Choi et al., 1997). As mentioned above, CAR has been 
implicated in the regulation of CYP2B genes. In CAR-null mice, CYP2B mRNA 
inducibility in response to phenobaibital is lost (Wei et al., 2000). Following 
formation of CAR/RXRa heterodimers, the xenobiotic-activated CAR is able to 
bind to the phenobaibital-responsive enhancer module (PBREM) located in upstream 
regions of CYP2B genes in several species, including human CYP2B6 (Honkakoski 
and Negishi, 2000). The PBREM contains two copies of a DR4 motif which, 
following successive mutations, results in gradual loss and finally abolition of CAR 
trans-activation activity (Sueyoshi et al., 1999).
Recently, evidence has emerged that CAR may also be involved in regulation 
of CYP3A genes. CYP2B and CYP3A genes in both rat and human hepatocytes are 
regulated by several of the same xenobiotics, including rifampicin and phénobarbital 
(Kocarek et al., 1995; Strom et al., 1996), and it has been demonstrated that there is a 
wide degree of overlap for ligands of PXR and CAR (Moore et al., 2000). 
Furthermore, it has also been demonstrated that CAR has the ability to bind to PXR 
response elements in both the proximal promoter and XREM of CYP3A4, and, in a 
type of functional symmetry, PXR is also able to bind to the PBREM in CYP2B 
genes (Xie et al., 2000b). Binding of CAR to PXR response elements has been 
shown to mediate activation of a transgene, composed of 13 kb of the CYP3A4 
5’-flanking region linked to an E. coli lacZ reporter gene, expressed in mice, as well 
as activating CYP3A4 reporter gene constructs in HepG2 cells (Goodwin et al.,
2002). Further evidence of the role of CAR in regulating CYP3A genes has been
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provided by studies performed in null mice. PXR-null mice aie able to support 
induction of CYP3A11 by phénobarbital, but in CAR-null mice the induction 
response is not observed (Wei et al, 2000; Xie et al., 2000a).
1.4.8 The role of the retinoid X receptor family in CYP3A induction
The retinoids comprise a group of compounds, including retinol (vitamin A) 
and its biologically active derivatives such as retinoic acid, and aie important 
regulators of normal cell growth and differentiation (Geisen et al., 1997). The 
retinoid X receptor (RXR) family of proteins aie nuclear receptors, activated solely 
by 9-cis retinoic acid, involved in the transduction of the retinoid signal (Heyman et 
al., 1992; Levin et al., 1992). There aie three isoforms of RXR; RXRa (NR2B1), p 
(NR2B2) and y (NR2B3). RXRa is noticeably abundant in liver, kidney, lung, 
muscle and spleen, and expression is also observed in brain, heait, testes, intestine 
and adrenal glands. RXRp is also expressed in these tissues, albeit at lower levels 
than RXRa. RXRy shows a much more limited tissue distribution than the other two 
RXR isoforms, but is detected in low levels in the liver, heart and muscle 
(Mangelsdorf et al., 1992).
Upon activation by ligand, RXRs can form homodimers that aie able to 
interact with hormone response elements on DNA, preferentially binding to DRl 
motifs. Binding of RXR homodimers to DR-1 motifs can cause activation of genes 
such as cellulai* retinol binding protein type II (Mangelsdorf et al., 1991). RXR 
proteins can also form heterodimers with the retinoic acid receptors (RAR; NRIB), 
allowing binding to retinoic acid response elements (RARE). In addition to forming 
heterodimers with RAR, RXR also acts as a heterodimerisation partner for many 
other nucleai' receptors, for example the vitamin D receptor, PXR and CAR, allowing 
binding to their respective response elements (Yu et al., 1991).
RXRa is present at high levels in the liver, indicating that it may play a 
significant role in liver-specific gene expression (Mangelsdorf et al., 1992). This is 
supported by RXRa -/- mouse foetuses having under-developed livers (Sucov et al., 
1994). Oculai' and caidiac malformations, similai' to those observed with vitamin A 
deficiency, aie also found in RXRa-null mice (Kastner et al., 1994). RXRa -/- mice 
do not survive beyond embryonic day 16, due to these cardiac abnormalities.
27
However, mice with a hepatocyte-specific mutation of RXRa are viable, although 
several metabolic pathways are compromised (Wan et al., 2000). RXRp shows a 
similai' expression pattern to RXRa, albeit at lower levels (Mangelsdorf et al., 1992). 
RXRp -/- mice appear normal except that the males aie sterile (Kastner et al., 1996). 
The cause of this sterility is thought to be lipid accumulation in Sertoli cells. In 
contrast to RXRa and p mutants, homozygous RXRy mutant mice develop normally 
and aie indistinguishable from their wild type littermates (Krçzel et al., 1996). This is 
surprising considering the tissue specific expression pattern (Ki'çzel et al., 1996). 
RXRy is now believed to “fine tune” the function of certain tissues, rather than the 
control of major developmental and physiological functions. Compound mutant mice 
(RXRa +/-, RXRP -/-, RXRy -/-) are essentially normal, displaying no obvious 
congenital or postnatal abnormalities, besides male sterility due to loss of RXRp 
(Ki’çzel et al., 1996). This suggests that there is a functional redundancy amongst 
RXRs, with RXRa alone being sufficient for completion of a number of RXR 
functions.
The role of RXRs in regulation of CYP3A genes appeal's to be supportive 
rather than obligate. Both human PXR and CAR must heterodimerise with RXRa to 
allow binding to the CYP3A4 promoter (Bertilsson et al., 1998; Blumberg et al., 
1998; Lehmann et al., 1998; Goodwin et al., 2002). Studies in RXRa deficient mice 
have shown that there is approximately fourfold less CYP3A1 basal mRNA 
expression, in compaiison to wild type mice (Wan et al., 2000; Cai et al., 2002). 
However, in response to both TCPOBOP (mCAR ligand) and PCN (mPXR ligand) 
CYP3A1 expression is still induced (Cai et al., 2002). These data suggest that control 
of CYP3A1 basal transcription is mediated by RXRa and that RXRp and y are 
insufficient to maintain this expression. As previously mentioned, there appears to be 
a functional redundancy among the RXRs, where in the absence of one isoform of 
RXR there is very little disruption to signalling pathways, suggesting the ability of 
the other two isoforms to substitute for the missing RXR (Krçzel et al., 1996). 
However, there are exceptions to this, as demonstrated by the male sterility of 
RXRp -/- mice (Kastner et al., 1996). In RXRa deficient mice, the CYP3A1 
induction response to PXR and CAR ligands is retained (Cai et al., 2002), suggesting 
that RXRp or y are able to heterodimerise with these receptors. The abundance of 
RXRa in the liver suggests it is the preferred heterodimerisation partner for PXR and
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CAR, but in the absence of RXRa, interactions with RXRP or y may occur. Further 
investigation is required to determine if this is the case.
1.4.9 The role of COUP-TFl in CYP3A induction
Chicken ovalbumin upstream promoter transcription factors (COUP-TF) are 
named after a group of transcription factors, which interact with the COUP DNA 
element that regulates transcription of the chicken ovalbumin gene (Bagchi et al.,
1987). Human COUP-TFl (NR2F1) was first cloned from HeLa cells, and encodes a 
protein of 46.2 kD (Wang et al., 1987). Between species, COUP-TFl DBDs and 
LBDs have over 96 % and 99 % similaiity among vertebrates, respectively (Qiu et 
al., 1996). This high degree of conservation suggests the importance of these factors, 
confirmed by the lethality of COUP-TFl null mice, with major defects in the central 
and peripheral neiwous systems (Pipaon et al., 1999). COUP-TFl appeals to be 
ubiquitously expressed and involved in the regulation of several important biological 
processes, such as neurogenesis and cellulai' differentiation (Cooney et al., 2001). 
COUP-TFl is expressed at high levels in several foetal tissues (Miyajima et al.,
1988), indicating a possible role during embryonic development. This is supported 
by the lethality of COUP-TFl null mice (Pipaon et al., 1999).
COUP-TFl exists as a stable homodimer, capable of binding to direct repeats 
of the nucleai' receptor half site AGGTCA with various spacings, although with 
preference to DR-1 elements (Cooney et al., 1992), COUP-TFl homodimers aie also 
capable of binding to everted repeats but with lower affinity than direct repeats 
(Cooney et al., 1992). This flexibility of COUP-TFl, with respect to DNA binding, 
allows COUP-TFl to compete for other nucleai' factor binding sites, thus regulating 
gene expression by the receptor that normally binds to that site. For example, 
COUP-TFl competes with HNF4 for a binding site on the human apolipoprotein CIII 
gene, thus negatively regulating expression (Mietus-Snyder et al., 1992). COUP-TFl 
can also heterodimerise with several nuclear receptors, such as ERa and AhR, 
forming functionally inactive complexes and therefore repressing gene activation by 
these receptors (Klinge et al., 1997; 2000). COUP-TFl also heterodimerises with 
RXR receptors, forming a transcriptionally inactive complex (Kliewer et al., 1992). 
Therefore, the effective concentration of RXR is reduced, thus directly inhibiting the
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activation functions of nuclear receptors that use RXR as a heterodimerisation 
partner.
Although widely regarded as a negative transcriptional regulator, COUP-TFl 
can also positively regulate gene transcription. It can do this by several different 
mechanisms. First, COUP-TFl is able to upregulate gene expression by directly 
binding to the gene and causing trans-activation. An example of this is the mouse 
Na'^/H’*' exchanger (NHE), where COUP-TFl binds to a response element in the 
promoter region of this gene, causing upregulation (Fernandez-Rachubinski and 
Fliegel, 2001). COUP-TFl can also positively regulate genes by acting as an 
accessory factor or as a co-activator. For example, COUP-TFl can act as a 
co-activator with HNF4 to trans-activate the HNFl gene (McNair et al, 2000) and 
also acts as an accessory factor for GR regulation of the phosphoenolpyiuvate 
caitoxykinase gene (Scott et a l, 1996).
The role of COUP-TFl in regulation of human CYP3A genes is uncleai*. 
However, studies examining the regulation of rat CYP3As have shown that 
COUP-TFl is involved in CYP3A2 regulation. COUP-TFl competes with 
PXR/RXR heterodimers for binding sites in the CYP3A2 promoter region and so 
negatively regulates gene expression (Huss et al, 1999). COUP-TFl has the ability 
to bind to everted repeats in gene promoters (Cooney et al, 1992), so it may be able 
to bind to the ER6 site in human CYP3A upstream regions, therefore preventing 
PXR/RXR binding (Bertilsson et al, 1998; Blumberg et al, 1998; Lehmann et al,
1998). This would implicate COUP-TFl as a negative regulator of CYP3A 
expression, similar to the situation observed with the rat CYP3A2 gene. Another 
possible role for COUP-TFl in human CYP3A regulation is suggested by the 
presence of COUP-TF response elements in the distal enhancer regions of both 
CYP3A4 and CYP3A7 (Goodwin et al, 1999; Bertilsson et al., 2001). Further 
investigation is required to determine the precise role of COUP-TFl in regulation of 
human CYP3A genes.
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1.4.10 The role of HNF and C/EBP proteins in CYP3A induction
Studies of typical hepatic genes have indicated that liver-specific gene 
expression is accomplished by the concerted action of a small number of 
liver-enriched transcription factors (LETFs) (Cereghini, 1996). Examples of such 
LETFs are hepatocyte nucleai* factor (HNF) 1, HNF3, HNF4 and CCAAT/enhancer 
binding proteins (C/EBP). LETFs aie essential for liver development and function 
(Cereghini, 1996). In most cases, two or more LETFs are responsible for expression 
of a hepatic gene. As expression of the CYP3As is high in liver, this suggests a 
potential role for LETFs in control of CYP3A gene expression.
C/EBP was originally isolated from the rat liver as a protein binding to 
CCAAT and enhancer core motifs (Antonson and Xanthopoulos, 1995). It is a 
member of the basic region leucine zipper (bZIP) family of transcription factors. 
There aie several C/EBP proteins; a, p, y, ô and s. However, only C/EBPa will be 
discussed further in this work, as no evidence is available for the involvement of the 
other isoforms in CYP3A regulation. C/EBPa appeals to control terminal 
differentiation of adipocytes and hepatocytes (Shugart and Umek, 1997), and also 
plays a major role in the maintenance of energy homeostasis (Wang et al., 1995). 
C/EBPa shows high expression levels in liver, lung, pancreas, small intestine and 
colon, pai’ticularly in fully differentiated cells (Antonson and Xanthopoulos, 1995). 
In the liver, C/EBPa expression begins just prior to birth and increases in the 
newborn (Diehl et al., 1994). C/EBPa is able to form homodimers (Calkhoven et al., 
1997), or heterodimers with other members of the C/EBP family (Cao et al., 1991; 
Williams et al., 1991), both of which aie able to interact with the C/EBP consensus 
binding site. Transcriptional regulation by C/EBPa can occur by two mechanisms 
- direct trans-activation and by acting as an accessory factor. For example, in 
transient transfection experiments, C/EBPa has been demonstrated to trans-activate 
expression of CYP2B promoter constructs (Luc et al., 1996) and is also able to 
mediate the responsiveness of phosphoenolpyruvate carboxykinase to cAMP 
signalling by acting as an accessory factor (Crosson and Roesler, 2000).
Several recent studies have suggested a role for C/EBPa in regulation of 
CYP3A genes. Putative C/EBP binding sites have been identified in the human 
CYP3A4 and CYP3A7 5’ regions and also in the rat CYP3A1 gene promoter
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(El-Sankary et al., 2002; Rodriguez-Antona et al., 2003; Ouiiin et al., 1997; 
Rodrigues et al., 2003). In the case of the rat gene, two putative C/EBPa binding 
sites are functional, with transfection of a C/EBPa expression plasmid into cells, 
along with a reporter gene constmct containing the relevant region of the CYP3A1 
promoter, resulting in increased expression of the reporter gene (Rodrigues et al.,
2003). Investigation into the role of C/EBPa in the regulation of human CYPSAs has 
also indicated that this factor is involved in CYP3A regulation. An investigation into 
the differential regulation of CYP3A4 and CYP3A7 showed that these genes aie 
differently trans-activated by C/EBPa, with CYP3A4 having at least two strong 
functional C/EBPa-responsive elements and CYP3A7 having only one of these 
(Ourlin et al., 1997). This was confirmed by a more recent study where, in HepG2 
cells infected with an adenoviral vector expressing C/EBPa, both basal CYP3A5 and 
CYP3A7 were up-regulated, but to a lower extent than CYP3A4 (Rodrigues-Antona 
et al., 2003). Studies in this laboratory have recently discovered a putative complex 
HNF3/CEBP binding site immediately upstream from the PXRE in the CYP3A4 
promoter which, when disnipted, causes a reduction in response to glucocorticoids 
but not to rifampicin (El-Sankary et al., 2002). This suggests that glucocorticoids 
may induce CYP3A4 via both PXR-dependent and -independent pathways, and that 
HNF3 or C/EBPa is potentially involved in the PXR-independent mechanism of 
CYP3A4 induction.
HNF3 proteins were originally identified by their ability to bind to the 
promoter of transthyretin and a 1-antitrypsin genes (Costa et al., 1989) and have 
subsequently been shown to paiticipate in expression of many other liver-specific 
genes, as well as genes expressed in intestine, lung and pancreas. There ai*e three 
isoforms of HNF3; HNFBa, HNF3P and HNF3y (Lai et al., 1991). Based on their 
multiple tai'gets in the liver and pancreas, a pivotal role for the HNF3 proteins in 
metabolism is suggested, as well as in liver and gut development (Ang et al., 1993). 
HNF3 proteins are monomeric transcription factors (Lai et al., 1991) that can 
regulate transcription by several different mechanisms. HNF3a has been shown to 
directly activate expression of proglucagon, a key gene involved in glucose 
homeostasis (Kaestner et al., 1999). HNF3 proteins also appear to promote gene 
activation by either altering chromatin structure or acting as accessory factors. On 
binding to DNA, HNF3 proteins can displace linker histones, resulting in chromatin
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opening and increased binding of other transcription factors (Cirillo et ai., 1998). 
HNF3 also acts as an accessory factor; HNF3 binding sites are frequently found close 
to those for the glucocorticoid receptor. Mutations of these HNF3 sites lead to a 
blunting of the glucocorticoid response, clearly showing the role of these proteins as 
accessory factors (Wang et al., 1996; Christoffels et al., 1998).
Several recent studies have implicated a role for HNF3 proteins in 
regulation of CYP3A genes. Potential HNF3 binding sites have been identified in the 
CYP3 A gene promoters and tai'geted dismption of the genes encoding HNF3 resulted 
in reduced transcription of several hepatocyte-specific genes, including several 
P450s (Kaestner et al., 1998; Delesque-Touchaid et al., 2000). A study examining 
the role of HNF3y in regulation of CYP3A4 basal expression demonstrated that 
HNF3y does not trans-activate CYP3A4 directly, but can cooperate with C/EBPa to 
enhance basal gene expression (Rodrigues-Antona et al., 2003). This effect was also 
observed with the CYP3A5 and CYP3A7 genes. HNF3y was shown to interact with 
a region -1738 bp upstream from the transcription start site, and approximately 50 bp 
upstream from the C/EBPa binding site, suggesting that binding of HNF3y results in 
localised chromatin remodelling, allowing better access for C/EBPa. This idea is 
supported by the prevention of the cooperative effect between the LETFs by a 
histone deacetylase inhibitor (Rodrigues-Antona et al., 2003). Studies in this 
laboratory have also identified a putative complex HNF3/CEBPa binding site, 
approximately 15 bp upstream from the ER6 in the CYP3A4 promoter region 
(El-Sankary et al., 2002). Interestingly, dismption of this site by site-directed 
mutagenesis resulted in a decreased response to glucocorticoids but not to rifampicin. 
These data provides evidence that glucocorticoids may induce CYP3A4 via both 
PXR-dependent and -independent pathways, and that HNF3 or C/EBPa is involved 
in the PXR-independent mechanism of CYP3A4 induction. This potential role for 
HNF3 in CYP3A4 induction may involve HNF3 acting as an accessory factor, by 
controlling the magnitude of the glucocorticoid response via GR, as is the case for 
the rat tyrosine aminotransferase gene (Roux et al., 1995).
Hepatocyte nuclear factor 4a (HNF4a) is a liver enriched transcription factor 
that is essential for liver development and function (Nagy et al., 1994; Cereghini,
1996). It was originally discovered, at the same time as HNF3, as a protein that
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interacted with the promoters of the transthyretin and a 1-antitrypsin genes (Costa et 
ah, 1989). It exists as stable homodimers in solution, and is unable to form 
heterodimers (Jiang et al., 1995). During development HNF4a is found only in the 
visceral endoderm, and disruption of this gene in the mouse leads to early embryonic 
death, caused by failure of the visceral endoderm to differentiate (Chen et ah, 1994), 
highlighting the importance of this factor during development. In the adult, HNF4a 
has limited tissue distribution, with high expression levels only observed in liver, 
intestine and kidney (Sladek et ah, 1990). HNF4a appears to be an important factor 
in the control of numerous hepatic genes, including those involved in glucose, fatty 
acid and cholesterol metabolism (Sladek, 1993). Mutations in the HNF4a gene are 
associated with maturity onset diabetes of the young type 1 (MODYl), a condition 
characterised by defective secretion of insulin (Yamagata et al., 1996).
HNF4a can control gene expression both directly and indirectly. Another 
LETF, HNFl, has been observed to be directly trans-activated by HNF4a via binding 
of this factor to the HNFl gene promoter (Miura and Tanaka, 1993). Alternatively, 
HNF4a can act as an accessory factor. In a manner similar* to HNF3, HNF4a can act 
as an accessory factor for glucocorticoid-mediated gene regulation. The 
phosphoenolpyrnvate carboxykinase gene is an example of a gene regulated in this 
manner. HNF4a binding to an accessory factor element in this gene promoter 
appears to enhance the response to glucocorticoid receptor activation (Wang et ah,
1999). HNF4a can also act by recruiting co-activators; it has recently been shown 
that HNF4a may deliver histone acetyltransferase containing co-activators to the 
promoter region, resulting in chromatin remodelling (Malik et ah, 2002). HNF4a is 
able to bind to DRl motifs in gene promoters (Nakshatri and Bhat-Nakshatri, 1998). 
This motif, however, has been shown to interact with other members of the nuclear 
receptor superfamily, including COUP-TFl and various RXR dimers (Mietus-Snyder 
et al., 1992; Nakshatri and Chambon, 1994). In fact, most HNF4 binding sites so far 
identified are also binding sites for other receptors (Mietus-Snyder et ah, 1992; 
Nakshatri and Chambon, 1994). There are exceptions to this however, for example 
the HNF4 sites in the a 1-antitrypsin and HNFl promoters aie specific for HNF4 only 
(Cereghini, 1996).
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HNF4a has been implicated as an important factor for the constitutive 
expression of several P450s, Putative binding sites for HNF4 exist in several 
promoter and enhancer sequences of P450 genes (Venepally et al., 1992) and 
analysis has shown that this factor plays a positive role in the regulation of a number 
of these, including rat CYP3A23 (Huss and Kasper, 1998). The role of HNF4a in the 
regulation of human CYP3As has recently been studied. Analysis of the CYP3A 
gene promoters has identified putative HNF4 response elements in both the proximal 
promoter and XREM of CYP3A4 and CYP3A7 (Hashimoto et al., 1993; Goodwin et 
al., 1999; Bertilsson et al., 2001) and also in the proximal promoter of CYP3A5 
(Jounaïdi et al., 1994). In human hepatocytes transfected with HNF4 antisense RNA, 
a concentration-dependent down regulation of both CYP3A4 and CYP3A5 was 
observed, indicating a role for HNF4a in the constitutive expression of these 
enzymes (lover et al., 2001). In cell-based reporter gene assays, CYP3A4 promoter 
activity was most pronounced in liver-derived cells and minimal in non-hepatic cells 
(Tirona et al., 2003). This confirms a role for an LETF in control of CYP3A4 
expression. Evidence is also available which suggest HNF4a also mediates 
xenobiotic induction of CYP3A4. The putative HNF4 binding site in the XREM of 
the CYP3A4 gene (Goodwin et al., 1999) shows significant loss in reporter activity 
when dismpted, cleaiiy, indicating this region to be critical in basal CYP3A4 
expression, and also in xenobiotic-induced expression (Tirona et al., 2003). In 
addition, adult mice with hepatic deletion of HNF4a have reduced basal and 
inducible expression of CYP3A (Tirona et al., 2003). This evidence cleaiiy supports 
a potential role for HNF4a in the control of CYP3A4 gene expression. The location 
of the HNF4 binding site in the CYP3A4 XREM is immediately upstream from the 
PXR responsive element (Goodwin et a l, 1999), which suggests that HNF4a may act 
as an accessory factor to PXR-mediated gene activation.
There is also evidence available that suggests HNF4a may also play a role in 
the regulation of other nuclear receptors, such as PXR and CAR, which aie involved 
in trans-activating CYP3A4. A study has demonstrated the importance of a DRl site, 
located -87 bp upstream from the PXR transcription start site, in activity of the PXR 
promoter. HNF4a was demonstrated to bind directly to this DRl site and 
trans-activate PXR gene expression (Wolbold et al., 2003). Studies in mice have 
shown that mRNA expression of PXR in the liver of the foetal HNF4a -/- knockout
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mouse is virtually undetectable (Li et a l, 2000). In adult mice, however, no change is 
observed in PXR expression between wild-type and HNF4a -/- mice, but a decrease 
is observed in expression of CAR (Tirona et al., 2003). This suggests that the role of 
HNF4a in regulation of PXR and CAR changes with development of the mice.
There are several pieces of evidence indicating a role for LETFs in regulation 
of CYP3A genes. It is clear that one or more of these factors are required for both 
basal and inducible expression of these enzymes.
1.4.11 The role of nuclear receptor co-activators and co-repressors in CYP3A
induction
Nucleai* receptor co-regulators can be broadly defined as cellulai* factors 
recruited by nucleai" receptors that complement their function as mediators of the 
cellulai* response to endocrine signals. Co-regulators are generally divisible into 
those that promote transcriptional activation when recruited (co-activators) and those 
that attenuate promoter activity (co-repressors).
Nucleai* receptor functions aie directed by specific activation domains, 
referred to as activation function 1 (AFl) on the N-terminus of the receptor, and AF2 
on the C-terminus of the LBD (reviewed by Glass and Rosenfeld, 2000). 
Crystallographic evidence has shown that a ligand-dependent shift in the position of 
several helices in AF2 creates a secure environment for co-activator binding (Shiau 
et al., 1998). Contact between nucleai* receptors and co-activators is mediated by an 
amphipathic helix on the surface of the co-activator, the LXXLL motif (Heery et al.,
1997). A lai*ge number of co-activators aie known to exist, and these can be 
separated into different groups, based on their function. A critical aspect of gene 
activation involves nucleosomal remodelling. There aie two general classes of 
chromatin remodellers; ATP-dependent nucleosome remodelling complexes and 
factors containing histone acetyltransferase activity (reviewed by Wu, 1997). The 
mechanism by which ATP-dependent chromatin remodellers act has not yet been 
clai'ified, but they are responsible for ATP-dependent or -associated local dismption 
of the nucleosome e.g. BRGl/hBrm (Khavaii et al., 1993; Muchardt and Yaniv, 
1993). Co-activator complexes with histone acetyltransferase activity increase the 
acétylation of lysine residues in histones, which in turn increases the rate of gene
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transcription (Brownell and Allis, 1996). This increase in transcription occurs 
because acétylation disrupts the interaction between the negatively charged DNA and 
positively charged lysine residues. In most cases, acetyltransferases aie not directly 
recmited by nuclear receptors, but associate with other co-activators that have higher 
affinity for the receptor. An example of a co-activator with acetyltransferase activity 
is CBP/p300 (Kiaus et al., 1999). Another class of co-activators aie those that aie 
crucial in providing contact between the nuclear receptor and the basal transcription 
machinery. For example, the TRAP/DRIP/ARC complex is recruited to nucleai* 
receptors in a ligand-dependent manner and enhances RNA polymerase II 
recmitment to the promoter (Rachez et al., 1998; Fondell et al., 1999; Naai* et al.,
1999).
Co-repressors aie proteins that aie able to interact with receptors and 
actively repress gene transcription. Examples of co-repressors are N-CoR (nucleai* 
receptor co-repressor) and SMRT (silencing mediator for retinoid and thyroid 
receptors). N-CoR is able to bind to several nuclear receptors, an example of which 
is the thyroid receptor. The N-CoR / TR interaction is disrupted by ligand binding 
(Horlein et al., 1995). SMRT acts in a similar* manner to N-CoR; examples of nuclear 
receptors able to interact with SMRT are RAR and TR (Chen and Evans, 1995). 
These co-repressors function by interacting with complexes containing proteins such 
as histone deacetylases. Histone deacetylases have the reverse action of the 
acetyltransferases and as such are able to “close” the chromatin structure, repressing 
transcription.
For each of the nuclear receptors that are potentially involved in regulation 
of CYP3A gene expression, several different co-regulators are likely to be 
associated. This results in a large and complex group of proteins that can affect the 
expression of CYP3As indirectly. As discussed in section 1.4.5, PXR appears to be 
the key receptor involved in xenobiotic-mediated induction of CYP3A4. Several 
studies in recent years have investigated the role of co-activators and co-repressors in 
PXR-mediated gene regulation. The study that initially discovered PXR in the mouse 
also demonstrated that, upon activation by steroids, PXR interacts with a co-activator 
protein called SRC-1 (steroid receptor co-activator protein-1) (Kliewer et al., 1998). 
SRC-1 is a co-activator that possesses intrinsic histone acetyltransferase activity
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(Spencer et al., 1997). This interaction between PXR and SRC-1 was later confirmed 
for human PXR (Lehmann et ah, 1998). More recent studies have also demonstrated 
interactions between PXR and several co-repressors. Mouse PXR has been observed 
to interact with RIP 140 (receptor interacting protein 140) (Masuyama et al., 2001) 
and Pit-1 (pituitaiy specific transcription factor 1) (Gonzalez and Caiiberg, 2002). 
Human PXR has been observed to interact with Pit-1 and SMRT (Gonzalez and 
Caiiberg, 2002; Takeshita et al., 2002). The interaction between PXR and SMRT 
appealed to inhibit both basal and rifampicin-induced transcriptional activity of PXR 
on the CYP3A4 promoter (Takeshita et al., 2002). The ability of PXR to interact 
constitutively with both SRC-1 and SMRT suggests that the relative balance of 
co-activators and co-repressors in cells may determine the transcriptional activity of 
PXR.
CAR also appeal's to play a role in regulation of CYP3A enzymes (section 
1.4.6). Many studies have investigated co-regulator proteins that are able to interact 
with CAR. The co-activators SRC-1, GRIPl (glucocorticoid receptor interacting 
protein 1) and PGC-la (PPARy co-activator la) have all been shown to interact with 
CAR (Muangmoonchai et al., 2001; Min et al., 2002; Shiraki et al., 2003), as have 
the co-repressors SMRT and Pit-1 (Dussault et al., 2002; Gonzalez and Caiiberg, 
2002).
Co-activators generally exist as part of large multi-protein complex, so for 
each of the proteins that interact with PXR and CAR, there are likely to be a much 
lai'ger number of regulatory proteins involved. If the other transcription factors, 
believed to be involved in CYP3A regulation, also interact with co-regulators there is 
potentially a very large number of co-activators and co-repressors that may play a 
role in the transcriptional control of CYP3A gene expression. Levels of these 
co-regulators in the cellular environment may indirectly determine the transcriptional 
response to xenobiotics.
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1.5 Aims of the Project
There are potentially a lai'ge number of transcription factors involved in the 
regulation of the human CYP3A genes. In the pharmaceutical industry, the use of in 
vitro methods is preferable when determining the safety of potential therapeutic 
agents. A tool increasingly used in these studies is the human hepatoma cell line 
HuH7. However, little is known about these cells, with respect to the expression of 
CYP3As and also nuclear receptors.
The aim of my work is to determine the niRNA expression levels of CYP3 As, 
and a number of transcription factors, in HuH7 cells, and to compare these levels 
with those measured in human liver and in primary cultures of human hepatocytes. I 
will also compai'e the effect of known in vivo CYP3A inducers, on the levels of 
CYP3As and nucleai* receptors in both HuH7 cells and primaiy human hepatocytes, 
and investigate any differences observed in the response to these xenobiotics. In 
pai'ticulai*, I hope to claiify the role of the transcription factors studied in regulating 
the expression of CYP3As and the mechanism by which this regulation occurs.
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2 Methods
2.1 Materials
All chemicals and other materials were purchased from Sigma-Aldrich, 
Poole, Dorset, UK, unless specified otherwise.
2.2 Cell characterisation at the mRNA level
2.2.1 Cell culture
HuH7 cells, a human hepatoma cell line (Nakabayashi et al., 1982), 
(generously donated by GlaxoSmithKline, Ware, UK) were stored in liquid nitrogen, 
in 91 % FBS and 9 % DMSO. To begin culturing the cells, a vial of cells was thawed 
at 37 °C and added to 10 ml of medium. Cells were centrifuged for 5 minutes at 
300 X g and resuspended in 15 ml fresh medium and added to a 75 cm^ vented tissue 
culture flask (Nunclon^^, Nunc Brand products, Roskilde, Denmark). The cells were 
incubated in a 5 % CO2 cell incubator at 37°C and medium was replaced after 24 
hours to remove any non-viable cells. HuH7 cells were cultured in Dulbecco’s 
modified eagle medium (DMEM) containing 10 % FBS, 2 mM L-glutamine, Ix non- 
essential amino acids (NEAA) and penicillin/streptomycin (100 U/ml penicillin, 
100 pg/ml streptomycin) (Invitrogen, Paisley, UK) and were passaged every four 
days at a ratio of 1:5. To passage cells, medium was aspirated and the cell layer 
washed with 5 ml PBS. 1 ml of trypsin-EDTA (0.25 % trypsin, 1 mM EDTA) was 
added and flask agitated gently at room temperature until cells had detached from the 
flask surface. The trypsin-EDTA was neutralised by addition of 4 ml medium 
containing 10 % FBS, The cells were then split, in a ratio of 1:5, into a final volume 
of 15 ml.
Primary human hepatocytes were obtained from the UK Human Tissue Bank, 
Leicester, UK. Donor information is shown in Table 2.1. Cells were supplied at the 
cell density and plate size requested, as described in section 2.1.2, and were cultured 
in William’s Medium E containing 2mM L-glutamine (JRH Biosciences, Andover, 
Hampshire, UK), 10 % heat-inactivated newborn calf serum (Invitrogen), 
penicillin/streptomycin/neomycin (50 U/ml, 50 pg/ml, 100 pg/ml) and insulin 
(1 mg/ml). All primary human hepatocyte culture, dosing and lysis were kindly
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carried out by Sandy Baldwin and Jo Bramwell at DMPK, GlaxoSmithKline (Ware, 
UK).
Table 2.1: Donor information for primary human hepatocytes.
Donor Sex Age Drug History
1 Male 78 Not known
2 Male 64 Not known
3 Male 65 Iron tablets 
Zetril
4 Female 20 Nil
2.2.2 Xenobiotic dosing of cells
HuH7 cells (passage 14 from receipt) were cultured in 25 cm^ culture flasks 
(Nunclon™, Nunc Brand products). Cells were dosed, in triplicate, 24 hours after 
passage; xenobiotics and doses used aie shown in Table 2.2.
The medium for dosing was prepaied by adding 0.1 % of the corresponding 
lOOOx stock of drug to produce the required concentration. Five millilitres of the 
appropriate dose medium was added to each flask and the cells were incubated for 48 
hours, at 37°C in a 5 % CO2 cell incubator, prior to total RNA extraction. In addition 
to triplicate flasks of each concentration, 12 flasks of cells were left untreated to 
provide basal mRNA expression levels.
Table 2.2: Xenobiotics used to treat cells.
Xenobiotic Vehicle Final Concentration (jiM)
PCN
Rlfampicin
Dexamethasone
Phénobarbital
DMSO
DMSO
DMSO
H2O
0, 0.1, 1 ,5 , 10, 50 
0, 0.1, 1 ,5 , 10, 50 
0, 0 .01 ,0 .1 , 1, 10, 50 
0, 1, 10, 50, 100, 200
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Primary human hepatocytes from donors 1 and 2 were cultured, at 7.5 x 10 
cells per collagen-coated 75cm^ flask (Becton Dickinson, Oxford, Oxfordshire, UK), 
in medium only to provide basal mRNA expression levels for human hepatocytes 24 
hours after isolation. For xenobiotic induction studies, primary human hepatocytes 
were cultured in collagen-coated 24-well plates (Becton Dickinson) at 3 x 10^  cells 
per well. Cells were exposed, in triplicate, for 48 hours to the same xenobiotics and 
concentrations as in Table 2.2, except medium was prepared for dosing by adding 
0.4% stock solution, rather than 0.1 %. Hepatocytes from donor 3 were used for 
PCN, rifampicin and dexamethasone dosing, and donor 4 for phénobarbital. Again, 
12 wells were left untreated to provide basal mRNA expression levels for human 
hepatocytes 72 hours after isolation.
2.2.3 Total RNA extraction
Total RNA was extracted from the cell lines using the RNeasy® Mini Kit 
(Qiagen, Crawley, Sussex, UK). The cells were harvested by lysis, with a guanidine 
isothiocyanate-containing buffer, directly in the culture dish. For primary human 
hepatocyte samples, cell lysates were frozen on dry ice to allow transport from 
GlaxoSmithKline, Ware, to the University of Surrey. Before total RNA extraction, 
lysates were defrosted at 37°C for 15 minutes. Total RNA was extracted from both 
HuH7 and primary human hepatocyte samples according to the manufacturer’s 
protocol. The RNA was eluted in a final volume of 30-50 pi of RNase-free water.
2.2.4 Assessment of RNA quality
3 pi of each RNA extract were electrophoresed on a 2 % agarose gel as 
described in section 2.4.1. If the ribosomal bands were sharp under UV light, with 
the 28S band appearing approximately twice as intense as the 18S band, the RNA 
was considered good quality. High molecular weight bands (>20 kb) indicated DNA 
contamination. RNA quality was also determined by spectrophotometry using the 
Genequant II RNA/DNA calculator (Amersham Biosciences, Little Chalfont, 
Buckinghamshire, UK). This provides an estimate of the purity of RNA, in the form 
of the A260/A280 ratio. Pure RNA has a ratio of 1.9-2.1 in 10 mM Tris-HCl pH 7.5; 
however, since the total RNA was eluted in unbuffered water, the ratio may vary 
with pH and hence values close to, but outside, this range were still progressed to 
subsequent stages.
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2.2.5 Measurement of RNA concentration
The concentration of the total RNA samples was determined using the 
Ribogreen® RNA quantitation kit (Molecular* Probes, Paisley, UK), as 
spectrophotometric determination is 1000-fold less sensitive. The manufacturer’s 
protocol was followed. A standard curve was prepared from the supplied 100 pg/ml 
ribosomal RNA (E.coli), giving a range of 0 to 1000 ng/ml. Samples were diluted 
300-1000 fold in IxTE (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). 100 pi of both 
standards and samples was mixed with the Ribogreen® RNA quantitation reagent 
and fluorescence measured at excitation/emission wavelengths of 485/530 nm 
respectively using a SpectraMax GeminiXS microplate fluorimeter controlled by 
SoftMax Pro version 4.0 software (Molecular Devices, Wokingham, Surrey, UK).
2.2.6 Determination of mRNA expression levels
To determine different gene expression at the mRNA level the following 
method was used, as previously described (Phillips et al., 2003). To determine 
expression levels in human adult and foetal liver, total RNA from human livers were 
purchased (Stratagene, La Jolla, California, USA; Clontech, Oxford, UK; Ambion, 
Huntingdon, Cambridgeshire, UK).
2.2.6.1 DNase I treatment
Total RNA extracts (HuH7, primaiy human hepatocytes, adult human liver 
and foetal human liver) were treated with RQl RNase-free DNase (Promega, 
Chai'bonnieres, France) prior to cDNA synthesis to remove any contaminating 
genomic DNA. RQl RNase-free DNase is a prepaiation of DNase I that maintains 
the integrity of RNA. 1 pg of the total RNA samples were made up to 8 pi with 
0.1 % DEPC H2O. 1 pi of 10 X DNase reaction buffer and 1 pi of RQl RNase-free 
DNase were added per sample and incubated at 3TC  for 30 mins, before 1 pi of stop 
solution (20 mM EGTA, pH 8.0) was added. The samples were incubated at 65°C for 
10 minutes to inactivate the DNase.
2.2.6.2 cDNA synthesis
Invitrogen’s Superscript First-strand Synthesis System for RT-PCR was used 
to synthesise cDNA. The manufacturer’s protocol was followed with some changes.
1.5 pi 10 mM dNTPs, 1.5 pi 0.5 mg/ml oligo (dT) 12-18 primer, and 1 pi of
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RNase-free water were added per sample of DNase-treated RNA. Reactions were 
incubated at 65°C for 5 mins, then cooled on ice for at least 2 mins. 2 pi of 0.1 M 
DTT, 1 pi RNaseOUT RNase inhibitor (40 U/pl), 0.25 pi Superscript II reverse 
tianscriptase (200 U/pl) and 1.75 pi RNase-free water were added per reaction. The 
plate was incubated at 42°C for 50 mins, before terminating the reaction at 70°C for 
15 mins. The samples were chilled on ice, before addition of 80 pi RNase-free water, 
to give a total volume of 100 pi per sample, and stored at -20°C until required.
2.2.Ô.3 Primer and probe design
Primer and probe sets for human CYP3A4, CYP3A5, CYP3A7, GAPDH, 
PXR, GRa, CAR, HNF4a, COUP-TFl, RXRa, RXRp and RXRy were designed by 
GlaxoSmithKline (Waie, UK) using Primer Express, version 2 (Applied Biosystems, 
Warrington, UK). Primer and probe sets for CYP3A43, HNF3a, C/EBPa and SP-1 
were designed in this laboratory, again using Primer Express software. The software 
designed primers and probes using the guidelines given in Table 2.3, and the 
nucleotide sequences of the primers and probes are shown in Table 2.4 (due to 
GlaxoSmithKline policy, sequences of primers and probes designed in-house are not 
listed, but are available on request).
Lyophilised primers were supplied by Sigma-Genosys (Haverhill, Suffolk, 
UK) and were diluted to a 0.1 mM stock concentration with 0.1 % DÈPC water. This 
stock was further diluted to prepare a working solution of 10 pM, in 250 pi aliquots 
to minimize contamination and any freeze-thawing effects. All primers were stored 
at -20°C. Probes were supplied dual-labelled with the reporter dye (6-FAM) at the 5’ 
end and the quencher dye (TAMRA) at the 3’ end. (Applied Biosystems and 
Sigma-Genosys). The probes were diluted to a working concentration of 5 pM and 
stored at -20‘’C.
2.2.6.4 Genomic DNA standards
Human genomic DNA (Promega) was sheared by passing through a 21-gauge 
needle 10 times. The human genomic DNA was then diluted to provide a stock 
solution of 10^  single strands per 5 pi (2 x 10"^  ss/pl), according to the theory in 
appendix 8.1. This standard was serially diluted to prepare 10"^ , 10^ , 10^  and 
10^  ss/5 pi standard solutions.
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Table 2.3; ABI Prism Primer Express software primer design guidelines.
Primer
Tm 5 8 -6 0 ° C  
20 -  80 % GC 
9 - 4 0  b ases in length
Less than 2°C difference In Tm between the two primers 
A maximum of two G/G at the 3 ’ end
Probe
Tm 10°C higher than the primer Tm
20 -  80 % GC
9 - 4 0  b ases in length
No G on the 5 ’ end
Less than 4 contiguous Gs
Must not contain more Gs than Gs
Amoiicon
50 -  150 base pairs in length
The 3’ end of the primer should be as close to the probe as possible
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2.2.6.5 Quantitative PCR
For each 96-well reaction plate, a bulk mix was prepared using the volumes 
given in Table 2.5. Twenty microlitres of bulk mix were added into each well of a 
96-well optical reaction plate (Applied Biosystems), along with 5 pi per well of 
cDNA, NTC (no template control) or genomic standard. The genomic standards and 
NTC reactions were in duplicate. The reaction plate was firmly sealed with an optical 
adhesive cover (Applied Biosystems) and loaded onto ABI Prism 7000 sequence 
detection system (Applied Biosystems). The reactions were run under the thermal 
cycler conditions shown in Table 2.6.
Once completed, the rnn was analysed using the ABI Prism® software 
(Applied Biosystems). This analysis provides Ct (threshold cycle) values and uses 
the standard curve produced (Logio [Copy number] vs. Ct) to calculate the copies of 
RNA per well from these Ct values. The analysed data were exported to Microsoft 
Excel for further analysis, which involved the calculation of transcripts / ng total 
RNA. These values were used to calculate the average of the triplicate samples.
Table 2.5: Reagent volumes for quantitative PCR.
pi per well pi per 96-well plate
Forward Primer (10 pM) 1 110
Reverse Primer (10 pM) 1 110
Probe (5 pM) 0.5 55
TaqMan® Universal PCR Mastermix 12.5 1375
0.1 % DEPC H2O 5 550
Table 2.6: Thermal cycler conditions for quantitative PCR.
Stage Temperature Time Cycles
1 50°C 2 mins 1
2 95°C 10 mins 1
3 95°C 15 se cs 40
60°C 1 min
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2.2.Ô.6 Statistical analysis
The results were analysed for significant differences using a one factor 
ANOVA with Bonferroni all means post hoc test (GraphPad Prism, version 4.0).
Principal components analysis (PCA) was performed both on absolute values 
and on receptor ratios, calculated from latin square tables, using the Multi Vaiiate 
Statistical Package (MVSP version 3.1, Kovach Computing Services, Pentraeth, 
Angelesey, UK). Principal components analysis consists of an eigenanalysis of a 
covariance matrix calculated on the original data. This is a way of identifying 
patterns in a large volume of data, and expressing these data in such a way as to 
highlight the major variables.
Cluster analysis (centroid clustering with Spearman’s co-efficient) was 
performed on both absolute receptor expression levels and on receptor ratios using 
the Multi Variate Statistical Package (MVSP version 3.1). Cluster analysis is a term 
used to describe a set of numerical techniques in which the main purpose is to divide 
the objects of study into discrete groups. The result is a dendrogram that shows the 
most similar objects linked most closely together.
2.3 Alteration of nuclear receptor complement in HuH7 cells
2.3.1 Endotoxin-free maxipreparation of plasmid DNA
An expression plasmid for human PXR (pSG5-hPXR; for plasmid map see 
appendix 8.2) was propagated using TOPI OF’ E. coli cells (Invitrogen). Plasmid 
DNA was then isolated using the Qiagen Endofree’^'"* Maxiprep kit, which uses a 
modified alkaline lysis method. Following filtration of the bacterial lysate, 
endotoxins are removed and plasmid DNA is bound to anion-exchange resin where 
impurities can be washed away. The protocol in the manufacturer’s technical manual 
was followed. The DNA concentration was determined spectrophotometrically, using 
the GeneQuant II RNA/DNA Calculator (Amersham Biosciences).
2.3.2 FuGENE 6 transfection of plasmid DNA
HuH7 cells (passage 15) were seeded on a 24-well plate (Becton Dickinson) 
at 45,000 cells/well and grown for 24 hours. Cells were transfected using FuGENE 6
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transfection reagent (Roche Diagnostics, Basel, Switzerland), a non-liposomal 
formulation of lipids. The manufacturer’s protocol for transfection of cells in 24-well 
plates was followed, with a 3:1 FuGENE 6:DNA ratio i.e. 0.6 pi FuGENE 6 and 
200 ng hPXR plasmid per well in 0.5 ml semm-free medium. 21 wells in total were 
transfected, the three remaining wells untransfected. After 24 hours incubation with 
transfection mix, medium was changed, and cells were dosed in triplicate with 
rifampicin in complete medium (for concentrations used see Table 2.2). In addition, 
three wells of transfected cells were treated with medium only, as were the three 
wells of untransfected cells. Cells were dosed for 48 hours before total RNA was 
extracted and mRNA levels determined as described in sections 2.1.3 - 2.1.6. Results 
were analysed for statistical significance using an unpaired t-test (GraphPad Prism, 
version 4.0)
2.3.3 rra/ïsIT®-TKO transfection of siRNA
HuH7 cells (passage 15) were seeded on a 24-well plate at 35,000 cells/well 
and grown for 24 hours. Cells were transfected using rran^IT-TKO® transfection 
reagent (MWG Biotech, Milton Keynes, UK), a reagent developed specifically for 
transfection of short interfering RNA (siRNA). The manufacturer’s protocol was 
followed with, per well, 2 pi of TransYT-TKO® reagent being diluted in 50 pi 
semm-free medium before addition of 3 pmol of SMARTpool^^ siRNA for 
COUP-TFl (MWG Biotech); complex formation was at room temperature for 20 
minutes. Following this incubation, transfection complex was added dropwise to 
250 pi complete medium in the well. Cells were incubated with the transfection 
complex for 24 hours, followed by 24 hours incubation with complete medium. Total 
RNA was extracted and mRNA levels determined as described in sections 2.1 .3-
2.1.6. Results were analysed for statistical significance using an unpaired t-test 
(GraphPad Prism, version 4.0).
2.4 Local chromosome conformation in HuH7 cells
2.4.1 DNase I sensitivity assay
2.4.1.1 DNase I digestion of intact nuclei
To determine local chromosome conformation around target genes, a DNase I 
sensitivity assay was performed. To isolate intact nuclei, the method used by Ashe et
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al. was followed (Ashe et al., 1997). HuH7 cells (passage 14; 1 x 10^  cells) were 
washed in ice cold PBS, and resuspended in 4 ml cold buffer HLB/NP40 (10 mM 
Tris pH 7.5, 10 mM NaCl, 2.5 mM MgCla, 0.5 % nonidet P40) before incubating on 
ice for 5 minutes. Cells were underlain with 1 ml cold HLB/NP40 containing 10 % 
sucrose and centrifuged for 5 minutes at 500 x g. The nuclei pellet was gently 
resuspended in 1 ml HLB/NP40 containing MnCL in place of MgCL before being 
divided into 5 aliquots. RQl RNase-free DNase (Promega) was added to the nuclei 
(0, 0.05,0.1, 0.4 and 1 U) and incubated at 3TC  for 10 minutes. 200 pi of stop buffer 
(0.6 M NaCl, 20 mM Tris, 10 mM EDTA, 1 % SDS, 0.5 mg/ml proteinase K) was 
added and incubated at 3TC  overnight. DNA was extracted and purified by 
phenol:chloroform extraction and ethanol precipitation, as described in section 2.4.2. 
The DNA pellet was resuspended in 160 pi TE buffer and incubated at 65°C for 20 
minutes until DNA had dissolved completely. Samples were stored at 4°C.
2.4.1.2 Restriction digest
The DNase I-treated genomic DNA was digested to produce fragments of the 
CYP3A4, PXR and GAPDH promoter regions. 20 pi (-10 pg) of each sample was 
digested with BamYYUHpal (40 units each) at 37°C overnight in Promega multi-core 
buffer with 0.1 mg/ml BSA, to produce a 5619 bp fragment containing the CYP3A4 
transcriptional start site (-4729 to +890 bp), HindLWClal (40 units each) at 3TC  
overnight in Promega multi-core buffer with 0.1 mg/ml BSA, to produce a 5332 bp 
fragment of the PXR promoter (-5124 to +208 bp) and Sfil/Bcll (40 units each) at 
50°C in Promega buffer B with 0.1 mg/ml BSA, to produce a 6587 bp fragment of 
the GAPDH promoter (-6431 to +156 bp).
2.4.1.3 Southern blotting
Southern blotting is named after Edwaid Southern, who developed the 
technique in the 1970s (Southern, 1975). Simply, Southern blotting is a method to 
transfer DNA from an agarose gel to a membrane, where specific sequences can be 
detected by probe hybridisation.
Digested DNA samples were mixed with Orange G loading dye and 
electrophoresed on a 14 x 11 cm 1 % agarose gel, for approximately 5 hours at
3.5 V/cm, as described in section 2.4.1. Following electrophoresis, the agarose gel
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was submerged in dénaturation buffer (1.5 M NaCl, 0.5 M NaOH) and incubated for 
30 minutes with gentle agitation to denature the DNA. Gel was rinsed briefly in H2O 
before being neutralised, for 30 minutes with gentle agitation, in neutralisation buffer 
(1.5 M NaCl, 0.5 M Tris pH 7.5). The gel was again rinsed in H2O.
The gel was placed upside down on Whatman^*^ 3MM filter paper, ensuring 
no air bubbles between filter paper and gel, on a platform in a large dish of 20X SSC 
(3 M NaCl, 0.3 M Tri-sodium citrate) as shown in Fig 2.1. Hybond N+ nylon 
membrane (Amersham Biosciences), soaked in 20X SSC and slightly larger than the 
gel, was placed carefully on top of the gel, again ensuring no air bubbles. On top of 
the membrane were placed 3 pieces of Whatman^^ 3MM filter paper, also soaked in 
20X SSC, and a stack of paper towels. A 500 g weight was placed on top of the 
apparatus and the DNA allowed to transfer from the gel to membrane overnight. 
Following disassembly of the apparatus, the membrane was heated in a Hybaid 
hybridisation oven at 80°C for 2 hours to fix the DNA to the membrane.
Fig 2.1: Diagrammatic representation of a capillary blotting apparatus.
stack of
Paper -------- ^
Towels
Hybond N+ 
membrane '
5 0 0 g  w eight Large glass plate
3MM filter 
paper
Gel
3MM filter 
paper Platform
20X SSC
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2.4.1.4 Synthesis and purification of labelled DNA probe
2.4.1.4.1 Synthesis and purification of DNA template
PCR was utilised to synthesise the required DNA fragment for radioactive 
probe synthesis. PCR reactions were assembled in DNA polymerase buffer 
(Promega), and contained 200 ng human genomic DNA (Promega), 50 pmol forward 
primer, 50 pmol reverse primer, 200 pM dNTPs and 5 units Taq DNA Polymerase 
(Promega). The PCR primers were designed using Primer Express, version 2 
(Applied Biosystems), and synthesised by MWG Biotech; the sequences of these 
primers are shown in Table 2.7. The primers for CYP3A4 were designed to amplify 
the region -951 to -344 bp upstream from the transcription start site, PXR primers to 
amplify -1036 to +126 bp and GAPDH primers were designed to amplify -1108 to 
-7 bp. The PCRs were performed in the Peltier Thermal Cycler (MJ-Reseaich 
PTC-200, DNA Engine) and the cycle parameters are given in Table 2.8.
Table 2.7: Sequences of primers used for PCR.
Primer Sequence
CYP3A4 forward primer 
CYP3A4 reverse primer 
PXR forward primer 
PXR reverse primer 
GAPDH forward primer 
GAPDH reverse primer
5' CTTGGTATCTATGGCAGGACC 
5’ TTCATGCGAACAAGGCACACG 
5 ’ GGTTGGGAAGTGGAAATTGG 
5' AAGAGTTGGGTTGGAGGGTG 
5’ TTCGGAGGGTGTGGGGAAGA 
5’ GGAGGGTGGGGGGTGAATTT
Table 2.8: Cycle parameters for PCR
Stage Temperature Time Gycles
1 94°G 2 mins 1
2 94*^ G 30 se cs 35
60°G 30 se c s
72°G 2 mins
3 72°G 10 mins 1
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The required PCR product was purified from contaminating genomic DNA 
and unincoi-porated primers using the QIAquick Gel Extraction kit (Qiagen). The 
PCR fragment was excised from a 1 % agarose gel (section 2.4.1) and solubilized in 
buffer before binding to a silica-gel membrane where impurities were washed away. 
The manufacturer’s protocol was followed.
To further purify the PCR products, the DNA fragments were 
phenohchloroform extracted and ethanol precipitated, as described in section 2.4.2. 
The pellet was resuspended in 50 pi H2O before DNA concentration was determined 
spectrophometrically, using the GeneQuant II RNA/DNA Calculator (Amersham 
Biosciences).
2.4.1.4.2 ^^ P Labelling of DNA probe
The PCR fragments were labelled with ^^ P by random priming. 50 ng of each 
DNA template was denatured by heating at 95”C for 5 minutes, followed by snap 
cooling on ice for 2 minutes. Denatured DNA template was added to Ready-To-Go 
DNA labelling beads (-dCTP) (Amersham Biosciences), along with 50 pCi 
[a-^^P] dCTP (3000 Ci/mmol; Amersham Biosciences) and water to 50 pi, and 
incubated at 37°C for 1 hour. To remove unincorporated nucleotides, the probe was 
purified using ProbeQuant^^ G-50 Micro Columns (Amersham Biosciences) 
according to the manufacturer’s protocol. Probes synthesised in this manner show a 
specific activity of >1 x 10^  dpm/pg. Before use, the probe was denatured at 95°C for 
5 minutes, followed by 2 minutes on ice.
2.4.1.5 Hybridisation
Nylon membranes, prepared as described in section 2.3.3, were rinsed briefly 
in water, then in pre-hybridisation buffer (50 % formamide, 6x SSC, 5x Denhardt’s 
solution, 0.5 % SDS, 400 pg/ml denatured herring sperm DNA (Promega)). 
Denhai'dt’s solution is prepared as a lOOx stock containing 20 mg/ml each of bovine 
semm albumin, Ficoli™ 40 and polyvinylpyrrolidone. The membrane was rolled 
cai'efully, nucleic acid side inwards, and placed in a hybridisation bottle. 10 ml of 
pre-hybridisation buffer was added and the blot carefully unrolled inside the bottle. 
The membrane was pre-hybridised, with rotation, at 42°C overnight in a Hybaid 
hybridisation oven. Pre-hybridisation buffer was removed and 10 ml hybridisation
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buffer added to bottle (pre-hybridisation buffer containing the denatured ^^P-labelled 
probe). The hybridisation proceeded overnight at 42°C with rotation.
Membranes were washed, at 65®C with vigorous shaking, for 2 x 5  mins with 
wash buffer 1 (2x SSC, 0.1 % SDS), 2 x 10 mins with wash buffer 2 (Ix SSC, 0.1 % 
SDS) and 4 x 5  mins with wash buffer 3 (O.lx SSC, 0.1 % SDS). Membranes were 
sealed in plastic bags before auto-radiography.
2.4.1.6 Auto-radiography
To visualise bands, Kodak X-Omat film was exposed to the blot overnight 
before developing. The film was developed in Kodak D-19 developer and fixed in 
Kodak Rapid Fixer before being photographed using the GeneGenius Bio Imaging 
System, controlled by GeneSnap version 4.01 softwaie (Syngene, Cambridge, UK). 
Bands were quantified by densitometry using GeneTools version 3.00.22 (Syngene) 
and analysed for significant differences with an unpaired t-test (GraphPad Prism, 
version 4.0).
2.4.2 Treatment of cells with a histone deacetylase inhibitor
To determine the effect of a chromatin-opening agent on expression of the 
CYP3As and nucleai* receptors, HuH7 cells (passage 16) were seeded on 6-well 
plates (Becton Dickinson) at a density of 250,000 cells/well. 24 hours post-plating, 
cells were pre-treated for 1 hour with either 0.1 % DMSO or 250 nM trichostatin A 
(TSA), a histone deacetylase inhibitor. Cells pre-treated with vehicle were then 
incubated for a further 24 or 48 hours with 0.1 % DMSO, and TSA pre-treated cells 
were exposed to either 250 nM TSA or 250 nM TSA +10 pM rifampicin, for 24 or 
48 hours. Following dosing for the appropriate period, total RNA was extracted and 
mRNA expression levels determined as described in sections 2.1.3-2.1.6. Results 
were analysed for statistical significance with a one factor ANOVA with Bonferroni 
all means post hoc test (GraphPad Prism, version 4.0).
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2.5 General Techniques
2.5.1 Agarose gel electrophoresis
Agai’ose gels were prepared by melting SeaKem® LE agarose in TAE buffer 
(0.04 M Tris-Acetate, 0.01 M EDTA). 200 ng/ml ethidium bromide dye was also 
added to the gel to allow detection of DNA. Samples were mixed with Va volume 
Orange G loading dye and loaded into the wells, once the gel was set. The gel was 
electrophoresed in TAE buffer at 15 V/cm, until the Orange G dye reached the end of 
the gel, then visualised under ultraviolet light and photographed using the 
GeneGenius Bio Imaging System, controlled by GeneSnap version 4.01 software 
(Syngene).
2.5.2 Phenol:chloroform extraction and ethanol precipitation of DNA
Samples were mixed with 1 volume of 1:1 phenol:chloroform by thorough 
voitexing, and centrifuged at 12,000 x g for 5 minutes. The upper aqueous layer was 
removed cai’efully and transfened to a fresh tube. Vio volume 3 M sodium acetate 
and 2 volumes of ice-cold absolute ethanol were added and mixed thoroughly before 
incubation at -20°C for at least 30 minutes. Samples were centrifuged for 15 mins at 
12,000 X g and the supernatant removed, being careful not to disturb the DNA pellet. 
The pellet was washed with 70 % ethanol and centrifuged at 12,000 x g for 5 mins. 
The 70 % ethanol was removed and the DNA pellet air-dried before resuspension in 
an appropriate volume of HgO or TE buffer.
55
3 Results of cell characterisation at the mRNA level
Host cell differences in responses to xenobiotics in cell lines of the same 
species have previously been observed (Swales et al., 2003). This variation in 
response was examined by comparing the receptor complement of the cells by 
semi-quantitative RT-PCR and determined the importance of relative receptor 
abundance, rather than absolute expression levels, to these responses. To examine the 
relationship between human liver, primaiy human hepatocytes and a human 
hepatoma cell line (HuH7), the mRNA levels of the human CYP3As, and a number 
of nuclear receptors involved in CYP3A regulation, were determined by quantitative 
PCR. The receptor complements of the cells were then compaied using multi-vaiiate 
statistical methods.
3.1 Variation in mRNA expression levels in human adult liver total 
RNA from different sources
Adult human liver total RNA was purchased from three different sources and 
used to determine mRNA expression levels of several factors, as described in section
2.2.6. It was discovered that total RNA from Ambion and Clontech gave very low 
signals for expression of all factors measured, examples of which aie shown in Fig 
3.1. The factors shown in Fig 3.1 were chosen to illustrate the differences between 
total RNA from the different sources as they represent examples of the CYP3As, 
ligand-activated receptors and general transcription factors. Expression levels of 
CYP3A4, CAR and C/EBPa detected in total RNA from Ambion and Clontech were 
significantly lower compaied to levels detected in the total RNAs from Stratagene.
To further investigate these differences, the quality of the RNA was assessed 
by determining mRNA expression levels of GAPDH, a commonly used 
housekeeping gene; levels of this gene should remain constant between samples if 
the integrity of the RNA is maintained. Fig 3.2 shows mRNA expression levels of 
GAPDH determined using cDNA synthesised from the adult human liver total RNA,
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Fig 3.1: Basal mRNA expression levels of CYP3A4, CAR and C/EBPa for adult 
human liver total RNA purchased from different sources.
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Values are given as mean transcript number per nanogram of input total RNA. Error bars represent the 
standard error of the mean for quadruplicate determinations. Significance of mRNA differences 
between sources were calculated by a one way ANOVA with Bonferroni all means post hoc test. 
**p<0.01, ***p<0.001 compared to Stratagene (male), ##p<0.01, ###p<0.001 compared to Stratagene 
(female).
Fig 3.2: Basal mRNA expression levels of GAPDH in adult human liver total 
RNA purchased from different sources.
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Values are given as mean transcript number per nanogram of input total RNA. Error bars 
represent the standard error of the mean for quadruplicate determinations. Significance of mRNA 
differences between sources were calculated by a one way ANOVA with Bonferroni all means post 
hoc test. *p<0.05, ***p<0.001 compared to Stratagene (male), #p<0.05, ###p<0.001 compared to 
Stratagene (female).
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purchased from the three different suppliers. GAPDH signal was detected at 
significantly lower levels in total RNA purchased from Clontech and Ambion 
compared to total RNAs purchased from Stratagene, indicating a loss of RNA 
integrity. It was decided to include only measurements taken from the two batches of 
RNA purchased from Stratagene in the results discussed in this chapter.
3.2 Basal mRNA expression of human CYP3As
Total RNA from adult and foetal human liver, untreated HuH7 cells and 
untreated primary human hepatocytes, 24 (donors 1 and 2) and 72 hours (donor 3) 
post-plating, were used to synthesise cDNA and perform quantitative PCR, as 
described in section 2.2, to determine basal expression levels of the human 
cytochrome P450 3As. Absolute mRNA levels of CYPs 3A4, 5, 7 and 43, expressed 
as transcripts detected per nanogram of total RNA, are shown in Fig 3.3.
CYP3A4 was the major CYP3A transcript expressed in adult liver (p<0.001) 
and primary human hepatocytes (24 hour) (p<0.01), with CYP3A7 being the major 
CYP3A in foetal liver (p<0.001). In primaiy human hepatocytes (72 hours), 
CYP3A5 was the highest expressed CYP3A (p<0.001), and in HuH7 cells, CYP3A5 
and CYP3A7 were both expressed at higher levels than the other CYP3A family 
members (p<0.001). In primaiy human hepatocytes, there was a significant decrease 
in expression of CYP3A4 from 24 to 72 hours post-plating, and significantly lower 
CYP3A5 (both 24 and 72 hours) and CYP3A7 (72 hours) expression than seen in 
human adult liver. In HuH7 cells, expression of all CYP3As, except CYP3A43, was 
significantly lower than in adult liver.
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Fig 3.3: Absolute basal expression of human CYP3As.
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CYP3A4
CYP3A5
CYP3A7
CYP3A43
Adult Liver Foetal Liver 24 Hour 
Primary
72 Hour 
Primary
Hepatocytes Hepatocytes
Hu H7
CYP3A4 CYP3A5 CYP3A7 CYP3A43
Adult Liver 4432.5 ± 354.6 2317.8 ±226.0 1195.4 ± 175.7 23.2 ± 5.6
Foetal Liver 20.4 ± 4.0 *** 827.8 ±168.1** 34762 ± 1369 *** 40.4 ± 7.9
24 hour Primary 
Hepatocytes
5902.2 ± 762.8 ### 893.7 ± 406.8 * 139.0 ±22.5 ### 28.9 ± 9.8
72 hour Primary 
Hepatocytes
55.7 ± 5.6 *** §§§ 434.5 ± 49.9 *** 28.5 ± 2.5 * ### 0.6 ±0.1 #
HuH7 3.3 ± 0.5 *•* §§§ 26.3 ± 3.3 *** 24.0 ± 4.7 * ### 4.3 ± 0.7 #
Values are expressed as mean transcript number per nanogram of input total RNA. Error bars 
represent standard error of the mean for quadruplicate determinations of n=2 (adult liver) and n=l 
(foetal liver), triplicate determinations of n=2 (24 hour primary hepatocytes), nine determinations of 
n=l (72 hour primary hepatocytes) and single determinations of n=12 (HuH7; data are mean of two 
independent experiments of n=6). Significance of CYP3A mRNA differences between sources were 
calculated by a one way ANOVA with Bonferroni all means post hoc test. *p<0.05, **p<0.01, 
***p<0.(X)l compared to adult liver, #p<0.05, ###p<0.(X)l compared to foetal liver, §§§ p<0.001 
compared to 24 hour primary hepatocytes.
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3.3 Basal mRNA expression of ligand-activated receptors
Total RNA from adult and foetal human liver, untreated HuH7 cells and 
untreated primaiy human hepatocytes (both 24 and 72 hours post-plating) were used 
to synthesise cDNA and perform quantitative PCR to determine basal expression 
levels of the ligand-activated receptors, as described in section 2.2. Absolute mRNA 
expression levels, expressed as transcripts detected per nanogram of total RNA, of 
PXR, GR and CAR are shown in Fig 3.4.
CAR was the major ligand-activated receptor in adult liver (p<0.001), foetal 
liver (p<0.01), primary human hepatocytes (72 hour) (p<0.001) and HuH7 cells 
(p<0.001), whereas in 24 hour primary hepatocytes both PXR and CAR were 
expressed at significantly higher levels than GR (p<0.05). In human liver, PXR was 
expressed at similai’ levels in both adult and foetal liver, but GR and CAR had 
significantly higher expression in foetal liver compared to adult liver. In primary 
human hepatocytes (24 hours), there was a significant increase (~5.5-fold) in PXR 
expression compaied to adult liver, but no difference in expression of GR and CAR. 
After a further 48 hours in culture, levels of both PXR and CAR were significantly 
lower than in adult liver. In HuH7 cells, levels of all the ligand-activated receptors 
were significantly lower than those seen in foetal liver, and both PXR and CAR 
showed lower expression compaied to adult liver.
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Fig 3.4: Absolute basal expression of human ligand-activated receptors.
PXR
GR
CAR
2100-1
1800-<zÛC 1500-BoO) 1200-c
B 9 0 0 -g.b(Ac 6 0 0 -21- 3 0 0 - j
Adult Liver Foetal Liver 24 Hour 72 Hour
Primary Primary
Hepatocytes Hepatocytes
HuH7
PXR GR CAR
Adult Liver 97.9 ± 20.9 12.8 ±4.1 469.4 ± 24.3
Foetal Liver 89.1 ± 12.3 426.2 ±71.8 *** 1745.6 ±304.8***
24 hour Primary 
Hepatocytes
576.3 ± 89.4 *** ### 62.5 ± 7.5 ### 477.3 ± 43.3 ###
72 hour Primary 
Hepatocytes
15.5 ±2.1 ***#§§§ 29.7 ± 4.3 ### 84.8 ± 8.9 ** ###
HuH7 5.0 ±1.5 ## §§§ 23.1 ±4.9### 52.7 ± 7.4 *** ###
Values are expressed as mean transcript number per nanogram of input total RNA. Error bars 
represent standard error of the mean for quadruplicate determinations of n=2 (adult liver) and n=l 
(foetal liver), triplicate determinations of n=2 (24 hour primary hepatocytes), nine determinations of 
n=l (72 hour primary hepatocytes) and single determinations of n=12 (HuH7; data are mean of two 
independent experiments of n=6). Significance of mRNA differences between sources were calculated 
by a one way ANOVA with Bonferroni all means post hoc test. **p<0.01, ***p<0.001 compared to 
adult liver, #p<0.05, ##p<0.01, ###p<0.001 compared to foetal liver, §§§ p<0.(X)l compared to 24 
hour primary hepatocytes.
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3.4 Basai mRNA expression of retinoid X receptors
Total RNA from adult and foetal human liver, untreated HuH7 cells and 
untreated primary human hepatocytes, both 24 and 72 hours post-plating, were used 
to synthesise cDNA and perform quantitative PCR to determine basal expression 
levels of the retinoid X receptors, as described in section 2.2. Absolute mRNA 
expression levels, expressed as transcripts detected per nanogram of total RNA, of 
RXRa, p, and y are shown in Fig 3.5. For all sources of total RNA, the expression of 
the RXRs followed the same pattern, with the mRNA expression profile being 
RXRa>RXRp>RXRy.
Fig 3.5: Absolute basal mRNA expression of the retinoid X receptors.
lOOOOn
1000 -
CEI^ 100 -O)I
%c(0
RXRa
Adult Liver Foetal 24 Hour 72 Hour 
Liver Primary Primary
Hepatocytes Hepatocytes
HuH7
RXRa RXRp RXRy
Adult Liver 458.3 ± 54.6 80.0 ± 14.0 10.7 ±3.5
Foetal Liver 507.7 ±112.3 404.1 ±70.3 *** 26.9 ± 2.5 ***
24 hour Primary 
Hepatocytes
853.6 ±315.3 63.1 ± 17.4### 10.5 ±0.2 ###
72 hour Primary 
Hepatocytes
102.3 ± 10 §§ 28.5 ± 2.9 ### 0.8 ±0.1 ” ###§§
HuH7 471.4 ±82.5 77.0 ± 15.9 ### 0.2 ±0.1 ***###§§
Values are expressed as mean transcript number per nanogram of input total RNA. Error bars 
represent standard error of the mean for quadruplicate determinations of n=2 (adult liver) and n=l 
(foetal liver), triplicate determinations of n=2 (24 hour primary hepatocytes), nine determinations of 
n=l (72 hour primary hepatocytes) and single determinations of n=12 (HuH7; data are mean of two 
independent experiments of n=6). Significance of CYP3A mRNA differences between sources were 
calculated by a one way ANOVA with Bonferroni all means post hoc test. **p<0.01, ***p<0.001 
compared to adult liver, ###p<0.001 compared to foetal liver, §§ p<0.01 compared to 24 hour primary 
hepatocytes.
6 2
3.5 Basal mRNA expression of general transcription factors
Total RNA from adult and foetal human liver, untreated HuH7 cells and 
untreated primary human hepatocytes, both 24 and 72 hours post-plating, were used 
to synthesise cDNA and perform quantitative PCR to determine basal expression 
levels of several general transcription factors, as described in section 2.2. Absolute 
mRNA expression levels, expressed as transcripts detected per nanogram of total 
RNA, of COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 are shown in Fig 3.6.
COUP-TFl was expressed at significantly lower levels in adult liver and 
primary hepatocytes (at both time points) compared to foetal liver but levels 
observed in HuH7 cells were similai* to those seen in the adult livers. SP-1 showed 
high expression in HuH7 cells compaied to adult liver and primary hepatocytes. The 
liver-enriched transcription factors were expressed at high levels in all sources, 
including HuH7 cells.
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Fig 3.6: Absolute basal mRNA expression of several general transcription 
factors.
500 n C0UP-TF1
HNF3a
HNF4a
C/EBPa
e  200
Adult Liver Foetal Liver 24 Hour 72 Hour
Primary Primary
Hepatocytes Hepatoc^es
HuH7
COUP-TFl HNF3a HNF4a C/EBPa SP-1
Adult Liver 186.2 ±33.6 60.8 ± 23.5 244.8 ±142.6 176.8 ±11.6 3.6 ± 0.6
Foetal Liver 440.2 ±25.1* 187.1 ± 19.6 276.1 ±54.7 69.3 ± 16.6 ** 50.0 ± 14.9
24 hour Primary 
Hepatocytes
1.0 ±0.1 ## 107.0 ±73.0 56.1 ± 19.2 27.3 ± 24.8 *** 6.3 ± 1.1
72 hour Primary 
Hepatocytes
3.9 ± 0.5 * ### 73.6 ± 7.9 24.9 ± 4.8 7.6 ±1.0 *** 8.9 ±2.1
HuH7 267.7 ±50.1 t t t 343.0 ±51.4
***§§§ttt
123.1 ±30.0 114.0 ± 17.6 
*§§tt
74.4 ±19.2 
**§t
Values are expressed as mean transcript number per nanogram of input total RNA. Error bars 
represent standard error of the mean for quadruplicate determinations of n=2 (adult liver) and n=l 
(foetal liver), triplicate determinations of n=2 (24 hour primary hepatocytes), nine determinations of 
n=l (72 hour primary hepatocytes) and single determinations of n=12 (HuH7; data are mean of two 
independent experiments of n=6). Significance of COUP-TFl mRNA differences between sources 
were calculated by a one way ANOVA with Bonferroni all means post hoc test. *p<0.05, **p<0.01, 
***p<0.001 compared to adult liver, ##p<0.01, ###p<0.001 compared to foetal liver, §p<0.05, 
§§p<0.01, §§§p<0.(X)l compared to 24 hour primary hepatocytes tp< 0 .0 1, ttp< 0 .01 , f f f  p<0.(X)l 
compared to 72 hour primary hepatocytes.
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3.6 Multi-Variate analysis of nuclear receptor mRNA levels
3.6.1 Principal component analysis of nuclear receptor mRNA levels
Principal component analysis (PCA) is a statistical technique for highlighting 
patterns in lai'ge datasets, and expressing the data in such a way as to highlight the 
major vaiiables. In addition, PCA can be represented graphically, allowing 
relationships between components to be drawn by visual comparison. Accordingly, 
PCA was used to compare absolute receptor mRNA levels between human liver, 
primary human hepatocytes and HuH7 cells and to indicate any similarities.
Fig 3.7 shows the scatter plot drawn from the PCA of absolute receptor 
mRNA expression (PXR, GR, CAR, RXR a, RXRp, COUP-TFl, HNF3a, HNF4a, 
C/EBPa, SP-1). RXRy mRNA levels were excluded from the PCA because 
expression levels were at the limit of detection for quantitative PCR analysis, and so 
may have prejudiced the results if included. As the scatter plot shows, there was little 
clustering evident although HuH7 cells, adult liver and 72 hour primary hepatocytes 
did show some similarity to each other. Both foetal liver and 24 hour primary 
hepatocytes showed little similarity to the other cells with respect to their receptor 
profiles.
Fig 3.7: Scatter plot of principal component analysis case scores for absolute 
receptor mRNA expression levels.
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PCA variable loadings for the receptors, and percentage variabilities, are 
listed in Table 3.1. The major variables were taken as receptors with PCA variable 
loadings of greater than 0.300; CAR was the receptor that determined variability 
between the cell types, with percentage variance of 53.0 %.
Table 3.1: Variations in basal absolute receptor mRNA expression levels.
Receptor PCA Variable 
Loadings
Percentage
Variability
COUP-TF1 0.211 12.1 %
RXRa 0.099 5.7 %
RXRp 0.168 9.6 %
HNF4a 0.112 6.4 %
CAR 0.923 53.0 %
PXR 0.000 0%
GR 0.229 13.1 %
HNF3a 0.000 0%
C/EBPa 0.000 0%
SP-1 0.000 0%
PCA variable loadings, representing 76.7 % of total variability, were calculated by principal 
component analysis (MVSP software, v3.1).
Table 3.2 lists the relative receptor ratios, determined by Latin Square 
analysis, and Fig 3.8 shows the scatter plot drawn from the PCA of relative receptor 
ratios. RXRy mRNA levels were excluded from the PCA because expression levels 
were at the limit of detection for quantitative PCR analysis, and so may have 
prejudiced the results if included.
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Table 3.2: Relative nuclear receptor ratios used for PCA and cluster analysis.
Adult Liver Foetal Liver HuH7 Primary Human 
Hepatocytes 
(24 hour)
Primary Human 
Hepatocytes
COUP-TF1:RXRa 0.406 0.867 0.570 0.001 0.038
COUP-TF1:RXRp 2.328 1.089 3.476 0.016 0.137
C0UP-TF1:HNF4a 0.760 1.594 2.175 0.018 0.157
C0UP-TF1;CAR 0.396 0.252 5.0833 0.002 0.046
COUP-TF1:PXR 1.902 4.941 53.448 0.002 0.252
C0UP-TF1;GR 14.493 1.033 11.573 0.016 0.131
COUP-TF1:HNF3a 3.062 2.352 0.781 0.009 0.053
COUP-TFl :C/EBPa 1.053 6.350 2.349 0.037 0.515
C0UP-TF1:SP-1 51.163 8.800 3.599 0.157 0.438
RXRa:RXRp 5.730 1.256 6.122 13.522 3.584
RXRa:HNF4a 1.872 1.839 3.830 15.228 4.108
RXRa:GAR 0.976 0.291 8.951 1.788 1.206
RXRa;PXR 4.681 5.699 94.119 1.481 6.600
RXRa:GR 35.669 1.191 20.379 13.660 3.444
RXRa:HNF3a 7.536 2.713 1.374 7.976 1.391
RXRa:C/EBPa 2.592 7.324 4.136 31.252 13.500
RXRa:SP-1 125.912 10.150 6.337 134.642 11.482
RXRp:HNF4a 0.327 1.464 0.626 1.126 1.146
RXRprCAR 0.170 0.232 1.462 0.132 0.337
RXRp;PXR 0.817 4.536 15.374 0.110 1.842
RXRp:GR 6.225 0.948 3.329 1.010 0.961
RXRp:HNF3a 1.315 2.159 0.225 0.590 0.388
RXRp:C/EBPa 0.452 5.830 0.676 2.311 3.767
RXRp:SP-1 21.975 8.079 1.035 9.958 3.204
HNF4a:CAR 0.521 0.158 2.337 0.117 0.294
HNF4a:PXR 2.500 3.099 24.574 0.097 1.606
HNF4a:GR 19.052 0.648 5.321 0.897 0.838
HNF4a;HNF3a 4.025 1.475 0.359 0.524 0.338
HNF4a:C/EBPa 1.384 3.983 1.080 2.052 3.286
HNF4a:SP-1 67.253 5.520 1.655 8.842 2.795
CAR:PXR 4.795 19.594 10.514 0.828 5.471
CAR:GR 36.535 4.096 2.277 7.638 2.855
CAR:HNF3a 7.719 9.328 0.154 4.460 1.153
CAR;C/EBPa 2.655 25.182 0.462 17.474 11.191
GAR:SP-1 128.969 34.899 0.708 75.284 9.518
PXR:GR 7.620 0.209 0.217 9.222 0.522
PXR;HNF3a 1.610 0.476 0.015 5.384 0.211
PXR:G/EBPa 0.554 1.285 0.044 21.099 2.045
PXR;SP-1 26.899 1.781 0.067 90.899 1.740
GR:HNF3a 0.211 2.277 0.067 0.584 0.404
GR:G/EBPa 0.073 6.148 0.203 2.288 3.919
GR:SP-1 3.530 8.521 0.311 9.856 3.333
HNF3a:G/EBPa 0.344 2.700 3.009 3.918 9.708
HNF3a:SP-1 16.709 3.741 4.610 16.882 8.257
G/EBPa:SP-1 48.579 1.386 1.532 4.308 0.851
Ratios calculated from mean transcript number per nanogram total RNA
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Fig 3.8: Scatter plot of principal component analysis case scores for relative 
receptor expression ratios.
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Foetal liver and 72 hours post-plating primary hepatocytes were clustered 
together, with HuH7 also showing some similarity to these cells. Both adult liver and 
24 hours post-plating primary hepatocytes showed little similarity to each other, and 
the other cell types, with respect to their relative receptor expression ratios.
PCA variable loadings for the relative receptor ratios, and percentage 
vai'iability, aie listed in Table 3.3. Ratios of SP-1 to RXRP and CAR were the major 
variables, with percentage vai'iability of 24.7 and 19.5 % respectively.
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Table 3.3: Variations in basal relative receptor expression ratios.
PCA Variable 
Loadings
Percentage
Variability
COUP-TF1:RXRa 0.000 0%
C0UP-TF1:RXRp 0.000 0%
COUP-TF1:HNF4a 0.000 0%
C0UP-TF1;CAR 0.000 0%
COUP-TF1:PXR 0.000 0%
COUP-TF1:GR 0.014 0.5 %
COUP-TFl :HNF3a 0.005 0.2 %
C0UP-TF1:C/EBPa 0.000 0%
COUP-TF1:SP-1 0.141 5.3 %
RXRa:RXRp 0.025 0.9 %
RXRa:HNF4a 0.022 0.8 %
RXRa:CAR 0.000 0%
RXRa:PXR 0.000 0%
RXRa:GR 0.084 3.2 %
RXRa:HNF3a 0.033 1.2%
RXRa:C/EBPa 0.038 1.4%
RXRa;SP-1 0.656 24.7 %
RXRp:HNF4a 0.000 0%
RXR&CAR 0.000 0%
RXRp:PXR 0.000 0%
RXRp:GR 0.011 0.4 %
RXRp:HNF3a 0.001 0%
RXRp:C/EBPa 0.000 0%
RXRp;SP-1 0.074 2.8 %
HNF4a:CAR 0.000 0%
HNF4a:PXR 0.000 0%
HNF4a:GR 0.046 1.7%
HNF4a;HNF3a 0.010 0.4 %
HNF4a:C/EBPa 0.000 0%
HNF4a:SP-1 0.217 8.2 %
CAR:PXR 0.000 0%
CAR;GR 0.117 4.4 %
CAR:HNF3a 0.021 0.8 %
CAR:C/EBPa 0.000 0%
CAR:SP-1 0.518 19.5%
PXR;GR 0.043 1.6%
PXR:HNF3a 0.016 0.6 %
PXR:C/EBPa 0.044 1.7%
PXR;SP-1 0.286 10.8%
GR;HNF3a 0.000 0%
GR:C/EBPa 0.000 0%
GR:SP-1 0.01.7 0.6 %
HNF3a:C/EBPa 0.000 0%
HNF3a-.SP-1 0.062 2.3%
C/EBPa:SP-1 0.156 5.9 %
PCA variable loadings, representing 69.5 % of total variability, were calculated by principal 
component analysis (MVSP software, v3.1).
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3.6.2 Hierarchical cluster analysis of nuclear receptor niRNA levels
Cluster analysis is a statistical technique that uses the data to determine 
similaiities between objects, and clusters these objects into discrete groups based on 
their similai’ity. The results aie displayed as a dendrogram that shows the most 
similai' objects linked most closely together. Cluster analysis was used to analyse 
both receptor mRNA levels and receptor ratios between liver, primaiy hepatocytes 
and HuH7 cells.
Fig 3.9 shows the dendrogram drawn from cluster analysis of absolute 
receptor mRNA expression levels. RXRy mRNA levels were excluded from the 
analysis because expression levels were at the limit of detection for quantitative PCR 
analysis, and so may have prejudiced the results if included. The scale on the 
dendrogram represents the Speaiman Correlation Coefficient, a measure of the 
similai'ity between the objects. Where the objects ‘fuse’, the value gives an indication 
of their similai'ity; a value of 1 indicates perfect correlation between the objects, 0 
indicates complete lack of correlation and -1 perfect inverse correlation.
Fig 3.9: Dendrogram drawn from cluster analysis of absolute receptor 
expression levels.
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The cluster analysis of absolute receptor expression levels shows that adult 
and foetal liver clustered together, with a correlation coefficient of 0.636. HuH7 cells 
also clustered with this group, but with a low correlation coefficient (0.089), 
indicating almost no similai'ity between these cells and adult or foetal liver. Primaiy 
human hepatocytes after 24 and 72 hours post-plating clustered together with a 
correlation coefficient of 0.794, indicating a high degree of similai'ity. All five 
cell-types clustered together with a correlation coefficient of -0.060.
Fig 3.10 shows the dendrogram drawn from cluster analysis of relative 
receptor ratios, values of which are listed in Table 3.2. RXRy mRNA levels were 
excluded from the analysis because expression levels were at the limit of detection 
for quantitative PCR analysis, and so may have prejudiced the results if included.
The cluster analysis of relative receptor expression ratios shows that adult and 
foetal liver clustered together, with a conelation coefficient of 0.384. Primaiy human 
hepatocytes after 24 and 72 hours post-plating clustered together with a correlation 
coefficient of 0.795, indicating a high degree of similarity. These two groups 
clustered together with a low correlation coefficient of 0.190. HuH7 cells did not 
show similarity to any of the other cell types with respect to receptor ratios, as 
represented by the vëry low correlation coefficient of -0.047.
Fig 3.10: Dendrogram drawn from cluster analysis of relative receptor 
expression ratios.
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3.6.3 Principal component analysis of nuclear receptor mRNA levels, 
excluding SP-1
SP-1 has been included in the previous analyses; however, it is a ubiquitously 
expressed transcription factor unlikely to play a key regulatory role in basal CYP3A 
expression. Indeed, evidence is available from previous work in this laboratory that 
SP-1 does not play a role in the basal expression of CYP3A4 (Bombail et al., 2003). 
Therefore, we repeated the PCA excluding SP-1 expression levels from the analysis. 
Principal component analysis of absolute receptor expression levels excluding SP-1 
did not alter the PCA scatter plot or variable loadings for the receptors previously 
shown in Fig 3.7 and Table 3.1. CAR remained the major vaiiable, with percentage 
variance of 53.0 %.
The scatter plot drawn from principal component analysis of relative receptor 
expression ratios, excluding SP-1 ratios, is shown in Fig 3.11. Foetal liver and 
primary hepatocytes (both 24 and 72 hours) were clustered closely together, 
indicating similai'ity in relative receptor abundance, but adult liver and HuH7 cells 
were not clustered, showing little similai'ity to each other or the other cell types.
Fig 3.11: Scatter plot of principal component analysis case scores for relative 
receptor expression ratios, excluding SP-1.
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PCA vaiiable loadings for the receptor ratios, and percentage variabilities, 
excluding SP-1 aie listed in Table 3.4. The major variables, according to percentage 
variances, were RXRa:PXR and COUP-TFl:PXR with 40.7 % and 23.5 % 
variability respectively.
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Table 3.4: Variations in basal relative receptor expression ratios, excluding 
SP-1.
PCA Variable 
Loadings Percentage Variability
COUP-TF1:RXRa 0.003 0.2 %
C0UP-TF1:RXRp 0.024 1.2%
C0UP-TF1:HNF4a 0.015 0.8 %
COUP-TF1:CAR 0.044 2.2 %
C0UP-TF1:PXR 0.468 23.5 %
C0UP-TF1:GR 0.074 3.7 %
C0UP-TF1;HNF3a 0.000 0%
COUP-TF1:C/EBPa 0.005 0.3 %
RXRa:RXRp 0.000 0%
RXRa:HNF4a 0.000 0%
RXRa:CAR 0.070 3.5 %
RXRa:PXR 0.810 40.7 %
RXRa:GR 0.064 3.2 %
RXRa:HNF3a 0.000 0%
RXRa;C/EBPa 0.000 0%
RXRp:HNF4a 0.000 0%
RXRp:CAR 0.011 0.6 %
RXRp:PXR 0.124 6.2 %
RXRp:GR 0.011 0.6 %
RXRp:HNF3a 0.000 0%
RXRp:C/EBPa 0.000 0%
HNF4a:CAR 0.019 1.0 %
HNF4a-.PXR 0.207 10.4%
HNF4a:GR 0.006 0.3 %
HNF4a:HNF3a 0.000 0%
HNF4a:C/EBPa 0.000 0%
CAR:PXR 0.033 1.7%
GAR:GR 0.000 0%
CAR;HNF3a 0.000 0%
CAR:C/EBPa 0.000 0%
PXR:GR 0.000 0%
PXR:HNF3a 0.000 0%
PXR:C/EBPa 0.000 0%
GR:HNF3a 0.000 0%
GR:C/EBPa 0.000 0%
HNF3a:C/EBPa 0.000 0%
PCA vaiiable loadings, representing 72.8 % of total variability were calculated by 
principal component analysis (MVSP software, v3.1).
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3.6.4 Hierarchical cluster analysis of nuclear receptor mRNA levels, excluding
SP-1
SP-1 was included in the previous cluster analyses; however, it is a 
ubiquitously expressed transcription factor unlikely to play a key regulatory role in 
basal CYP3A expression, hideed, evidence is available from previous work in this 
laboratory that SP-1 does not play a role in the basal expression of CYP3A4 
(Bombail et al., 2003). Therefore, we repeated the cluster analysis, excluding SP-1 
expression levels from the analysis. Cluster analysis of absolute receptor expression 
levels excluding SP-1 did not alter the grouping pattern or correlation coefficients 
from the dendrogram previously shown in Fig 3.9.
The dendrogram drawn from cluster analysis of relative receptor expression 
ratios, excluding SP-1 ratios, is shown in Fig 3.12. A high degree of similai'ity was 
again seen between the two groups of primary human hepatocytes, with a correlation 
coefficient of 0.751. Foetal liver also clustered with the primary human hepatocytes, 
although with much less similai'ity (Spearman coefficient of 0.204). HuH7 cells and 
adult liver clustered together, with a correlation coefficient of 0.303, and this group 
clustered with the remaining three cell-types with a Speaiman coefficient of -0.169.
Fig 3.12: Dendrogram drawn from cluster analysis of relative receptor ratios, 
excluding SP-1.
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3.7 Discussion
3.7.1 Methodology
Quantitative PCR was selected to study the basal expression of cytochrome 
P450 3As and nuclear receptors because it allowed us flexibility to look at a lai'ge 
number of genes in a large number of samples, while achieving the high specificity 
required to distinguish between closely related mRNA species (Freeman et al., 
1999). Quantitative RT-PCR is more specific than semi-quantitative RT-PCR, adding 
the specificity of the probe to that of the primers. The use of an optical system in the 
sequence detector also enables the fluorescence spectra of the reactions to be 
measured continuously during PCR amplification, allowing more accurate 
quantification during the log phase of PCR product accumulation. The technique is 
also rapid, reliable, and sensitive; the use of an external standard curve allows the 
accurate determination of mRNA transcript number, from as little as ten transcripts 
per reaction.
As with most scientific techniques, there are disadvantages, as well as 
advantages, to the use of quantitative RT-PCR. Both the instrumentation and 
reagents are expensive, and the design of the fluorogenic probes is complicated. 
However, these problems were partly eliminated in this work by the generosity of the 
DMPK depai'tment of GlaxoSmithKline.
Before RT-PCR, the total RNA extracts were quantified and DNase I-treated, 
and cDNA synthesised. These processes are likely to introduce errors into the 
analysis. The Ribogreen® RNA quantitation assay (Molecular Probes) is a sensitive 
(1000-fold more sensitive than spectrophotometry) assay to allow measurement of 
RNA concentrations. However, the fluorescent dye used in this assay is a nucleic 
acid stain and so is able to detect DNA as well as RNA in the samples. This can 
introduce inaccuracies into the experiment, as contaminating genomic DNA was not 
removed from the samples until after quantification, and therefore the RNA 
concentration measured may not be accurate. This problem can be removed by either 
incoi'porating a DNase I-treatment step into the RNA extraction protocol (RNase-free 
DNase set in conjunction with RNeasy mini kit; Qiagen) or into the Ribogreen assay 
(Ribogreen® RNA-specific quantitation kit with DNase I; Molecular Probes).
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The RNA extraction step is the source of most variability observed during 
RT-PCR, as reverse transcriptase enzymes are highly sensitive to salts and alcohol 
remaining from these extractions, therefore inter-tube and inter-experiment 
variability are common in the reverse transcription step (Freeman et al., 1999). Total 
RNA for all samples, other than for the human livers, was extracted using the same 
method and DNase I-treatment and cDNA synthesis was carried out in the same 
manner for all samples, including the human liver total RNAs; this should have 
reduced the variability in reverse transcription efficiency.
It may have improved the experimental procedure to have the multiple cDNA 
samples measured in triplicate, as this may have increased the significance of 
differential gene expression between cell types. Triplicate readings of the samples 
were not done in these experiments due to time and cost considerations. However, 
QRT-PCR has been shown to be highly reproducible, so the lack of triplicate 
readings should not affect the accuracy of the results (Yin et al., 2001). This 
reproducibility has been shown in my work, where mean basal values for HuH7 cell 
transcripts, which were the results of two independent experiments, show small 
standard errors.
For the determination of target gene expression in human liver, total RNA 
was purchased from three sepaiate sources. Unfortunately, total RNA purchased 
from Ambion and Clontech gave significantly low expression, compaied to total 
RNA from Stratagene, for all factors measured. The reason for these low signals 
appeared to be the quality of the RNA; significantly lower GAPDH mRNA was also 
detected in these samples, suggesting the integrity of the RNA was compromised. 
This may have occurred during transportation. Efficiency of cDNA synthesis may 
also have contributed to the low expression levels detected; total RNA purchased 
from Ambion was supplied in 1 niM sodium citrate pH 6.4, from Stratagene in 
0.1 mM EDTA pH 8.0 and from Clontech in nuclease-free water. The different 
buffer compositions may have altered the cDNA synthesis efficiency; however, the 
suppliers of the RNA state, in the product inserts, that the buffer components will not 
interfere with enzymatic reactions.
To claiify expression patterns in human liver, ideally at least three different 
lots of total RNA should have been used for Q-PCR for both adult and foetal liver, to
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increase the n value. Large inter-individual variations have been observed in 
expression of the CYP3A enzymes, and so a lai'ger number of samples are necessary 
to get a deal' idea of expression patterns in human liver: this must be taken into 
account when interpreting the data. This also applies to primary human hepatocytes, 
where hepatocytes from only one (72 hour) and two (24 hour) donors were used to 
determine basal tai'get gene expression. The effect of time in culture on gene 
expression in primary human hepatocytes would also be best determined using cells 
from the same donor for both time points, again because large variations in CYP3A 
expression are seen between individuals. Due to expense and lack of availability, we 
were unable to increase the number of different donors for both adult and foetal 
livers and primaiy hepatocytes in these experiments.
Two different multi-vaiiate statistical methods are used to analyse the data. 
Principal component analysis reduces the dimensionality of the data and highlights 
the major variables. PCA can also be used to produce a scatterplot, a graphical 
mapping of the data. However, the clustering provided by PCA scatter plots is based 
on only two or three dimensions. It is therefore more useful to group the objects 
using hierai'chical cluster analysis, a technique that divides the objects into discrete 
groups based on the chaiacteristics of these objects.
3.7.2 Basal mRNA expression of human CYP3As
In adult liver, the expression profile of the CYP3As is 
CYP3A4>CYP3A5>CYP3A7>CYP3A43. This confirms published data, where 
CYP3A4 is considered to be the major CYP3A in human liver (Schuetz et al., 1994). 
Expression of both CYP3A5 and CYP3A7 mRNAs were detected in the human liver 
samples we tested. Initial evidence suggested CYP3A5 was expressed in only 20 % 
of liver samples tested, and CYP3A7 was a foetal-specific CYP3A (Wrighton et al., 
1989; Komori et al., 1990). However, more recent evidence has demonstrated 
expression of CYP3A5 in over a third of adult Caucasian livers and expression of 
CYP3A7 in over 50 % of adult livers (Kuehl et al., 2001; Schuetz et al., 1994). 
Levels of CYP3A43 expression also appear to confirm previous studies, where very 
low levels of CYP3A43 have been detected in adult human liver (Gellner et al., 
2001; Westlind et al., 2001).
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In foetal liver, the CYP3A expression profile is 
CYP3A7»CYP3A5>CYP3A43>CYP3A4. Again, expression levels of these 
enzymes appeal* to confirm previous data, with CYP3A7 being the major foetal 
CYP3A and expressed at significantly higher levels than CYP3A4 (Schuetz et al., 
1994; Shimada et al., 1996). CYP3A43 is expressed at very low levels in foetal liver, 
supporting observations by other groups (Domanski et al., 2001).
In 24 hour post-plating primaiy human hepatocytes, the CYP3A expression 
profile matches that of adult liver, with CYP3A4 being the major CYP3A mRNA 
expressed. However, 72 hour post-plating, the expression of all CYP3As, except 
CYP3A43, drops significantly compared to adult liver, with CYP3A5 becoming the 
major CYP3A expressed. Expression of CYP3A4 mRNA is significantly lower 
compaied to 24 hour primaiy hepatocytes. This supports evidence from other studies, 
where expression of CYP3A4 decreases with time in culture (Silva et al., 1998; 
Bowen et al., 2000). CYP3A43 expression may not change with time in culture as it 
is already expressed at extremely low levels.
In HuH7 cells, the expression profile of the CYP3As is 
CYP3A5>CYP3A7>CYP3A4>CYP3A43. Levels of all the CYP3As, except 
CYP3A43, are significantly lower than in adult liver, with CYP3A4 levels in HuH7 
cells less than 0.1 % of those seen in adult liver. This supports previous work in this 
laboratory, where another human hepatoma cell line (HepG2) was shown to express 
over 100-fold less CYP3A4 than human liver (Swales et al., 2003). The relatively 
low expression of the CYP3As seen in HuH7 cèlls suggests a disniption to basal 
pathways of CYP3A regulation. A previous study of HepG2 cells has indicated a 
reversion to a foetal phenotype, which may in part explain the decrease in CYP3A4 
expression (Kelly and Darlington, 1989). Although expression levels aie 
significantly lower than those seen in foetal liver, CYP3A7 is expressed at 
significantly higher levels than CYP3A4 in HuH7 cells, which suggests these cells 
may also have dedifferentiated to express a foetal phenotype.
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3.7.3 Absolute basal mRNA expression levels of nuclear receptors
Absolute levels of PXR observed in 72 hour human hepatocytes and HuH7 
cells are significantly lower than those seen in both adult and foetal liver. 
Significantly lower levels of PXR have also been observed in HepG2 cells compared 
to human adult liver (Swales et al., 2003). This may in part explain the low 
expression of CYP3A4 and CYP3A7 seen in both these hepatoma cell lines, as PXR 
appeal's to be the primary regulator of both CYP3A4 and CYP3A7 gene activation 
(Bertilsson et al., 1998; Blumberg et al., 1998; Lehmann et al., 1998; Pascussi et al.,
1999). However, we have tested this hypothesis (section 5.1) and discovered no 
increase in expression of CYP3A4 or CYP3A7 when PXR levels are increased in 
HuH7 cells. The reason for low PXR expression in these human hepatoma cell lines 
is uncleai'; GR has been shown to induce expression of PXR, but there aie no 
significant changes in GR expression between adult liver and HuH7 cells (Pascussi et 
al., 2000a). HNF4a is a transcription factor also implicated in regulation of PXR; 
however no significant differences are seen in HNF4a expression between adult liver 
and HuH7 cells (Wolbold et al., 2003). Low PXR expression may therefore be due to 
lack of another regulatory protein or may also be a chromosomal effect; if the PXR 
gene promoter is surrounded by condensed chromatin, access for regulatory factors 
will be hindered resulting in low transcriptional activation. Interestingly, PXR 
expression in primaiy human hepatocytes, 24 hours post-plating, is significantly 
higher than seen in adult liver, approximately 5-fold more. A previous study has 
shown inter-individual vaiiation in expression of PXR in human liver, with 27-fold 
vai'iability in mRNA expression (Chang et al., 2003). Whereas the 5-fold higher 
expression of PXR in 24 hour primary hepatocytes, compaied to adult liver, seen in 
my work is well within the range of inter-individual variability seen in the human 
population, it cannot be discounted that such an increase is a direct result of the 
hepatocyte isolation procedure; increasing the sample number will clarify this 
change.
Expression of both GR and CAR are significantly higher in foetal compared 
to adult liver. This may indicate a role for both of these receptors during 
development. Glucocorticoids are known to play key roles in cell proliferation and 
differentiation and the elevated expression of GR mRNA in foetal liver may indicate
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that this receptor is important during foetal development (Ailhaud et al., 1994). 
Previous work has shown an increase in GR protein expression in the liver from 
15-day old foetal rats to 21-day post-natal rats (Kalimi et al., 1988). However, GR 
has also been shown to have a short half-life in foetal compaied to adult rat liver; the 
higher expression of GR mRNA in foetal liver seen in this study may be a 
compensation for the short half-life of the GR protein (Kalimi et al., 1988). No data 
on expression of CAR in foetal liver has yet been published, but expression of 
CYP2B, a gene primaiily regulated by CAR, appears at birth in rat liver (Rich and 
Boobis, 1997; Honkakoski et al., 1998). This contradiction of expression patterns for 
CYP2B and CAR may indicate the presence of other factors that suppress CYP2B 
expression in the foetus, despite the presence of high levels of CAR. Expression of 
CAR in human adult liver has also been shown to highly vaiiable between 
individuals, with 240-fold vaiiability in mRNA levels, and these CAR expression 
levels showed significant correlation with CYP2B6 mRNA levels (Chang et al., 
2003). The foetal liver analysed in my work may be from an individual with high 
expression levels of CAR; it would be interesting to determine CYP2B6 expression 
in this foetal liver. If CYP2B6 in humans is expressed in a similar manner to CYP2B 
in rats i.e. appeal's at birth, this would indicate the presence of a negative regulatory 
protein, or lack of a positive regulator, in foetal livers that is responsible for 
repressing CYP2B6 transcription. Alternatively, the high levels of CAR message 
seen in foetal liver may not be an indication of the levels of functional CAR protein 
present; this could be claiified by determining expression of CAR protein in foetal 
liver by western blotting.
The expression profile of the retinoid X receptors is RXRa>RXRp>RXRy for 
all cell types examined. This expression profile matches that previously observed in 
liver, with RXRa being the most abundant RXR and RXRy being expressed only at 
very low levels (Mangelsdorf et al., 1992). The maintenance of high mRNA 
expression of RXRa supports the evidence already available that this receptor is 
critical for the regulation of several key metabolic pathways in the liver (Wan et al.,
2000). RXRp and y may act as competitors for RXRa functionality in the regulation 
of CYP3A genes, but as expression levels and ratios of the RXRs aie similai" in all 
cells tested this is unlikely to play an important role in causing the differences 
between the cells.
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COUP-TFl is a key factor expressed during foetal development, as indicated 
by the lethality of COUP-TFl null mice (Pipaon et al., 1999). Combined with the 
high expression of COUP-TFl mRNA seen in foetal liver in both my work, and 
others (Miyajima et al., 1988), this indicates a potential role for COUP-TFl in liver 
organogenesis. Interestingly, COUP-TFl expression in primaiy hepatocytes, even at 
24 hours post-plating, is much lower than in human liver. This may be due to a 
change in phenotypic differentiation in cultured hepatocytes, although the levels of 
COUP-TFl do not reflect the foetal phenotype. SP-1 is another transcription factor 
differentially expressed during development, with higher levels observed in neonatal 
mice compaied to adults (Saffer et al., 1991). High levels of SP-1 aie observed in 
both foetal liver and HuH7 cells compared to the other cell types, providing further 
evidence for a potential role for SP-1 in foetal development and also for HuH7 cells 
having a dedifferentiated phenotype.
Multi-vaiiate statistical analysis of the receptor mRNA expression levels 
allows us to identify major vaiiables between the cell types and also cluster the cell 
types together based on their similarity. Expression levels of RXRy were omitted 
from these analyses, as RXRy was present at barely detectable levels. Analysis was 
also performed with or without inclusion of SP-1 levels, as this ubiquitous 
transcription factor is unlikely to play a key regulatory role for CYP3A genes; 
previous work in this laboratory has provided evidence to suggest it is not involved 
in basal expression of CYP3A4 (Bombail et al., 2003).
Principal component analysis of absolute receptor expression determined 
CAR as the major variable between human liver, primaiy hepatocytes and HuH7 
cells, with percentage variance of 53 %. The scatter plot drawn from the PCA case 
scores does not show any real clustering between the cell types, although foetal liver 
appeal's to be the most dissimilar to the other cell types as it is an outlying point on 
the plot. The cluster analysis dendrogram is a more useful technique for clustering 
cell types together, based on their similai'ity in nucleai' receptor mRNA expression. 
Adult and foetal livers are grouped together, indicating a high degree of similarity 
between absolute receptor expression in these tissues. HuH7 cells also cluster with 
this group; however, there is little similarity between HuH7 and human liver, as
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indicated by a conelation coefficient close to zero. 24 and 72 hours post-plating 
primary human hepatocytes aie clustered together with a high degree of similai'ity, 
but this group shows low similarity with the other cell types, again having a 
correlation coefficient of close to zero. Conclusions from this analysis aie that, with 
respect to absolute receptor expression, foetal and adult livers show high similai'ity to 
each other, as do primary human hepatocytes at 24 and 72 hours post-plating. HuH7 
cells show very little similai'ity to any other cell type. This supports previous data 
from this laboratory, where absolute receptor expression in HepG2 cells is dissimilai' 
to human liver (Swales et al., 2003).
3.7.4 Relative mRNA expression levels of nuclear receptors
There is increasing evidence of cross-talk between nucleai* receptors, with a 
number of different transcription factors being implicated in regulation of CYP3A 
genes. PXR and CAR compete for binding sites, ligands and also heterodimerisation 
partner RXRa (Xie et al., 2000b; Moore et al., 2000). GR has also been implicated in 
regulating the expression of PXR, CAR and RXRa, thus having an indirect role in 
controlling expression of CYP3A genes (Pascussi et al., 2000a; Pascussi et al., 
2000b). HNF3a, HNF4a, C/EBPa and COUP-TFl have also been implicated in 
CYP3A gene regulation, as described in sections 1.4.9- 1.4.10. It is likely that a 
combination of the above factors aie responsible for the control of CYP3A gene 
expression, therefore it may be the relative abundance of the nucleai' receptors that 
determines the CYP3A induction profile and not the individual receptor levels.
PCA of the relative receptor ratios, including SP-1, resulted in the clustering 
of foetal liver with 72 hours post-plating human hepatocytes and, to a lesser degree, 
HuH7 cells. Adult liver and 24 hours post-plating human hepatocytes showed little 
similai'ity to each other or the other cells. The hierai'chical cluster analysis did not 
provide a result that agreed with the PCA. Adult and foetal livers are clustered 
together, as are 24 and 72 hour human hepatocytes. HuH7 cells show almost no 
similarity to the other cell types, as demonstrated by the low correlation coefficient.
PCA analysis of the relative receptor ratios, excluding SP-1, resulted in the 
clustering of foetal liver with 72 hour human hepatocytes, and to a lesser degree, 24 
hour human hepatocytes. Both adult liver and HuH7 cells showed little similarity to
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the other cells. The hierai'chical cluster analysis did not provide a result that 
completely agreed with the PCA, Primary human hepatocytes, 24 and 72 hours, were 
clustered together with a high degree of similaiity. Foetal liver joined this cluster at a 
higher level, HuH7 cells were clustered together with adult liver, but with a low 
correlation coefficient.
Although SP-1 expression levels were discaided from the multi-variate 
analyses to allow us to determine the major vaiiables, the cluster analysis of receptor 
ratios including SP-1 is perhaps a better indicator of similarities between cell types 
rather than analysis without inclusion of SP-1. This is due to the nature of the cluster 
analysis, where the more information you input, the better the analysis. Of the 
dendrograms produced from the cluster analysis of receptor ratios with or without 
SP-1, more attention should perhaps be paid to the dendrogram produced when 
including SP-1 ratios, as more information was included in the analysis. This 
analysis has grouped 24 and 72 hour primaiy human hepatocytes together, indicating 
high similaiity in their transcription factor profiles. Interestingly, 72 hour 
hepatocytes did not show more similaiity to foetal rather than adult liver, which we 
would have expected as hepatocytes are thought to de-differentiate with time in 
culture. Adult and foetal livers aie grouped together, although with relatively low 
correlation. This is unsuiprising, as differences in transcription factor profiles aie 
expected with changes in level of differentiation. HuH7 cells show almost no 
similarity to any of the other cell types, with a correlation very close to zero. This 
suggests there aie major differences in the transcription factor profile of these cells 
compaied to human livers, which may impact on there ability to express CYP3As 
and respond to inducing agents.
The major variables between the cell types, as determined by PCA when SP-1 
is excluded from the analysis, were RXRa:PXR and COUP-TFl;PXR and these 
ratios may, in pait, be responsible for the low expression of CYP3A4 seen in foetal 
liver, HuH7 cells and 72 hour primaiy hepatocytes. However, RXRa is expressed 
highly in all these cell types and therefore is unlikely to be interfering with CYP3A4 
transcriptional activation, since there have been no reports, to my knowledge, of 
negative transcriptional action by RXRa. It is more likely that COUP-TFl and PXR 
expression levels are responsible for decreased expression of CYP3A4 genes in
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HuH7 cells. A possible explanation for this could be COUP-TFl competing for PXR 
binding sites or for the PXR heterodimerisation partner, RXRa. COUP-TFl may be 
competing with secondary factors e.g. HNF or C/EBPa for DNA binding sites or 
may be able to physically interact with PXR itself and prevent PXR binding to the 
DNA. Further investigation is required to establish the precise role of COUP-TFl in 
CYP3A regulation.
3.7.5 Caveats of present work
It must be remembered that the levels of expression used in these analyses are 
for mRNA, and may not accurately reflect levels of receptor protein in the cell. 
Ideally, nucleai* receptor protein levels should be measured to give an accurate 
overview of receptor complement in the cells; unfortunately, the technology 
available for protein analysis. Western Blotting, is time consuming and dependent 
upon availability of suitable high-quality specific antibodies.
Perhaps more importantly, expression levels given for adult and foetal livers, 
and also the primaiy hepatocytes aie taken from a very small sample set i.e. one or 
two donor livers for each category. This must be taken into account, as large inter­
individual variations have previously been observed for a number of the factors we 
have investigated. A larger sample set would give us a better overall view of the 
transcription profile of these cells, minimizing the interference of inter-individual 
differences on the analyses.
There are also an infinite number of factors that may be involved in 
transcriptional regulation of CYP3A. In this analysis, only mRNA levels of eleven 
transcription factors were determined. There are likely to be a number of other 
transcription factors, and also co-regulators, involved in the transcription machinery 
and it has previously been suggested that gene trans-activation may depend on the 
relative expression of co-activators and co-repressors in the cell (Shibata et al., 
1997). If the target genes examined were expanded to include co-regulators, this may 
alter the results of the multi-variate analysis and give us further clues to the identity 
of proteins critical to CYP3A gene regulation.
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3.7.6 Summary
Analysis of the basal expression of CYP3A enzymes and transcription 
factors, in adult and foetal livers, HuH7 cells and primary human hepatocytes, has 
demonstrated differences between these cell types. HuH7 cells express very low 
levels of the CYP3As and the transcription factor profile of these cells is entirely 
different to those of human livers and also primaiy hepatocytes. This altered profile, 
or perhaps another aspect of HuH7 cells such as chromatin status, may be 
responsible for the decreased expression of the CYP3A enzymes. Further 
investigation is required to claiify this, and also to evaluate any differences between 
HuH7 cells and primary hepatocytes with respect to xenobiotic induction of the 
CYP3AS.
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4 Xenobiotic exposure and expression of CYP3As and 
nuclear receptors
Analysis of the basal expression of nuclear receptors in human liver, primaiy 
human hepatocytes and HuH7 cells indicated dissimilarity between HuH7 cells and 
the other cell types with respect to the receptor complement of the cell (Chapter 3). I 
hypothesise that differences in the receptor complement may affect the induction of 
CYP3A genes in these cells. Quantitative PGR was used to measure the mRNA 
expression of CYP3As and several nucleai* receptors, in both primary human 
hepatocytes and HuH7 cells, following exposure to the known CYP3A inducers 
PCN, rifampicin, dexamethasone and phenobaibital, over a concentration response 
curve.
4.1 The effect of PCN on CYP3A and nuclear receptor mRNA 
expression in primary human hepatocytes and HuH7 cells
4.1.1 Pregnenolone 16a carbonitrile
Pregnenolone 16a carbonitrile (PCN; Fig 4.1) is a synthetic 
antiglucocorticoid of moleculai* weight 341.5. It is commonly used in the 
experimental study of glucocorticoid-inducible genes, and is able to induce CYP3A 
enzymes both m vivo and in vitro in a number of species, including humans, by 
transcriptional activation (Gonzalez et al., 1985; Kocarek et al., 1995; Baiwick et al., 
1996).
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Fig 4.1: Chemical structure of PCN
4.1.2 The effect of PCN on CYP3A mRNA expression
Total RNA was extracted from primaiy human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.1, 1,5, 10 and 50 pM PCN. One microgram of each 
total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43. The level of each CYP3A mRNA detected in primary human hepatocytes 
following PCN exposure, expressed as percentage of vehicle control, are shown in 
Fig 4.2. 50 pM PCN caused a statistically significant induction of CYP3A4 mRNA 
compared to levels observed in cells treated with DMSO, coiTesponding to a 242 % 
increase. No significant changes in levels of CYP3A5, CYP3A7 and CYP3A43 
mRNA were observed due to PCN dosing.
The levels of each CYP3A mRNA detected in HuH7 cells following PCN 
exposure, expressed as percentage of vehicle control, are shown in Fig 4.3. No 
statistically significant changes in levels of CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43 mRNA were observed due to PCN dosing.
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Fig 4.2: CYP3A mRNA expression in primary human hepatocytes following
PCN exposure.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
vehicle control (26.3, 201.7, 5.9 and 0.6 transcripts per nanogram total RNA for CYP3A4, CYP3A5, 
CYP3A7 and CYP3A43 respectively). Variation between repeat (n=3 except CYP3A43 lOpM and 
CYP3A7 50pM where n= 1 ) measurements was less than 20 % for all data points. The statistical 
significance of changes in CYP3A mRNA expression in cells following 48 hours PCN exposure 
compared with cells treated with vehicle only is shown where ** represents p<0.01 as determined by a 
one way ANOVA with Bonferroni all means post hoc test.
Fig 4.3: CYP3A mRNA expression in HuH7 cells following PCN exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
PCN, expressed as percentage of vehicle control (4.1, 23.7, 25.9 and 1.9 transcripts per nanogram total
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RNA for CYP3A4, CYP3A5, CYP3A7 and CYP3A43 respectively). Variation between repeat (n=3) 
measurements was less than 20 % for all data points.
4.1.3 The effect of PCN on ligand-activated receptor mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.1, 1,5, 10 and 50 pM PCN. One microgram of each 
total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for the ligand-activated receptors PXR, GR 
and CAR. The levels of each ligand-activated receptor mRNA detected in primary 
human hepatocytes and HuH7 cells following PCN exposure, expressed as 
percentage of vehicle control, are shown in Figures 4.4 and 4.5 respectively. No 
statistically significant changes in levels of PXR, GR or CAR mRNA were observed 
due to PCN dosing in either cell type.
Fig 4.4: Ligand-activated receptor mRNA expression in primary human 
hepatocytes following PCN exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
PCN, expressed as percentage of vehicle control (9.3, 28.8 and 49.9 transcripts per nanogram total 
RNA for PXR, GR and CAR respectively). Variation between repeat (n=3) measurements was less 
than 20 % for all data points.
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Fig 4.5: Ligand-activated receptor mRNA expression in HuH7 cells following
PCN exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
PCN, expressed as percentage of vehicle control (7.3, 22.2 and 63.0 transcripts per nanogram total 
RNA for PXR, GR and CAR respectively). Variation between repeat (n=3) measurements was less 
than 20 % for all data points.
4.1.4 The effect of PCN on retinoid X receptor mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.1, 1,5, 10 and 50 pM PCN. One microgram of each 
total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for the retinoid X receptors RXRa, RXR(3 and 
RXRy. The levels of each transcription factor mRNA detected in primary human 
hepatocytes and HuH7 cells following PCN exposure, expressed as percentage 
vehicle control, are shown in Figures 4.6 and 4.7 respectively. In HuH7 cell samples, 
RXRy mRNA expression was below or very near the detection limit of the system 
and so in some cases the n value is less than 3. No statistically significant changes in 
levels of RXRa, RXRp or RXRy mRNA were observed due to PCN dosing in either 
cell type.
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Fig 4.6: Retinoid X receptor mRNA expression in primary human hepatocytes
following PCN exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
PCN, expressed as percentage of vehicle control (59.2, 26.2 and 0.3 transcripts per nanogram total 
RNA for RXRs a, P and y respectively). Variation between repeat (n=3) measurements was less than 
20 % for all data points.
Fig 4.7: Retinoid X receptor mRNA expression in HuH7 cells following PCN 
exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
PCN, expressed as percentage of vehicle control (595.5, 78.6 and 0.8 transcripts per nanogram total 
RNA for RXRs a, p and y respectively). Variation between repeat (n=3, except for n=l for RXRy 1 
and 5pM, n=2 for RXRy 50pM) measurements was less than 20 % for all data points.
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4.1.5 The effect of PCN on general transcription factor mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.1, 1,5, 10 and 50 pM PCN. One microgram of each 
total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for the general transcription factors 
COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1. The levels of each transcription 
factor mRNA detected in primary human hepatocytes and HuH7 cells following PCN 
exposure, expressed as percentage vehicle control, are shown in Figures 4.8 and 4.9 
respectively. No statistically significant changes in levels of COUP-TFl, HNF3a, 
HNF4a, C/EBPa or SP-1 mRNA were observed due to PCN dosing in either cell 
type.
Fig 4.8: General transcription factor mRNA expression in primary human 
hepatocytes following PCN exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
PCN, expressed as percentage of vehicle control (3.1, 47.6, 14.2, 5.77 and 8.8 transcripts per 
nanogram total RNA for COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points.
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Fig 4.9: General transcription factor mRNA expression in HuH7 cells following
PCN exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
PCN, expressed as percentage of vehicle control (219.1, 420.4, 173.0, 58.8 and 77.2 transcripts per 
nanogram total RNA for COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points.
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4.2 The effect of rifampicin on CYP3A and nuclear receptor 
mRNA expression in primary human hepatocytes and HuH7 
cells
4.2.1 Rifampicin
Rifampicin (3-[4-methylpiperazinylimiiiomethyl] rifamycin; Fig 1.4) is a 
macrolide antibiotic of molecular weight 823 and is one of the most active 
antituberculosis agents available. Rifampicin inhibits initiation of RNA synthesis in 
prokaryotic cells by binding to DNA-dependent RNA polymerase (Wehrli, 1983) and 
is a known inducer of CYP3As in a number of species (Kocarek et al., 1995).
4.2.2 The effect of rifampicin on CYP3A mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.1, 1, 5, 10 and 50 pM rifampicin. One microgram of 
each total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43. The levels of each CYP3A mRNA detected in primary human 
hepatocytes following rifampicin exposure, expressed as percentage of vehicle 
control, aie shown in Figure 4.10. Rifampicin significantly induced expression of 
both CYP3A4 and CYP3A7 at 10 pM (5.37- and 2.79-fold respectively) and 50 pM 
(5.11- and 2.38-fold respectively) in primaiy human hepatocytes. No significant 
changes in levels of CYP3A5 or CYP3A43 mRNA were observed due to rifampicin 
dosing.
The levels of each CYP3A mRNA detected in HuH7 cells following 
rifampicin exposure, expressed as percentage of vehicle control, aie shown in Fig 
4.11. No statistically significant changes in levels of CYP3A4, CYP3A5, CYP3A7 or 
CYP3A43 mRNA were obseived due to rifampicin dosing.
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Fig 4.10: CYP3A mRNA expression in primary human hepatocytes following
rifampicin exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours rifampicin 
exposure, expressed as percentage of vehicle control (64.2, 660.0, 27.6 and 0.7 transcripts per 
nanogram total RNA for CYP3A4, CYP3A5, CYP3A7 and CYP3A43 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points. The statistical significance 
of changes in CYP3A mRNA expression compared with cells treated with vehicle only is shown 
where * represents p<0.05, **p<0.01 and ***p<0.001 as determined by a one way ANOVA with 
Bonferroni all means post hoc test.
Fig 4.11: CYP3A mRNA expression in HuH7 cells following rifampicin 
exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours rifampicin 
exposure, expressed as percentage of vehicle control (3.4, 19.5, 15.4 and 2.5 transcripts per nanogram 
total RNA for CYP3A4, CYP3A5, CYP3A7 and CYP3A43 respectively). Variation between repeat 
(n=3) measurements was less than 20 % for all data points.
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4.2.3 The effect of rifampicin on ligand-activated receptor mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.1, 1,5, 10 and 50 pM rifampicin. One microgram of 
each total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for PXR, GR and CAR. The levels of each 
ligand-activated receptor mRNA detected in primary human hepatocytes and HuH7 
cells following rifampicin exposure, expressed as percentage of vehicle control, are 
shown in Figures 4.12 and 4.13 respectively. No statistically significant changes in 
levels of PXR, GR or CAR mRNA were observed due to rifampicin dosing in either 
cell type.
Fig 4.12: Ligand-activated receptor mRNA expression in primary human 
hepatocytes following rifampicin exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours rifampicin 
exposure, expressed as percentage of vehicle control (14.2, 29.4 and 83.8 transcripts per nanogram 
total RNA for PXR, GR and CAR respectively). Variation between repeat (n=3) measurements was 
less than 20 % for all data points.
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Fig 4.13: Ligand-activated receptor mRNA expression in HuH7 cells following
rifampicin exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours rifampicin 
exposure, expressed as percentage of vehicle control (3.9, 23.7 and 58.8 transcripts per nanogram total 
RNA for PXR, GR and CAR respectively). Variation between repeat (n=3) measurements was less 
than 20 % for all data points.
4.2.4 The effect of rifampicin on retinoid X receptor mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.1, 1,5, 10 and 50 pM rifampicin. One microgram of 
each total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for the retinoid X receptors RXRa, RXRp and 
RXRy. The levels of each transcription factor mRNA detected in primary human 
hepatocytes and HuH7 cells following rifampicin exposure, expressed as percentage 
of vehicle control, are shown in Figures 4.14 and 4.15 respectively. In HuH7 cell 
samples, RXRy mRNA expression was below or very near the detection limit of the 
system and so in some cases the n value is less than 3. No statistically significant 
changes in levels of RXRa, RXRp or RXRy mRNA were observed due to rifampicin 
dosing in either cell type.
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Fig 4.14: Retinoid X receptor mRNA expression in primary human hepatocytes
following rifampicin exposure
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Values are mean transcript number per nanogram of input total RNA, following 48 hours rifampicin 
exposure, expressed as percentage of vehicle control (89.4, 32.5 and 0.8 transcripts per nanogram total 
RNA for RXRs a, p and y respectively). Variation between repeat (n=3) measurements was less than 
20 % for all data points.
Fig 4.15: Retinoid X receptor mRNA expression in HuH7 cells following 
rifampicin exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours rifampicin 
exposure, expressed as percentage of vehicle control (423.9, 64.4 and 0.1 transcripts per nanogram 
total RNA for RXRs a, p and y respectively). Variation between repeat (n=3, except for n=l for RXRy 
0 and 0.1 pM, n=2 for RXRy 1, 5 and lOpM) measurements was less than 20 % for all data points.
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4.2.5 The effect of rifampicin on general transcription factor mRNA
expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.1, 1,5, 10 and 50 pM rifampicin. One microgram of 
each total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for the general transcription factors 
COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1. The levels of each transcription 
factor mRNA detected in primary human hepatocytes and HuH7 cells following 
rifampicin exposure, expressed as percentage of vehicle control, are shown in 
Figures 4.16 and 4.17 respectively. No statistically significant changes in levels of 
COUP-TFl, HNF3a, HNF4a, C/EBPa or SP-1 mRNA were observed due to 
rifampicin dosing in either cell type.
Fig 4.16: General transcription factor mRNA expression in primary human 
hepatocytes following rifampicin exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours rifampicin 
exposure, expressed as percentage of vehicle control (4.4, 57.0, 21.0, 7.2 and 6.0 transcripts per 
nanogram total RNA for COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points.
\00
Fig 4.17: Genera! transcription factor mRNA expression in HuH7 cells
following rifampicin exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours rifampicin 
exposure, expressed as percentage of vehicle control (218.1, 570.3, 145.2, 114.2 and 76.4 transcripts 
per nanogram total RNA for COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points.
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4.3 The effect of dexamethasone on CYP3A and nuclear receptor 
mRNA expression in primary human hepatocytes and HuH7 
cells
4.3.1 Dexamethasone
Dexamethasone (9a-fluoro-16a-methylprednisolone; Fig 4.18) is a synthetic 
glucocorticoid steroid of molecular* weight 392.5. It acts via the glucocorticoid 
receptor and is involved in regulation of T-cell survival, growth and differentiation 
(Riccai'di et ah, 1999). It is commonly used as an anti-inflammatory and 
immunosuppressive agent, and is paiticulaily effective in cases where water retention 
is undesirable e.g. cerebral oedema. Dexamethasone is a known inducer of CYPSAs 
in several species (Kocarek et al., 1995).
Fig 4.18: Chemical structure of dexamethasone
OH
HO.
4.3.2 The effect of dexamethasone on CYP3A mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.01, 0.1, 1 , 10 and 50 pM dexamethasone. One 
microgram of each total RNA was used to synthesise cDNA, which was used for 
quantitative PCR reactions using primers and probe sets for CYP3A4, CYP3A5, 
CYP3A7 and CYP3A43. The levels of each CYP3A mRNA detected in primary 
human hepatocytes, expressed as percentage of vehicle control, following 
dexamethasone exposure are shown in Figure 4.19.
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Fig 4.19: CYP3A mRNA expression in primary human hepatocytes following
dexamethasone exposure.
3000-1
■S 2 0 0 0 -
CYP3A4
CYP3A5
CYP3A7
CYP3A43
B 1000Q.
CCO
0.01 0.1 1 10 
Dexamethasone (|iM)
Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
dexamethasone, expressed as percentage of vehicle control (37.6, 449.1, 9.7 and 0.6 transcripts per 
nanogram total RNA for CYP3A4, CYP3A5, CYP3A7 and CYP3A43 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points. The statistical significance 
of changes in CYP3A mRNA expression in dexamethasone treated cells compared with cells treated 
with vehicle only is shown where * represents p<0.05, **p<0.01 and ***p<0.001 as determined by a 
one way ANOVA with Bonferroni all means post hoc test.
Significant increases in expression of both CYP3A4 and CYP3A7 were 
obtained, even at the lowest concentration of dexamethasone tested. Maximum 
inductions of 2523 and 1276 % were observed, for CYP3A4 and CYP3A7 
respectively, at 50 pM dexamethasone. Statistically significant increases in CYP3A5 
mRNA levels were observed following exposure to 1 and 50 pM dexamethasone, 
with a maximum induction of 440 % seen at 1 pM. Increases were also observed in 
CYP3A43 mRNA levels with dexamethasone treatment, but only the increase seen at 
1 pM dexamethasone (671 %) was statistically significant.
The levels of each CYP3A mRNA detected in HuH7 cells, expressed as 
percentage of vehicle control, following dexamethasone exposure are shown in Fig 
4.20. No statistically significant changes in levels of CYP3A4, CYP3A5, CYP3A7 or 
CYP3A43 mRNA were observed due to dexamethasone dosing.
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Fig 4.20: CYP3A mRNA expression in HuH7 cells following dexamethasone
exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
dexamethasone, expressed as percentage of vehicle control (2.6, 32.3, 14.5 and 5.8 transcripts per 
nanogram total RNA for CYP3A4, CYP3A5, CYP3A7 and CYP3A43 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points.
4.3.3 The effect of dexamethasone on ligand-activated receptor mRNA
expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.01, 0.1, 1, 10 and 50 pM dexamethasone. One 
microgram of each total RNA was used to synthesise cDNA, which was used for 
quantitative PCR reactions using primers and probe sets for PXR, GR and CAR. The 
levels of each ligand-activated receptor mRNA detected in primary human 
hepatocytes and HuH7 cells, expressed as percentage vehicle control, following 
dexamethasone exposure are shown in Figures 4.21 and 4.22 respectively. No 
statistically significant changes in levels of PXR, GR or CAR mRNA were observed 
due to dexamethasone dosing in either cell type.
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Fig 4.21: Ligand-activated receptor mRNA expression in primary human
hepatocytes following dexamethasone exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 
hours exposure to dexamethasone, expressed as percentage of vehicle control (1 0 .2 , 
28.0 and 68.2 transcripts per nanogram total RNA for PXR, GR and CAR respectively). 
Variation between repeat (n=3) measurements was less than 20 % for all data points.
Fig 4.22: Ligand-activated receptor mRNA expression in HuH7 cells following 
dexamethasone exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
dexamethasone, expressed as percentage of vehicle control (2.4, 10.5 and 30.8 transcripts per 
nanogram total RNA for PXR, GR and CAR respectively). Variation between repeat (n=3) 
measurements was less than 20 % for all data points.
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4.3,4 The effect of dexamethasone on retinoid X receptor mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.01, 0.1, 1, 10 and 50 pM dexamethasone. One 
microgram of each total RNA was used to synthesise cDNA, which was used for 
quantitative PCR reactions using primers and probe sets for the retinoid X receptors 
RXRa, RXRp and RXRy. The levels of each transcription factor mRNA detected in 
primary human hepatocytes, expressed as percentage of vehicle control, following 
dexamethasone exposure are shown in Figure 4.23. Statistically significant increases 
in RXRa mRNA levels were observed for 1 and 50 pM dexamethasone (260 and 
213 % respectively). No significant changes in levels of RXRp or RXRy were 
observed due to dexamethasone dosing.
The levels of each RXR mRNA detected in HuH7 cells, expressed as 
percentage of vehicle control, following dexamethasone exposure are shown in Fig 
4.24, In HuH7 cell samples, RXRy mRNA expression was below or very neai* the 
detection limit of the system and so in some cases the n value is less than 3. No 
message for RXRy was detected in HuH7 cells treated with 50 pM dexamethasone. 
No statistically significant changes in levels of RXRa, RXRp or RXRy mRNA were 
observed due to dexamethasone dosing.
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Fig 4.23: Retinoid X receptor mRNA expression in primary human hepatocytes
following dexamethasone exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
dexamethasone, expressed as percentage of vehicle control (64.2, 27.9 and 0.9 transcripts per 
nanogram total RNA for RXRs a, P and y respectively). Variation between repeat (n=3) measurements 
was less than 20 % for all data points. The statistical significance of changes in RXR mRNA 
expression in dexamethasone treated cells compared with cells treated with vehicle only is shown 
where * represents p<0.05 and **p<0.01 as determined by a one way ANOVA with Bonferroni all 
means post hoc test.
Fig 4.24: Retinoid X receptor mRNA expression in HuH7 cells following 
dexamethasone exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
dexamethasone, expressed as percentage of vehicle control (277.5, 32.1 and 0.2 transcripts per 
nanogram total RNA for RXRs a, p and y respectively). Variation between repeat (n=3, except for 
n=l for RXRy 0, 0.01 and 0.1 pM, n=2 for RXRy 1 and lOpM) measurements was less than 20 % for 
all data points, n.d. = not detected.
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4.3.5 The effect of dexamethasone on general transcription factor mRNA
expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 0.01, 0.1, 1, 10 and 50 pM dexamethasone. One 
microgram of each total RNA was used to synthesise cDNA, which was used for 
quantitative PCR reactions using primers and probe sets for the general transcription 
factors COUP-TFl, HNFBa, HNF4a, C/EBPa and SP-1. The levels of each 
transcription factor mRNA detected in primary human hepatocytes and HuH7 cells, 
expressed as percentage of vehicle control, following dexamethasone exposure are 
shown in Figures 4.25 and 4.26 respectively. No statistically significant changes in 
levels of COUP-TFl, HNFBa, HNF4a, C/EBPa or SP-1 mRNA were observed due 
to dexamethasone dosing in either cell type.
Fig 4.25: General transcription factor mRNA expression in primary human 
hepatocytes following dexamethasone exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
dexamethasone, expressed as percentage of vehicle control (5.4, 55.0, 15.0, 6.6 and 10.2 transcripts 
per nanogram total RNA for COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points.
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Fig 4.26: General transcription factor mRNA expression in HuH7 cells
following dexamethasone exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
dexamethasone, expressed as percentage of vehicle control (175.8, 462.5, 49.1, 134.4 and 45.3 
transcripts per nanogram total RNA for COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 respectively). 
Variation between repeat (n=3) measurements was less than 20 % for all data points.
109
4.4 The effect of phénobarbital on CYP3A and nuclear receptor 
mRNA expression in primary human hepatocvtes and HuH7 
cells
4.4.1 Phénobarbital
Phenobaibital (5-ethyl-5-phenyl-2,4,6-pyrimidinetiione; Fig 1.4) is a 
bai'biturate of molecular weight 232.2. It has anaesthetic, sedative, hypnotic and 
anticonvulsant properties and was first recognised as an antiepileptic agent in 1912. 
The precise mechanism of its action is unclear, although it is known to enhance the 
action of the neurotransmitter G ABA by modulating GABAa receptors (reviewed by 
Smith and Riskin, 1991). Phénobarbital is a known inducer of GYPS As, although it 
is more commonly known as a CYP2B inducing agent (Kocarek et al., 1995; 
Waxman and Azaroff, 1992).
4.4.2 The effect of phénobarbital on CYP3A mRNA expression
Total RNA was extracted from primary human hepatocytes (donor 4) and 
HuH7 cells that had been exposed to 0, 1, 10, 50, 100 and 200 pM phénobarbital. 
One microgram of each total RNA was used to synthesise cDNA, which was used for 
quantitative PGR reactions using primers and probe sets for GYP3A4, GYP3A5, 
GYP3A7 and GYP3A43. The levels of each GYP3A mRNA detected in primary 
human hepatocytes, expressed as percentage of vehicle control, following 
phénobarbital exposure are shown in Figure 4.27. Statistically significant increases in 
GYP3A4 mRNA expression were seen at phenobaibital concentrations above 50 pM, 
with a maximum 127 % increase following exposure to 200 pM phenobaibital. 
GYP3A5 expression was significantly induced at 10 and 50 pM phenobaibital, with a 
maximum 346 % induction at 10 pM phénobarbital. No significant changes in 
GYP3A7 mRNA levels were observed. GYP3A43 was significantly induced at a 
single concentration of phénobarbital, 50 pM, with a 286 % increase in expression.
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Fig 4.27: CYP3A mRNA expression in primary human hepatocytes following
phénobarbital exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
phénobarbital, expressed as percentage of vehicle control (1210.0, 1726.6, 525.9 and 19.5 transcripts 
per nanogram total RNA for CYP3A4, CYP3A5, CYP3A7 and CYP3A43 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points. The statistical significance 
of changes in CYP3A mRNA expression in phénobarbital treated cells compared with cells treated 
with vehicle only is shown where * represents p<0.05 and **p<0.01 as determined by a one way 
ANOVA with Bonferroni all means post hoc test.
The level of each CYP3A mRNA detected in HuH7 cells, following 
phénobarbital exposure, is shown in Fig 4.28. No signals were detected in cDNA 
synthesised from HuH7 cells dosed with 10 pM phénobarbital, so this concentration 
was omitted from the figure. No statistically significant changes in levels of 
CYP3A4, CYP3A5, CYP3A7 or CYP3A43 mRNA were observed due to 
phénobarbital dosing.
I l l
Fig 4.28: CYP3A mRNA expression in HuH7 cells following phénobarbital
exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
phénobarbital, expressed as percentage of vehicle control (2.9, 11.5, 14.6 and 2.5 transcripts per 
nanogram total RNA for CYP3A4, CYP3A5, CYP3A7 and CYP3A43 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points.
4.4.3 The effect of phénobarbital on ligand-activated receptor mRNA
expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 1, 10, 50, 100 and 200 pM phénobarbital. One 
microgram of each total RNA was used to synthesise cDNA, which was used for 
quantitative PCR reactions using primers and probe sets for PXR, GR and CAR. The 
levels of each ligand-activated receptor mRNA detected in primary human 
hepatocytes and HuH7 cells, expressed as percentage of vehicle control, following 
phénobarbital exposure are shown in Figures 4.29 and 4.30 respectively. No signals 
were detected in cDNA synthesised from HuH7 cells dosed with 10 pM 
phénobarbital, so this concentration was omitted from Figure 4.30. No statistically 
significant changes in levels of PXR, GR or CAR mRNA were observed due to 
phénobarbital dosing in either cell type.
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Fig 4.29: Ligand-activated receptor mRNA expression in primary human
hepatocytes following phénobarbital exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
phénobarbital, expressed as percentage of vehicle control (25.8, 74.0 and 583.7 transcripts per 
nanogram total RNA for PXR, GR and CAR respectively). Variation between repeat (n=3) 
measurements was less than 20 % for all data points.
Fig 4.30: Ligand-activated receptor mRNA expression in HuH7 cells following 
phénobarbital exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
phénobarbital, expressed as percentage of vehicle control (3.4, 14.3 and 49.4 transcripts per nanogram 
total RNA for PXR, GR and CAR respectively). Variation between repeat (n=3) measurements was 
less than 20 % for all data points.
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4.4.4 The effect of phénobarbital on retinoid X receptor mRNA expression
Total RNA was extracted from primary human hepatocytes and HuH7 cells 
that had been exposed to 0, 1, 10, 50, 100 and 200 pM phénobarbital. One 
microgram of each total RNA was used to synthesise cDNA, which was used for 
quantitative PCR reactions using primers and probe sets for RXRa, RXRp or RXRy. 
The levels of each retinoid X receptor mRNA detected in primary human 
hepatocytes and HuH7 cells, expressed as percentage of vehicle control, following 
phénobarbital exposure are shown in Figures 4.31 and 4.32 respectively. No signals 
were detected in cDNA synthesised from HuH7 cells dosed with 10 pM 
phénobarbital, so this concentration was omitted from Figure 4.32. In HuH7 cell 
samples, RXRy mRNA expression was below or very near the detection limit of the 
system and so in some cases the n value is less than 3. No statistically significant 
changes in levels of RXRa, RXR(3 or RXRy mRNA were observed due to 
phénobarbital dosing in either cell type.
Fig 4.31: Retinoid X receptor mRNA expression in primary human hepatocytes 
following phénobarbital exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
phénobarbital, expressed as percentage of vehicle control (382.2, 175.9 and 27.7 transcripts per 
nanogram total RNA for RXRs a, P and y respectively). Variation between repeat (n=3) measurements 
was less than 20 % for all data points.
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Fig 4.32: Retinoid X receptor mRNA expression in HuH7 cells following
phénobarbital exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
phénobarbital, expressed as percentage of vehicle control (339.0, 72.4 and 0.1 transcripts per 
nanogram total RNA for RXRs a, p and y respectively). Variation between repeat (n=3 except for n=l 
RXRy 0 pM and n=2 RXRy 50 pM) measurements was less than 20 % for all data points, n.d. = not 
detected.
4.4.5 The effect of phénobarbital on general transcription factor mRNA
expression
Total RNA was extracted from primary human hepatocytes and HuHV cells 
that had been exposed to 0, 1, 10, 50, 100 and 200 pM phénobarbital. One 
microgram of each total RNA was used to synthesise cDNA, which was used for 
quantitative PCR reactions using primers and probe sets for the general transcription 
factors COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1. The levels of each 
transcription factor mRNA detected in primary human hepatocytes and HuH7 cells, 
expressed as percentage of vehicle control, following phénobarbital exposure are 
shown in Figures 4.33 and 4.34 respectively. No signals were detected in cDNA 
synthesised from HuH7 cells dosed with 10 pM phénobarbital, so this concentration 
was omitted from Figure 4.34. No statistically significant changes in levels of 
COUP-TFl, HNF3a, HNF4a, C/EBPa or SP-1 mRNA were observed due to 
phénobarbital dosing in either cell type.
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Fig 4.33: General transcription factor mRNA expression in primary human
hepatocytes following phénobarbital exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
phénobarbital, expressed as percentage of vehicle control (13.6, 349.9, 398.2, 38.4 and 18.7 transcripts 
per nanogram total RNA for COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points.
Fig 4.34: General transcription factor mRNA expression in HuH7 cells 
following phénobarbital exposure.
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Values are mean transcript number per nanogram of input total RNA, following 48 hours exposure to 
phénobarbital, expressed as percentage of vehicle control (216.5, 356.4, 83.1, 135.7 and 117.4 
transcripts per nanogram total RNA for COUP-TFl, HNF3a, HNF4a, C/EBPa and SP-1 respectively). 
Variation between repeat (n=3) measurements was less than 20 % for all data points.
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4.5 Discussion
4.5.1 Methodology
There are several advantages and disadvantages to our procedures for total 
RNA extraction, DNase I digestion, cDNA synthesis and quantitative PCR; these 
have previously been discussed in section 3.7.1.
Human hepatocytes used for the induction studies were derived from two 
different donors; the phénobarbital study was performed in a different batch of 
hepatocytes than those used for the other three xenobiotics. Ideally, the study should 
have been performed on several different cultures of hepatocytes, and used all four 
xenobiotics in each culture; this would have provided a clearer picture of the 
responses to the xenobiotics and negated any inter-individual effects. Due to cost, 
time and availability considerations, we were not able to expand the study in this 
manner, and as such it must be remembered that data are representative of only a 
small number of individuals and not the population as a whole.
4.5.2 The effect of xenobiotics on CYP3A expression in primary human
hepatocytes and HuH7 cells
50 jxM PCN produced a 2.4-fold increase in expression of CYP3A4 in 
primary human hepatocytes, a relatively small induction response. This weak 
response to PCN has been miiTored in other studies, where PCN was observed to be 
a weak to medium inducer of CYP3A4 (Bai'wick et al., 1996; El-Sankaiy et al., 
2001). In addition, PCN has been shown to be only a weak activator of human PXR, 
and this poor affinity is the most likely explanation for the low induction of CYP3A4 
gene expression observed with this compound (Jones et al., 2000). No induction of 
CYP3A5, CYP3A7 and CYP3A43 mRNA expression in primary human hepatocytes 
with PCN exposure was observed in this study. Little information is available in the 
literature on the effect of PCN on CYP3A5, CYP3A7 and CYP3A43 expression. 
However, evidence is available to suggest PXR is able to trans-activate CYP3A7 
gene expression and so PCN should be able to weakly induce CYP3A7 (Pascussi et 
al., 1999; Bertilsson et al., 2001). A previous study has also implicated PXR as a 
mediator of CYP3A5 induction (Landes et al., 2003). However, PCN is a relatively
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weak activator of human PXR, and so any PXR-mediated induction of CYP3 A5 and 
CYP3A7 by PCN is likely to be very small, and potentially immeasurable in this 
system.
Rifampicin treatment of primary human hepatocytes induced expression of 
CYP3A4, and also CYP3A7, at concentrations of 10 and 50 pM. Rifampicin is 
known to be a CYP3A4 inducer, with various groups reporting between 2- to 
236-fold induction in primary human hepatocytes (Schuetz et al., 1993a; Bowen et 
al., 2000; Gellner et al., 2001). In the current study, the maximum CYP3A4 
induction was 5.4-fold; these differences in amplitude of induction responses suggest 
there may be inter-individual vaiiations in response to rifampicin. This effect is most 
likely to be due to different splice variants of human PXR, as rifampicin is a PXR 
ligand, and some PXR splice variants have been shown to have reduced 
transactivation activity (Hustert et al., 2001; Koyano et al., 2004). This hypothesis 
could be confirmed by studying the transcripts in our sample of hepatocytes; if 
correct our sample should contain a low activity variant of PXR. Alternatively, 
differences in expression of auxiliary transcription factors between individuals may 
be responsible for the inter-individual differences. CYP3A7 has previously been 
shown to be induced by 25 pM rifampicin in primary human hepatocytes and 
expression of this gene has also been shown to be regulated by PXR (Greuet et al., 
1996; Pascussi et al., 1999; Bertilsson et al., 2001). Although both CYP3A4 and 
CYP3A7 appear to be primarily regulated by PXR, maximum induction of CYP3A7 
was approximately half the maximum induction of CYP3A4, indicating potential 
differences in the response to xenobiotics. Such differences could suggest differences 
in the action of auxiliary transcription factors and/or chromatin formation ar ound the 
CYP3A4 and CYP3A7 promoters.
No induction of CYP3A5 mRNA was observed with rifampicin treatment in 
primary human hepatocytes. This result disagrees with two recent studies, where a 
2-fold increase in CYP3A5 mRNA was observed in HepG2 cells with 10-15 pM 
rifampicin (Landes et al., 2003; Usui et al., 2003). The induction of CYP3A5 
expression observed by the other groups is very weak, with a maximum of 2 -fold 
induction, hr my study, there is an apparent 1.5-fold increase in CYP3A5 mRNA at 
10 pM rifampicin, but this is not statistically significant; an increase in the number of
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samples may increase the statistical relevance of this result. The lack of CYP3A5 
induction seen in the primary human hepatocytes used in our study may also be an 
inter-individual effect; repetition of the experiment with hepatocytes from different 
donors may result in statistically significant induction of CYP3A5. However, we 
may conclude that any induction of CYP3A5 is likely to be minor in comparison to 
the induction of CYP3A4.
CYP3A43 induction by rifampicin has been observed recently in primary 
human hepatocytes, with a 39-fold increase in expression with 10 pM rifampicin 
(Gellner et al., 2001). I did not observe any statistically significant induction of 
CYP3A43 mRNA in primary human hepatocytes; however an apparent 2-fold 
increase in expression was observed with 10 pM rifampicin. This may become 
statistically significant if the number of samples is increased. The lack of CYP3A43 
induction seen in the primary human hepatocytes used in our study may also be an 
inter-individual effect; repetition of the experiment with hepatocytes from different 
donors may result in statistically significant induction of CYP3A43. However, we 
may conclude that any induction of CYP3A43 is likely to be minor in comparison to 
the induction of CYP3A4.
Dexamethasone was the strongest inducer of CYP3A4 expression in primary 
human hepatocytes, with a maximum induction of 25-fold at 50 pM. The induction 
response occurred at concentrations as low as 10 nM dexamethasone (6 .3-fold 
induction) suggesting dexamethasone is a potent inducer of CYP3A4. This induction 
of CYP3A4 mRNA at nanomolar concentrations of dexamethasone agrees with 
observations by another group, where induction also occurred at 10 nM 
dexamethasone (Pascussi et al., 2001). Pascussi et al hypothesised that this induction 
of CYP3A4 by nanomolar* dexamethasone was mediated by GR-induction of PXR 
expression; however, we do not observe any increase in PXR expression following 
dexamethasone treatment in this study. This may suggest that an alternative, as yet 
undescribed, mechanism is responsible for mediating the nanomolar* response to 
dexamethasone. At micromolat* dexamethasone concentrations, the CYP3A4 
induction response is likely to be directly mediated by PXR. hiitial studies suggested 
that dexamethasone is a very weak activator of PXR; however these studies were 
carried out using 10 pM dexamethasone (Bertilsson et al., 1998; Blumberg et al..
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1998; Lehmann et al., 1998). More recent work has demonstrated an EC50 of 
>>10 pM dexamethasone for activation of PXR, with strong activation observed at 
supramicromolai’ concentrations (>10 pM) of dexamethasone, which may account 
for the high level of CYP3A4 induction seen at 50 pM (Pascussi et al,, 2001).
CYP3A7 expression in primary human hepatocytes is also induced by all 
concentrations of dexamethasone used in this study, with maximum induction 
obseiwed at 50 pM (12.8-fold). Other groups have also observed CYP3A7 induction 
by dexamethasone (Schuetz et al., 1993a; Kiusekopf et al., 2003). These results agree 
with those observed for rifampicin treatment, with similarities seen between 
induction profiles of CYP3A4 and CYP3A7, confirming a role for PXR in CYP3A7 
gene regulation. CYP3A5 mRNA expression is increased at all dexamethasone 
concentrations but only changes at 1 and 50 pM are statistically significant; levels 
observed at other concentrations may become significant if the sample number is 
increased. CYP3A5 regulation by dexamethasone has been observed previously, with 
significant induction occurring at concentrations from 100 nM to 10 pM 
dexamethasone (Hukkanen et al., 2003; Kiusekopf et al., 2003). This evidence 
implies the involvement of the glucocorticoid receptor, and not PXR, in CYP3A5 
regulation, as PXR is only weakly activated by dexamethasone at these 
concentrations (Bertilsson et al., 1998; Blumberg et al., 1998; Lehmann et al., 1998). 
Levels of CYP3A43 mRNA aie also increased with dexamethasone treatment but 
only increases with 1 pM dexamethasone aie significant; again, changes seen at the 
other dexamethasone doses may become significant if the sample number is 
increased. Induction of CYP3A43, approximately 3-fold, has previously been 
obseiwed at 20 pM dexamethasone in HepG2 cells (Kiusekopf et al., 2003). Further 
investigation into CYP3A43 gene regulation is required, although evidence seen in 
this, and other, studies has indicated a possible role for PXR.
Phenobaibital induced expression of CYP3A4 mRNA at concentrations 
above 50 pM, with a maximum fold induction of 12.7. This induction of CYP3A4 by 
phenobaibital agrees with observations from other groups, where CYP3A4 activity 
and mRNA aie increased with phenobaibital treatment (Madan et al., 2003; Raucy, 
2003; Usui et al., 2003); concentrations used in the published studies ranged from 
8 6  pM to 1 mM; the concentration response curve used in our study falls within these
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limits. Such concentrations of phénobarbital used to treat cells is much higher than 
that of rifampicin, and reflects the different EC50 values of the two dioigs, as 
obseiwed in reporter gene assays for CYP3A4 (9.7 and 1.6 pM respectively; 
El-Sankai*y et al., 2001). The maximum fold induction observed with phénobarbital 
treatment is higher than that observed with rifampicin; this is unexpected as 
rifampicin shows a similar*, if not higher, maximal induction to phénobarbital in 
reporter gene assays (El-Sankaiy et al., 2001). However, other studies have 
demonstrated the differences in CYP3A4 inducibility between cultures and with 
different dixigs; in effect, no culture responds in exactly the same manner as another 
(Madan et al., 2003). Hepatocytes used for the phénobarbital induction study in this 
work were derived from a different source than those used for the other three 
xenobiotics. Ideally, the study should have been performed on several different 
cultures of hepatocytes, and used all four* xenobiotics in each culture; this would 
have provided a clearer picture of the responses to the different xenobiotics. Due to 
cost, time and availability considerations, we were not able to expand the study in 
this manner*.
CYP3A5 was also significantly induced by phénobarbital in primary human 
hepatocytes, although only at 10 and 50 pM phénobarbital and not the higher doses 
used. This does not agree with Schuetz et al. (1993a), who observed no change in 
expression of CYP3A5 protein with phénobarbital exposure in human hepatoma 
cells; however, this observation was from a cell line and we also observed no 
induction of CYP3A5 in the cell line we tested. The same group also observed no 
CYP3A5 protein induction by phénobarbital in a human colon carcinoma cell line 
(Schuetz et al., 1996b). It must be noted however, that in these publications data was 
representative of only one replicate and therefore will not be statistically valid. A 
different group has demonstrated induction of CYP3A5 by phénobarbital in A549 
cells, a lung adenocarcinoma cell line, and so there is evidence available for the 
existence of phénobarbital regulation of CYP3A5 expression (Hukkanen et al., 
2000). The mechanism responsible for this regulation may involve PXR and/or CAR.
No increase in expression of CYP3A7 was observed with phénobarbital 
treatment. This agrees with another study, where no CYP3A7 induction was 
observed with 8 6  pM phénobarbital (Usui et al., 2003). This is surprising, as
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CYP3A7 is induced in a manner similar* to CYP3A4 when exposed to rifampicin and 
dexamethasone. A PXR- and CAR-responsive element is also present in the 
CYP3A7 XREM (Bertilsson et al., 2001); this suggests that CYP3A7 should be 
inducible by pherrobarbital. The lack of CYP3A7 induction by phénobarbital may be 
an individual effect, and if the experiment were repeated in a different culture of 
primary human hepatocytes, an increase in expression might be observed. 
Alternatively, it is possible that the maximum concentration of phénobarbital used in 
this work (200 pM) may not be adequate to induce CYP3A7; it may be necessary to 
treat cells with millimolar* phénobarbital to produce a response. However, we may 
conclude that any induction of CYP3A7, if it does occur, is not likely to be clinically 
relevant as CYP3A7 has been shown to have a substantially lower metabolic 
capability than either CYP3A4 or CYP3A5 (Williams et al., 2002).
No induction of CYP3A43 mRNA expression was observed with 
phénobarbital. Little evidence is available concerning mechanisms of CYP3A43 
regulation, although induction by rifampicin and dexamethasone has been observed 
(Gellner et al., 2001; Krusekopf et al., 2003). This suggests a role for* PXR, which 
may implicate phénobarbital as an inducer* of CYP3A43. Further experiments are 
required, with a higher* range of phénobarbital concentrations and a lar ger number of 
primary human hepatocyte cultures, to determine if phénobarbital is a CYP3A43 
inducer and the precise mechanism of this induction.
In HuH7 cells, no induction of any of the CYP3As was observed with 
xenobiotic exposure, indicating a disruption to regulatory pathways within this cell 
line. A recent study has shown an increase in CYP3A7 mRNA levels in HuH7 cells 
following rifampicin treatment; however, this induction was not supported by 
statistics and so may be treated as speculative (Pascussi et al., 1999). The lack of 
response to xenobiotics may, in part, be due to the alteration in relative expression 
ratios of RXRa and COUP-TFl to PXR observed in HuH7 cells. The relative 
receptor* abundance of these factors was determined to be a major variable between 
human liver, primary hepatocytes and HuH7 cells, as discussed in Chapter* 3. 
Previous studies using CYP3A4 reporter gene constructs in HuH7 cells have 
demonstrated the lack of induction of this reporter gene unless a PXR expression 
plasmid is co-transfected into the cells (Linda Moore, GlaxoSmithKline, personal
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communication). This supports the hypothesis that low PXR expression, compared to 
COUP-TFl and RXRa, may be responsible for the non-responsiveness of these cells 
to CYP3A4 inducers. It must be remembered, however, that reporter gene constructs 
do not mirror the situation in genomic DNA, and as such chromatin status is not 
accounted for. Although altered nuclear receptor expression does appear* to be 
important to the loss of CYP3A induction responses, local chromatin conformation 
may also play a role; if the chromatin is ‘closed’ transcription factors may not be able 
to bind to their* response elements in the CYP3A promoter regions and therefore no 
induction will occur. This will be further investigated in the next chapter*.
4.5.3 The effect of xenobiotics on nuclear receptor expression in primary
human hepatocytes and HuH7 cells
In primar y human hepatocytes, only induction of RXRa was observed with 
exposure to any of the xenobiotics tested (1 and 50 pM dexamethasone). No 
statistically significant change in any nuclear* receptor* mRNA expression was seen in 
HuH7 cells exposed to xenobiotics. RXRa has previously been shown to be 
regulated by the glucocorticoid receptor* (Pascussi et al., 2000a); this is supported by 
the induction of RXRa levels by dexamethasone treatment seen in our work. The 
study by Pascussi et al. (2000a) showed induction of RXRa protein and mRNA at 
100 nM dexamethasone; however* I did not see any significant mRNA induction at 
this concentration, although there is an apparent 2 -fold increase in expression, 
compared to control. This lack of statistical significance may be due to small sample 
size.
Apparent 1.5- to 3-fold increases were observed in expression of both PXR 
and CAR mRNA with dexamethasone exposure, but these changes were not 
significant. Earlier studies have demonstrated induction of both these receptors in a 
glucocorticoid receptor-dependent manner (Pascussi et al., 2000a; Pascussi et al., 
2000b). PXR was induced by 1 pM dexamethasone, but 5 pM rifampicin had no 
effect, indicating dexamethasone activation of GR, rather than PXR, as the 
mechanism responsible for* this induction (Pascussi et al., 2000a). CAR is regulated 
in a similar* manner, with induction by dexamethasone but not rifampicin, supporting 
a role for GR-mediated regulation (Pascussi et al., 2000b). Ideally, my study should 
be repeated, with a larger number of donors and larger sample size. This may reveal
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changes in expression of PXR and CAR not observed in primary hepatocytes from 
this donor. Due to time, cost and availability considerations this repetition was not 
feasible.
4.5.4 Summary
Analysis of the mRNA expression of the human CYP3A enzymes and several 
nuclear receptors in HuH7 cells and primary human hepatocytes following exposure 
to known CYP3A-inducing xenobiotics has indicated that pathways controlling 
regulation of the CYP3As and nuclear receptors gene expression in HuH7 cells 
appear to be disrupted. I have determined the major variables between HuH7 cells 
and other liver cell types, with respect to relative receptor abundance, and 
hypothesise that the disruption to regulatory pathways may be, in part, an effect of 
the altered receptor profile of these cells, particularly ratios of COUP-TFl and RXRa 
to PXR. Further investigation is required to determine the importance of these 
receptor ratios, and also to examine the role of the nuclear chromatin, on CYP3A 
expression and inducibility.
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5 Regulation of CYP3A expression in HuH7 cells
The CYP3A induction response to xenobiotics observed in primary 
hepatocytes was not present in HuH7 cells. We hypothesise that the receptor 
complement and chromatin status of HuH7 cells may, in pai't, be responsible for this 
phenomenon, suggesting a disiuption to regulatory pathways in these cells. Analysis 
of the basal expression of nuclear- receptors in human liver, primary human 
hepatocytes and HuH7 cells indicated dissimilarity between HuH7 cells and the other 
cell types with respect to the receptor complement of the cell (Chapter 3). In 
particular-, levels of PXR relative to COUP-TFl and RXRa are major variables 
between HuH7 cells and in vivo liver and primary hepatocytes.
To examine the potential mechanisms underlying this phenomenon, I next 
modulated the levels of these receptors, in both positive and negative directions. The 
impact of chromatin status around the CYP3A gene cluster was also examined.
5.1 Alteration of nuclear receptor complement in HuH7 cells
5.1.1 The effect of Increased PXR levels in HuH7 cells
HuH7 cells transfected with pSG5-hPXR, a human PXR expression plasmid, 
were treated with medium only or exposed to 0, 0.1, 1,5, 10 or 50 pM rifampicin for 
48 hours before total RNA was extracted. One microgram of each total RNA was 
used to synthesise cDNA, which was used for quantitative PCR reactions using 
primers and probe sets for CYP3A4, CYP3A7, PXR and COUP-TFl, as described 
previously (Section 2.2).
The basal mRNA expression levels of PXR and COUP-TFl, expressed as 
percentage of untransfected control, aie shown in Fig 5.1. As expected, levels of 
PXR were significantly higher in HuH7 cells transfected with pSG5-PXR compaied 
to untransfected cells, with a 3800 % increase in mRNA expression. This increase 
was confirmed by Western blotting (Nick Plant, personal communication). No 
significant changes in mRNA expression of COUP-TFl were observed. The ratio of
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Fig 5.1: Basal expression of PXR and COUP-TFl mRNAs in HuH7 cells
transfected with a PXR expression plasmid.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
control (79.7 and 1492.9 transcripts per nanogram total RNA for PXR and COUP-TFl respectively). 
Variation between repeat (n=3) measurements was less than 20 % for all data points. The statistical 
significance of changes in PXR mRNA expression in PXR-transfected cells compared with 
untransfected cells is shown where ** represents p<0.01 as determined by an unpaired t-test.
COUP-TFl to PXR mRNA expression was 0.74 in transfected HuH7 cells, compared 
to 53.4 observed in untransfected cells and 1.9 observed in adult liver. The basal 
mRNA expression levels of CYP3A4 and CYP3A7, expressed as percentage of 
control, are shown in Fig 5.2. No significant changes in basal mRNA expression 
levels of either CYP3A were observed, although an apparent 2-fold increase was 
observed in expression of CYP3A7.
The levels of CYP3A4 and CYP3A7 mRNA expression following exposure 
of PXR-transfected HuH7 cells to 0, 0.1, 1,5, 10 and 50 pM rifampicin, are shown in 
Fig 5.3. No statistically significant changes in expression, compared to control, were 
observed in rifampicin-treated cells.
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Fig 5.2: Basal expression of CYP3A4 and CYP3A7 mRNAs in HuH7 ceils
transfected with a PXR expression plasmid.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
control (10.1 and 401.5 transcripts per nanogram total RNA for CYP3A4 and CYP3A7 respectively). 
Variation between repeat (n=3) measurements was less than 20 % for all data points.
Fig 5.3: The effect of rifampicin on CYP3A4 and CYP3A7 mRNA expression in 
HuH7 cells transfected with a PXR expression plasmid.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
vehicle control (3.2 and 177.1 transeipts per nanogram total RNA for CYP3A4 and CYP3A7 
respectively). Variation between repeat (n=3) measurements was less than 20 % for all data points.
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5.1.2 The effect of inhibition of COUP-TFl in HuH7 cells
RNAi (RNA-mediated interference) is a relatively new technique that results 
in sequence-specific gene silencing (Fire et al., 1998). This technique uses the cells’ 
response to double stranded RNA (dsRNA) to produce this gene silencing. It is a 
highly consei*ved process in eukaryotes, and is thought to be an antiviral defence 
mechanism. Attempts to induce RNAi using long dsRNA in mammalian cell lines 
met with limited success, due to induction of the interferon response (Ui-Tei et al., 
2000). However, in 2001, it was demonstrated that short RNA duplexes, of 19-23 
base pairs in length, could be introduced into mammalian cells in culture without 
inducing an interferon response (Elbashir et al., 2001). Duplex siRNAs, on 
introduction into the cell, aie bound to a cellulai’ protein complex, called 
RNA-induced silencing complex (RISC), and this complex becomes activated by 
unwinding of the RNA duplex. Activated RISC then cleaves mRNA of the same 
sequence as the duplex, thereby inhibiting target gene expression.
Total RNA was extracted from HuH7 cells transfected with SMARTpool™ 
siRNA tai'geted against COUP-TFl for 24 hours, followed by 24 hours incubation 
with complete medium only. One microgram of each total RNA was used to 
synthesise cDNA, which was then used for quantitative PCR reactions using primers 
and probe sets for CYP3A4, CYP3A5, CYP3A7, PXR and COUP-TFl. The basal 
expression levels of PXR and COUP-TFl mRNA in HuH7 cells following 
transfection with siRNA for COUP-TFl, expressed as percentage of control, aie 
shown in Fig 5.4. COUP-TFl mRNA expression in cells transfected with siRNA was 
24 % of that observed in untransfected HuH7 cells. This was confirmed by Western 
blotting (Nick Plant, personal communication). No change was observed in PXR 
mRNA expression. The ratio of COUP-TFl:PXR mRNA expression was 14.0 in 
transfected HuH7 cells, compared to 53.4 observed in untransfected cells (Table 3.2).
The basal mRNA expression levels of CYP3A4, CYP3A5 and CYP3A7, 
following transfection of siRNA for COUP-TFl, expressed as percentage of control, 
aie shown in Fig 5.5. No significant changes in expression of CYP3A4 and CYP3A7 
were observed in transfected cells compared to untransfected cells. A statistically 
significant increase (163 %) in mRNA expression of CYP3A5 in HuH7 cells 
transfected with siRNA targeted against COUP-TFl was observed.
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Fig 5.4; Basal expression levels of PXR and COUP-TFl mRNAs in HuH7 cells
transfected with siRNA for COUP-TFl.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
control (7.32 and 355.6 transcripts per nanogram of total RNA for PXR and COUP-TFl respectively). 
Variation between repeat (n=3) measurements was less than 20 % for all data points. The statistical 
significance of changes in COUP-TFl mRNA expression in transfected cells compared with 
untransfected cells is shown where * represents p<0.05 as determined by an unpaired t-test.
Fig 5.5; Basal expression levels of CYP3A4, CYP3A5 and CYP3A7 mRNAs in 
HuH7 cells transfected with siRNA for COUP-TFl.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
control (1.1, 14.9 and 28.1 transcripts per nanogram of total RNA for CYP3A4, CYP3A5 and 
CYP3A7 respectively). Variation between repeat (n=3) measurements was less than 20 % for all data 
points. The statistical significance of changes in CYP3A5 mRNA expression in transfected cells 
compared with untransfected cells is shown where * represents p<0.05 as determined by an unpaired 
t-test.
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5.2 The effect of chromatin conformation on CYP3A and nuclear 
receptor gene expression in HuH7 cells
5.2.1 Local chromatin conformation of CYP3A, PXR and GAPDH genes
To investigate if low expression and inducibility of CYP3A and PXR genes 
in HuH7 cells occurs at the chromosomal level, a DNase I sensitivity assay was 
performed to examine the local chromatin conformation around these genes 
compared to GAPDH, a gene with ‘open’ chromatin status around its promoter 
region (Myers et al., 2001). Intact nuclei from 2 x 10^  HuH7 cells were digested with 
0, 0.05, 0.1, 0.4 and 1 unit of DNase I for 10 minutes, followed by digestion with 
restriction enzymes designed to produce fragments of the gene promoter regions 
approximately 5.5 kb in size. Disappearance of these fragments with DNase I 
digestion is dependent upon the access of DNase I to the DNA, and hence is a 
measure of the local chromatin structure. Band intensity was quantified by Southern 
blotting and hybridisation with specific ^^P-labelled probes for CYP3A4, PXR and 
GAPDH promoter regions (Section 2.4.1.4). Southern blots of the digested DNA, 
hybridised with probes for CYP3A4, PXR and GAPDH proximal promoters, are 
shown in Fig 5.6.
The probe designed against the CYP3A4 promoter region did not appeal* to 
be specific, with at least three different sized fragments being clearly identified in 
each lane. Given the high degree of similarity between promoter regions of CYP3A4 
and CYP3A7, and to a lesser extent CYP3A5, it is possible that the extra fragments 
on the blot represent these genes. Analysis of BamWJHpal restriction sites in the 
promoter regions of these genes gives DNA fragments of sizes corresponding to 
these bands (CYP3A4 5619 bp; CYP3A5 7404 bp; CYP3A7 4464 bp). The high 
moleculai* weight (>8 kb) DNA fragment visible in the first lane of this blot is 
unidentified, but may be a result of incomplete digestion of the sample DNA by the 
restriction enzymes. Inspection of the fragments representing the CYP3A proximal 
promoter regions shows that, even with incubation at the highest concentration of 
DNase 1(1 unit), the DNA had not been completely digested, as fragments were still 
visible.
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Fig 5.6: DNase I sensitivity analysis of CYP3A4, PXR and GAPDH 5*-flanking 
regions.
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A) BamHl/Hpal digested HuH7 genomic DNA hybridised with probe for the CYP3A4 promoter 
region. B) HindllVClal digested HuH7 genomic DNA hybridised with probe for the PXR promoter 
region. C) Sfil/Bcll digested HuH7 genomic DNA hybridised with probe for the GAPDH promoter 
region.
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The probe designed against the PXR promoter region also detected more than 
one fragment; this was again likely to be due to incomplete digestion of the genomic ^  
DNA samples by the restriction enzymes. Inspection of these fragments showed that, 
even with incubation at the highest concentration of DNase I (1 unit) the fragment 
had not been completely digested, as the fragment was still visible.
The probe designed against the GAPDH proximal promoter was specific, 
with only one fragment appearing in each lane. Inspection of this blot showed that at 
DNase I concentrations of 0.4 and 1 unit the DNA fragment appealed completely 
digested, as no fragments were visible in these lanes.
Densitometry was used to quantify signal intensities from the fragments on 
the blots. These values were used to calculate percentage DNase I sensitivity, by 
dividing the intensity of the fragments at each DNase I concentration by intensity of 
the control fragment (0 units DNase I) and subtracting from 100 %; these values are 
shown in Fig 5.7. In compaiison to the GAPDH promoter region, DNase I sensitivity 
was apparently reduced for both the CYP3A genes and PXR promoter regions, 
suggestive of increased chiomatin condensation at these loci, as compaied to the 
GAPDH gene. Of the CYP3A gene promoters, CYP3A4 was the least sensitive to 
DNase I digestion and CYP3A7 showed the highest DNase I sensitivity, indicating 
differences in chromatin status across the CYP3A gene cluster
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Fig 5.7: DNase I sensitivity of GAPDH, CYP3A4 and PXR 5'-Ranking regions.
c/5
I
§zQ
A CYP3A4 ■ GAPDH 
▼ CYP3A5 •  PXR 
♦ CYP3A7
Data
0.4 0.6
DNase I (units)
are the mean of triplicate determinations of a single experiment
1.0
5.2.2 Effect of trichostatin A on HuH7 cells
Trichostatin A ([R-(E,E)]-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6- 
dimethyl-7-oxo-2,4-heptadienamide) is a Streptomyces product of molecular weight 
302.4; the chemical structure of this compound is shown in Fig 5.8. It is a specific 
histone deacetylase inhibitor at nanomolai' concentrations, causing chromatin 
opening. Trichostatin A is known to enhance the efficacy of certain anticancer agents 
that target DNA (Kim et al., 2003), and may also be involved in cell cycle 
progression and apoptosis (Yoshida et al., 1995).
Fig 5.8: Chemical structure of the histone deacetylase inhibitor trichostatin A.
OH
133
Total RNA was extracted from HuH7 cells exposed for 24 or 48 hours to 
250 nM trichostatin A with or without 10 pM rifampicin. One microgram of each 
total RNA was used to synthesise cDNA, which was used for quantitative PCR 
reactions using primers and probe sets for CYP3A4, CYP3A5, CYP3A7, PXR, GR, 
CAR, COUP-TFl, HNF4a and C/EBPa.
The level of CYP3A4, CYP3A5 and CYP3A7 mRNA expression, following 
xenobiotic dosing for 24 and 48 hours, aie shown in Fig 5.9. Statistically significant 
increases were observed in CYP3A4 expression with trichostatin A treatment for 
both 24 and 48 hours, with a maximum increase in expression to 347 % of control 
levels after 48 hours exposure. No significant difference was observed in CYP3A4 
expression between HuH7 cells treated with trichostatin A only and cells treated with 
both trichostatin A and 10 pM rifampicin. No significant differences were observed 
in CYP3A5 expression following exposure to trichostatin A for both 24 and 48 hours 
compared to control cells. No significant differences were observed in CYP3A5 
expression between cells treated with trichostatin A only and cells treated with 
trichostatin A and 10 pM rifampicin. CYP3A7 expression was significantly lower in 
cells treated with trichostatin A for 24 hours compaied to cells treated with vehicle 
only, with a maximum decrease in expression to 9.1 % of control levels. No 
significant difference is observed in CYP3A7 expression between cells treated with 
trichostatin A only and cells treated with trichostatin A and 10 pM rifampicin.
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Fig 5.9: mRNA expression levels of CYP3A4, CYP3A5 and CYP3A7 following
exposure to trichostatin A in the presence or absence of rifampicin.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
vehicle control (2.9, 76.0 and 56.4 transcripts per nanogram total RNA for CYP3A4, CYP3A5 and 
CYP3A7 after 24 hours exposure respectively; 5.7, 111.8 and 80.0 transcripts per nanogram total 
RNA for CYP3A4, CYP3A5 and CYP3A7 after 48 hours exposure respectively). Variation between 
repeat (n=3) measurements was less than 20 % for all data points. The statistical significance of 
changes in CYP3A mRNA expression in xenobiotic treated cells compared with cells treated with 
vehicle only are shown where * represents p<0.05, **p<0.01 and ***p<0.001 as determined by a one 
way ANOVA with Bonferroni all means post hoc test.
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The levels of PXR, GR and CAR mRNA expression, following xenobiotic 
dosing for 24 and 48 hours, ai*e shown in Fig 5.10. Statistically significant decreases 
in expression of all the ligand-activated receptors were observed with trichostatin A 
treatment for 24 hours, compared to vehicle only. Expression of CAR was also 
significantly decreased after 48 hours treatment with trichostatin A compaied to 
vehicle only, although the level of this significance also decreased.
The levels of COUP-TFl, HNF4a and C/EBPa mRNA expression, following 
xenobiotic dosing for 24 and 48 hours, are shown in Fig 5.11. Statistically significant 
decreases in expression of COUP-TFl and HNF4a, but not C/EBPa, were observed 
with trichostatin A treatment for 24 hours, compaied to vehicle only. No significant 
changes in expression were observed for any of the factors following 48 hours 
exposure to trichostatin A.
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Fig 5.10: mRNA expression levels of the ligand-activated receptors following
exposure to trichostatin A in the presence or absence of rifampicin.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
vehicle control (14.4, 48.2 and 414.6 transcripts per nanogram total RNA for PXR, GR and CAR after 
24 hours exposure respectively; 23.8, 46.4 and 594.7 transcripts per nanogram total RNA for PXR, 
GR and CAR after 48 hours exposure respectively). Variation between repeat (n=3) measurements 
was less than 20 % for all data points. The statistical significance of changes in mRNA expression in 
xenobiotic treated cells compared with cells treated with vehicle only are shown where * represents 
p<0.05, **p<0.01 and ***p<0.001 as determined by a one way ANOVA with Bonferroni all means 
post hoc test.
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Fig 5.11: mRNA expression levels of COUP-TFl, HNF4a and C/EBPa following
exposure to trichostatin A in the presence or absence of rifampicin.
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Values are mean transcript number per nanogram of input total RNA expressed as percentage of 
vehicle control (665.2, 104.9 and 106.0 transcripts per nanogram total RNA for COUP-TFl, HNF4a 
and C/EBPa after 24 hours exposure respectively; 1316.5, 289.2 and 184.8 transcripts per nanogram 
total RNA for COUP-TFl, HNF4a and C/EBPa after 48 hours exposure respectively). Variation 
between repeat (n=3) measurements was less than 20 % for all data points. The statistical significance 
of changes in mRNA expression in xenobiotic treated cells compared with cells treated with vehicle 
only are shown where * represents p<0.05 as determined by a one way ANOVA with Bonferroni all 
means post hoc test.
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5.3 Discussion
5.3.1 Methodology
Several different methods were used to investigate the potential reason for the 
observed disruption of regulatory pathways within HuH7 cells. Transfection 
techniques were used to alter the nucleai' receptor complement of the cells, with 
transfection of an expression plasmid used to increase expression of PXR and 
transfection of siRNA used to decrease the expression of COUP-TFl. The effect of 
chromatin status on CYP3A and nucleai" receptor gene expression was also 
examined, using both a DNase I sensitivity assay and also a histone deacetylase 
inhibitor.
5.3.1.1 Alteration of the nuclear receptor profile of the cells
FuGENE 6 transfection reagent (Roche Diagnostics) was selected for 
transient transfection of HuH7 cells with the hPXR expression plasmid as this 
method has been previously used, and optimised, in this laboratory (Bombail et al., 
2003). High transfection efficiency was obtained using this transfection method, as 
demonstrated by the significant increase in expression of PXR in transfected cells 
compaied to control cells (38-fold increase).
TransIT®-TKO transfection reagent was selected for transfection of 
SMARTpool™ siRNA for COUP-TFl, as this reagent has been developed 
specifically for transfection of siRNA into a wide vaiiety of cell lines. 
SMARTpool™ siRNA is a pool of four different siRNAs designed against the same 
tai'get gene. MWG Biotech utilises a set of thirty thiee guidelines for the design of 
these siRNAs and the use of a pool of four siRNAs instead of only one results in a 
higher chance and level of gene knockout, with each siRNA pool guaranteed to work 
>97 % of the time with a knockdown of 50 % or more. 76 % knockdown of 
COUP-TFl expression was achieved using SMARTpool™ siRNA with 
TransIT®-TKO reagent, although higher knockdown may be achieved with further 
optimisation; due to time and cost considerations I was unable to cairy out this 
optimisation. Incubation of the cells with the transfection mix was for 24 hours, 
followed by a further 24 hours incubation with medium alone. The estimated half-life 
of COUP-TFl protein is 30 hours (http://ca.ext)asv.org). meaning that levels of
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COUP-TFl protein, as well as mRNA, in the cell would have greatly decreased by 
the time of total RNA extraction.
5.3.1.2 DNase I sensitivity assay
Analysis of local chromatin status aiound CYP3A4 and PXR genes, 
compaied to GAPDH, were analysed using a DNase I sensitivity assay. HuH7 cell 
nuclei were digested with DNase I at concentrations of 0, 0.05, 0.1, 0.4 and 1 unit. 
This range of concentrations resulted in complete digestion of the GAPDH promoter 
region at 0.4 units of DNase I; it may have been better to use more concentrations in 
the range between 0.1 and 0.4 units to allow better visualisation of differences in 
sensitivity between the tai’get genes. Following DNase I digestion, the DNA was 
digested with restriction enzymes to produce similar-sized fragments of the target 
gene promoter regions. For the CYP3A and PXR blots there aie higher molecular 
weight bands than expected; these are likely to be due to incomplete digestion by the 
restriction enzymes. Higher concentrations and/or longer digestion times may be 
necessary to completely digest the DNA.
It may be informative to repeat the experiment using primary human 
hepatocytes instead of HuH7 cells. This will confirm if there is a difference in the 
chromatin status of these genes between the cell types. Also, compai’ison of the target 
genes with a gene known to have condensed chiomatin surrounding its promoter 
region, rather than open, may help analysis of the relative chromatin status for 
CYP3A and PXR.
5.3.1.3 Histone deacetylase inhibition
Trichostatin A, a histone deacetylase inhibitor, was used to remodel the 
chiomatin template in HuH7 cells to allow me to determine the effect of opening the 
chromatin on expression of CYP3As and several transcription factors. However, as 
well as being a specific histone deacetylase inhibitor (Yoshida et al., 1990), TSA is 
an agent that can inhibit cellulai’ proliferation in a number of cell lines including 
HuH7. It is also able to induce apoptosis via a novel mechanism, involving activation 
of the intrinsic death pathway by inducing the caspase-independent cleavage and 
activation of Bid (Siavoshian et al., 2000; Peart et al., 2003; Yamashita et al., 2003). 
This apoptotic effect of the drug had severe consequences for the cells, with a lai’ge
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number of cells dying even after only 24 hours of TSA exposure. This toxicity is a 
major limitation regaiding data inteipretation. Ideally, it would be best to use an 
agent without adverse effects on the cells; unfortunately, there aie limited 
alternatives available to allow us to study the effect of chromatin opening on CYP3A 
gene expression. Other histone deacetylase inhibitors e.g. sodium butyrate and also 
DNA methylase inhibitors e.g. 5-azacytidine induce growth airest and apoptosis in 
human hepatoma cells (Wang et al., 1998).
From the results in section 5.2.2, I observed differences between the 
responses to trichostatin A after 24 and 48 hours e.g. after 24 hours there aie large 
decreases in expression of a number of genes, but after 48 hours there is no 
difference between vehicle and TSA treated cells. This may reflect the short half-life 
of TSA: cells were only dosed at the beginning of exposure, and so TSA may have 
degraded during the 48 hour experimental period, effectively decreasing the 
concentration in the medium. A study by another group has previously shown the 
short half-life of TSA, with hyperacetylation of histones disappearing after only 15 
hours exposure to the drug (Arts et al., 1995; Siavoshian et al., 2000). However, it is 
interesting to note that the increase in CYP3A4 expression was still maintained 48 
hours after dosing, suggesting that effects of TSA treatment can be longer term. 
Repetition of the experiment, with re-dosing after 12 to 24 hours, would have given 
me a more accurate idea of the effect of trichostatin A after 48 hours exposure.
5.3.2 Mechanisms of disruption of CYP3A regulation in HuH7 cells
In previous chapters, I demonstrated the low basal expression of CYP3A 
genes in HuH7 cells, and also the lack of induction of these genes by known 
inducing agents. I also determined the major vaiiables between HuH7 cells and other 
liver cell types, with respect to nuclear receptor expression levels. My hypothesis 
was that relative receptor abundance in HuH7 cells may have been responsible for 
the altered CYP3A expression patterns, in paitieulai* ratios of RXRa and COUP-TFl 
to PXR. I tested this hypothesis by changing these ratios, either increasing expression 
of PXR by transfection of an expression plasmid, or decreasing expression of 
COUP-TFl, by RNA interference. Whereas increasing PXR expression restored 
COUP-TFl:PXR to levels seen in vivo, reduction of COUP-TFl expression was not 
enough to restore this ratio. Neither of these experiments resulted in an increase in
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basal CYP3A4 or CYP3A7 expression, or restoration of the induction response. In 
CYP3A4 promoter reporter gene assays in HuH7 cells, no activation is observed in 
the basal system in response to inducers, with co-transfection of a PXR expression 
plasmid required for the induction response to be observed (Linda Moore, GSK, 
personal communication). This dispaiity between the response of the reporter genes 
and genomic DNA may be explained if we take into account the differences in the 
nature of the DNA between these two systems. Transiently transfected reporter genes 
aie based on plasmid DNA in a non-chromosomal location, with no associated 
proteins; however, genomic DNA is packaged into nucleosomes, where DNA is 
wrapped around a number of proteins (Kornberg, 1974). This has an effect on the 
trans-activation of genes; if the gene promoter is tightly packaged in the 
nucleosomes, access to the DNA for transcription factors and other proteins 
necessary for the transcription machinery will be hindered (Wu, 1997).
I investigated the effect of the chromatin stmcture on gene expression in 
HuH7 cells, and also determined the DNase I sensitivity of the CYP3A and PXR 
gene promoters compaied to GAPDH. Using a DNase I sensitivity assay, I observed 
that the promoter regions of the CYP3A and PXR genes were less sensitive to DNase 
I than the GAPDH promoter, a gene with hyperacetylation of its promoter region, 
resulting in a relaxed chromatin conformation (Myers et al., 2001). This suggests that 
the chromatin aiound the CYP3A and PXR gene promoters is condensed and perhaps 
provides an explanation for the low expression of the CYP3As and PXR genes 
observed in HuH7 cells. The differences observed in the chromatin status across the 
CYP3A gene cluster, with CYP3As 5 and 7 showing higher DNase I sensitivity than 
CYP3A4, also reflect the differences observed in mRNA expression of these genes in 
HuH7 cells, with CYP3A4 expressed at lower levels than both CYP3A5 and 
CYP3A7.
It would have been useful to repeat the DNase I sensitivity assay using 
primary human hepatocytes in place of HuH7 cells, to allow me to compaie the two 
cell types. This would confirm whether the chromatin aiound the CYP3A and PXR 
genes is more condensed in HuH7 cells compared to primary human hepatocytes, 
and again provide supporting evidence for the role of the chromatin structure in 
limiting expression of PXR and CYP3A4 in HuH7 cells.
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If low gene expression levels in HuH7 cells aie due to an increase in 
condensed chromatin, the use of a chromatin-opening agent should result in an 
increase in gene expression.
A histone deacetylase inhibitor was used to investigate the effect of altering 
chromatin structure on the expression of a number of genes in HuH7 cells, including 
the CYP3As. Trichostatin A has previously been used to show an increase in 
constitutive expression of CYPl in two different human cell lines, but increases in 
TCDD-inducible expression were shown to be cell line-specific (Nakajima et al., 
2003). In rat hepatocytes, inhibition of histone deacetylation did not increase 
constitutive CYPl A expression, but did result in an increase in TCDD-induced 
expression, again showing the effect of TSA to be cell specific and perhaps 
indicating a higher level of control (Xu et al., 1997). It must be noted however, that 
the toxicity of TSA is a major limitation regarding data inteipretation in these 
experiments. Exposure of HuH7 cells to 250 nM TSA in my work resulted in a 
significant increase in constitutive expression of CYP3A4; although this increase did 
not restore levels to those observed in adult liver, this indicates that the condensed 
chromatin stmcture is in pait responsible for low basal CYP3A4 expression. TSA 
exposure, however, did not restore rifampicin-niediated induction of CYP3A4.
There are several possible explanations for the above results, for example a 
higher order of chromatin structure that does not involve histone acétylation, limiting 
tianscription factor accessibility to the promoter region. The most likely explanation, 
however, is one I have already investigated in pait. Histone acétylation results in 
chiomatin opening, allowing transcription factors better access to gene promoter 
regions (Pazin and Kadonaga, 1997). But, if the relevant transcription factors are 
expressed at very low levels, the increased accessibility to the DNA will not have 
any effect, as there aie no factors available to bind. This is likely in the case of 
CYP3A4; PXR is expressed at very low levels in HuH7 cells and co-transfection of 
an expression plasmid is required before an induction response is gained from 
CYP3A4 reporter gene constmcts. TSA treatment is therefore unlikely to restore 
genomic CYP3A4 inducibility unless a PXR expression plasmid is co-transfected 
into the cells. Indeed, such a hypothesis is in line with the CYPl observations
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mentioned above; cell-specific effects of TSA on expression of CYPl may be a 
result of limited expression of the AhR in some cell types. An experiment 
investigating if this hypothesis is correct is unfortunately extremely challenging. The 
stresses produced individually by the transfection protocol and the trichostatin A 
(TSA) treatment aie high (Siavoshian et ah, 2000); combining these two methods 
together would result in an unacceptably high level of cell death. Attempts were 
made by me to undertake this experiment, but cell survival was not within acceptable 
limits, and therefore abandoned.
Levels of CYP3A5 and CYP3A7 mRNA expression were also determined 
following exposure of HuH7 cells to TSA. CYP3A5 expression was not altered with 
TSA treatment. CYP3A7 expression, however, decreased significantly with TSA 
exposure after 24 hours. This decrease was also observed with a number of other 
genes measured, such as PXR, GR, CAR, COUP-TFl and HNF4a. This decrease in 
expression may be explained in a number of ways. HuH7 cells perhaps express a 
high level of negative regulatory proteins involved in regulation of these genes. 
Opening of the chromatin would allow these factors access to DNA binding sites on 
the gene promoters, therefore repressing gene trans-activation. Alternatively, the 
toxicity of TSA may be affecting the total RNA (Siavoshian et al., 2000). As the 
expression of the genes measured is normalised to total RNA, any alteration in the 
composition of this RNA may affect the value given. For example, TSA may result 
in an increase in stress response genes being activated in the cells, therefore 
increasing the amount of total RNA and decreasing the copies per nanogram of total 
RNA of other genes.
An interesting contradiction in the results gained in this work is seen for 
PXR. DNase I sensitivity analysis of the PXR promoter region suggested that the 
chiomatin around this gene is condensed. However, no increase was observed in 
expression of PXR following TSA exposure. A possible explanation for this may be 
that factors involved in regulating PXR aie absent. These factors may be proteins 
involved in transcriptional activation, such as nucleai’ receptors and co-regulatory 
proteins, or an endogenous ligand required for PXR transcriptional activation. This 
could be further investigated by determining which regions (DNA binding motifs) of 
the PXR promoter are protected during DNase I foot-printing assays, and then
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determining the proteins able to bind to these regions. Site-directed mutagenesis 
could then be used to investigate the effect of disrupting these binding motifs on 
gene trans-activation. Another possible explanation for the lack of effect of TSA on 
PXR expression may be that the PXR gene is controlled by chiomatin structure not 
involving histone acétylation, for example DNA méthylation or perhaps a higher 
order of chromatin structure such as the dynamic three-dimensional spatial 
organisation of the genome inside the nucleus (Bird, 2002; van Driel et al., 2003). 
Previous studies have shown that transcriptionally active gene loci tend to be 
positioned at the surface of the chiomosomal fibre, and epigenetic regulation of gene 
expression may involve repositioning of these loci thiough changes in large-scale 
chiomatin structure (Verschure et al., 1999; van Driel et al., 2003).
Contradictions were observed between this work and published data. A 
previous study determined expression of HNF4a and C/EBPa following exposure of 
HuH7 cells to TSA (Yamashita et al., 2003). In this latter study, an increase in 
expression of both these genes was observed; in my work, a decrease in expression 
of these genes was observed. A reason for this dispaiity may be the method used. 
Yamashita et al. dosed their cells for 72 hours before extiaction of total RNA and 
then measured gene expression by semi-quantitative RT-PCR. I dosed our cells for 
24 and 48 hours before extraction of total RNA, although the values obtained after 48 
hours may not be accurate, as I did not re-dose after 24 hours. Also, Yamashita et al. 
did not observe any difference in cell number after 24 hours TSA exposure, whereas 
I noticed a lai’ge decrease in the number of cells attached to the culture dish. Another 
group has obsei’ved a large decrease in cell viability following 24 hours exposure to 
TSA (Chiba et ah, 2003). This indicates a difference in sensitivity to TSA-induced 
apoptosis between batches of HuH7 cells. This may be due to the passage number of 
the cells used; in this work we used only cells up to passage 16, as previous studies 
have shown changes in human hepatoma cell line phenotype and CYP3A4 
inducibility above passage number 16 (Ogg et ah, 1999). Yamashita et al. did not 
give a passage number for the cells they used in their study and so it may be that 
these cells were of high passage number.
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5.3.3 Summary
Investigation into the regulation of the human CYPSAs has indicated a 
number of reasons in the disruption of both constitutive and inducible expression of 
these enzymes. We hypothesised that low expression of PXR, in relation to 
COUP-TFl and RXRa, was in part responsible for low expression of CYP3A4 and 
CYP3A7 in HuH7 cells. However, increased expression of PXR in these cells did not 
result in an increase in constitutive or inducible CYP3A expression. Decreased 
COUP-TFl expression also had no effect on CYP3A4 and CYP3A7 constitutive 
expression, but did result in a significant increase in expression of CYP3A5. Further 
investigation is required to clarify the role for COUP-TFl in regulation of CYP3A5 
gene expression; however, from the results gained in my work, COUP-TFl appears 
to play a negative regulatory role in CYP3A5 gene trans-activation.
Chromatin stmcture aiound CYP3A and PXR gene promoter regions is less 
sensitive to DNase I digestion than GAPDH, indicating a more condensed chiomatin 
conformation around these loci. Opening of the chromatin in HuH7 cells, by 
inhibition of histone deacetylation, resulted in an increase in the expression of 
CYP3A4, but not the other transcripts measured, including PXR. This indicates 
control of PXR expression is at a higher order of chiomatin structure, or that a key 
regulatory factor is absent. Chiomatin opening did not restore the CYP3A4 induction 
response to rifampicin, and so I further hypothesised that a combination of both 
chiomatin status and relative receptor abundance in HuH7 cells is responsible for 
low constitutive and inducible CYP3A expression. This hypothesis requires further 
investigation that is not within the scope of this thesis.
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6 Discussion
The aim of this work was to use transcriptomic analysis to investigate the 
molecular mechanisms underlying the observed differences in response of primary 
human hepatocytes and HuH7 hepatoma cell line to CYP3A transcriptional 
activators. In doing so I aimed to increase knowledge both on the applicability of 
hepatoma cell lines to in vitro assays, as well as the mechanisms controlling CYP3A 
expression in vivo.
Primary human hepatocytes are the preferred in vitro tool to study human 
dmg metabolism but there are a number of drawbacks to their use in research, 
especially when investigating CYP3A gene regulation. Laige inter-individual 
variations in expression of the CYP3 A enzymes have been observed in both my work 
and that of other groups (Westlind et ah, 1999; Ozdemir et ah, 2000). Differences 
have also been observed in CYP3A responses to xenobiotics between individuals 
(Madan et ah, 2003). This necessitates the need for laige sample groups to allow 
accurate evaluation of the regulation of CYP3A enzymes; availability of good 
quality, viable human hepatocytes is restricted and expensive, so there are difficulties 
present in obtaining adequate sample numbers to allow this analysis.
Human hepatoma cell lines are a tool used in both academia and the 
pharmaceutical industry; this is due to their more ‘user-friendly’ handling and 
significant cost benefits compared to using primary human hepatocytes. However, 
the use of these hepatoma cells must be governed by our knowledge of the cell line, 
both the advantages and disadvantages. HepG2 cells aie a human hepatoma cell line 
that has previously been used to great extent in scientific research (El-Sankary et al., 
2001; Pascussi et al., 2001); however, HuH7 cells are becoming more prevalent as 
they are a faster growing and more ‘user-friendly’ cell line than HepG2 (Linda 
Moore, GlaxoSmithKline, personal communication). However, as I have 
demonstrated in this work, there are disadvantages and limitations to their use at 
present and these need to be given appropriate consideration when designing 
experimental procedures involving their use.
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I determined constitutive expression of the human CYPSAs in HuH7 cells by 
quantitative PCR. The expression profile of these enzymes in HuH7 cells differed 
from that seen in the other cell types tested, with expression of all CYPSAs except 
CYP3A43 significantly lower than in human adult liver. It should be noted that the 
observed lack of decrease in CYP3A43 levels may be an artefact of the low basal 
expression in adult liver, close to the detection limit of the Q-PCR analysis. Any 
decrease may therefore be lost in the noise associated with measurements at/close to 
the detection limit of any system. Levels of CYP3A4 expression were less than 
0.1 % of those observed in adult liver, suggesting large-scale disruption of basal 
expression pathways in this cell line. Constitutive expression of several nuclear 
receptors was also determined; analysis of the relative expression levels of these 
receptors indicated that whereas ligand-activated transcription factors were similai* in 
their relative expression, their absolute expression was significantly lower. Little 
similarity between HuH7 cells and the other cell types was observed, with little 
similaiity also between primary human hepatocytes and human adult liver suggesting 
that culture does significantly alter the phenotype of these cells. The major 
determinants of the vaiiability between the cell types were the relative expression 
levels of COUP-TFl and RXRa to PXR.
I further investigated the differences between HuH7 cells and primary human 
hepatocytes by determining the effect of known in vivo CYP3A inducing agents on 
the genomic expression of CYP3As and nuclear receptors. Whereas HuH7 cells have 
been used extensively and successfully in CYP3A reporter gene assays to determine 
compounds that aie inducers of CYP3A4, they did not show any genomic 
transcriptional activation to the inducers in my studies. This appaient contradiction 
was investigated by examining the effect of several factors on genome-based 
expression of CYP3A genes. The reporter gene assay protocol requires 
co-transfection of a PXR expression plasmid into the cells before a 
xenobiotic-mediated response is obtained (Linda Moore, GlaxoSmithKline, personal 
communication), and work in this thesis has shown that PXR expression levels in 
HuH7 cells are low, potentially explaining the necessity of increasing expression 
before CYP3A reporter gene induction occurs. However, whereas a simple increase 
in PXR expression can remedy problems associated with the use in reporter gene 
assays of HuH7 cells, such does not appeal' to be the case in studies of genomic
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regulation of CYP3A in HuH7 cells. This has been demonstrated in my work by the 
lack of induction of the genomic CYP3A4 gene by typical inducers in both basal 
HuH7 cells and in PXR-transfected cells. This implies a difference in regulatory 
control between the reporter gene construct and the genomic DNA, other than the 
relative transcription factor expression profile of the cells.
Baiwick et al demonstrated that species specificity with regard to 
xenobiotic-mediated activation of CYP3 A gene expression was determined in part by 
host cell environment (Baiwick et al., 1996). This was extended in our laboratory to 
show that responses to xenobiotics were, in pait, determined by the relative 
transcription factor expression profile of the cell (Swales et al., 2003). Artificial 
manipulation of transcription factors within HuH7 cells, however, did not affect 
either constitutive or xenobiotic-mediated expression of CYP3A4, leading to the idea 
that a higher level of control may exist. Evidence is available to show that in 
hepatoblastomas, histone deacetylase expression is slightly higher than in normal 
liver, suggesting a difference in chromatin status between cancerous and normal 
tissue (Gray et al., 2000). A number of studies support this, demonstrating changes in 
chiomatin status during tumourigenesis, often resulting in gene-silencing (Baylin and 
Herman, 2000). Examination of local chromatin status around CYP3A and PXR 
genes suggested increased condensation of chromatin at these loci might underlie the 
low expression of these genes. Treatment of HuH7 cells with a histone deacetylase 
inhibitor, causing an increase in the signatures for open chromatin, resulted in 
increased constitutive expression of CYP3A4, supporting my hypothesis. However, 
it should be noted that these enhanced expression levels were not restored to the 
levels observed in vivo, nor was the response to rifampicin restored. This suggests 
different levels of control aie involved in the non-permissive nature of HuH7 to 
genomic expression of CYP3A genes, and may be a combination of several factors, 
including both local chromatin status and the transcription factor expression profile 
of the cells. Higher order chromatin status may also be implicated, as other studies 
have shown the importance of chromosomal structure on gene expression (Verschure 
et al., 1999; van Driel et al., 2003). The different levels of control of CYP3A gene 
expression aie summaiised in Fig 6.1, showing the importance of both the 
transcription factor profile and the chromatin structure of the cells.
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Fig 6.1: Different levels of control of CYP3A gene expression.
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While an increase was observed in constitutive CYP3A4 expression following 
exposure to a chromatin-opening agent, restoration to levels seen in vivo was not 
observed nor was the induction response to xenobiotics. This suggests that a 
combination of factors is involved in the disruption of CYP3A regulatory pathways 
in HuH7 cells and further investigation is required to clarify this. Investigation of 
local chromatin structure not involving histone acétylation, such as DNA 
méthylation, or of large-scale chromatin structure such as the dynamic 
three-dimensional packaging of the heterochromatin in the nucleus, are studies that 
may elucidate further mechanisms of CYP3A control (Verschure et al., 1999; van 
Driel et al., 2003). Expansion of the pool of transcription factors measured to include 
other nuclear receptors e.g. HNF3y, and also to encompass co-regulatory proteins 
e.g. SRC-1, may allow us to further examine differences in the expression profile of 
the cells and identify more proteins influencing CYP3A expression in HuH7 cells. If 
this knowledge can be obtained it may be possible to use this information to 
somehow stably transform the HuH7 cells, either by manipulating the expression
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profile ai'tificially or by altering the chromatin structure, so that they can support 
genomic CYP3A induction pathways and provide a valuable research tool for use in 
both academia and the phai'maceutical industry.
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8 Appendices
8.1 Genomic DNA standards calculation
The human genome is 3.22 x 10^  bp and the molecular weight of 1 bp is 
660 g, so the molecular weight of the human genome is
3.22 X 10^  X 660 = 2.1252 x lO'^ g.
The human genome is diploid such that 1 genome contains 2 copies; therefore 
a molar solution of the haploid genome contains 1.06 x 10^  ^g/1. One mole contains 
6.02 X 10^  ^ molecules according to Avogadro’s number, but DNA contains two 
single strands so each mole of the human haploid gene contains 1.2 x 10^ "^  single 
strands. Therefore, 1.06 x 10*^  g contains 1.2 x 10^ "^  single strands, and so 1 g 
contains 1.13 x 10*^  single strands.
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8.2 pSG5-hPXR vector map
SV40
Ampr
Cla 1(376)
b-globin intron
■ C/fl 1(1255)pSG5-hPXR
5684 bp
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Poly A 
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